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ABSTRACT
The role of various polyglutamine (polyGln) aggregated states in the disease
mechanism of expanded CAG repeat disorders continues to be a perplexing subject. We
are interested in learning more about these species and the relationship between the
aggregation pathways. We have developed an innovative staining technique that allows,
for the first time, the visualization of small polyGln aggregates, which we refer to as
aggregation foci (AF), that are functionally distinguished by their ability to serve as seeds
for amyloid growth. The aggregation foci stain should prove useful in the Huntington’s
disease research as a tool for the identification of a functional class of aggregates that was
previously undescribed. The ability to account for different aggregates may provide a
better correlation with neurodegeneration. Using this method we were able to detect at
least four phenotypic classes of aggregates in stable PC12 cells engineered for inducible
expression of different polyGln repeat length forms of a green fluorescent protein-fused
huntingtin (htt) exon-1 fragment: 1) small, recruitment-competent, cytoplasmic AF, 2)
large, cytoplasmic, perinuclear, green-fluorescent, recruitment-inert htt aggregates, 3)
cytoplasmic, perinuclear, green-fluorescent, recruitment-competent aggregates, and 4)
small, nuclear, recruitment-inert, green-fluorescent aggregates. Each species can be found
either in isolation or co-existing within the same microscope field depending on the time
post-induction and Gln repeat-length. In our studies, AF tend to be the earliest species
that appear in the cells. The PC12 cells generally did not exhibit indications of toxicity
due to the polyGln species, and thus provided a good model to study the aggregation
pathway without the bias of cell death. Biochemical data were gathered to understand the
vi

properties of each distinct aggregate specie. We also examined the ability of two separate
compounds (curcumin and demecolcine) to alter the aggregation pathway. Each
experiment was designed to obtain knowledge about possible precursor/product
relationships that exist among the species, with the ultimate goal of gaining insight into
the aggregation pathways responsible for the formation of the amyloid-like AF and larger
inert aggregates that arise in these the cell lines expressing various polyGln repeatlengths. We interpret this data as indicating that the two species are on competing
assembly pathways.
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CHAPTER 1
LITERATURE REVIEW
1.1 Protein folding disorders:
OVERVIEW
A large number of human diseases arise from the inability of peptides or proteins
to properly assume their native conformation. These conditions, often collectively
referred to as protein conformational, or protein folding disorders, span diverse
conditions that are widespread and are not confined to any particular organ or tissue (see
Table 1.1 for a summary of amyloidoses) [Carrell and Lomas 1997; Uversky 1999;
Ahmad et al. 2005; Westermark et al. 2005; Chiti and Dobson 2006]. Conformational
disorders arise when there is a change in the size, shape, or amount of a protein resulting
in the deposition of an aberrant form – which may be amyloid or some other type of
protein aggregate – within tissues. Protein folding disorders can be categorized into two
major groups: 1) those involving only the brain, and 2) those affecting the remainder of
the body. This section will provide a brief introduction to the protein folding disorders
that result in amyloid or amyloid-like deposits; after which, a more detailed description of
a subset of these illnesses, the polyglutamine (polyGln or polyQ) repeat diseases, will be
provided.
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Table 1.1: Human protein folding disorders (Amyloidoses)
Aggregating
peptide or protein

Native structure(s)
of peptide or
protein #

Affected tissue /
Syndrome

Expanded
polyglutamine diseases

Various polyglutamine
containing proteins
(CAG)

Intrinsically unfolded; βsheet; α-helices;
combination α+β;
unknown (See Table 1.2)

Cerebral cortex,
Purkinje cells, basal
ganglia, etc.

Alzheimer’s disease

β-amyloid precursor
protein (Aβ)

Intrinsically unfolded

Cerebral cortex,
hippocampus, basal
forebrain, etc.

Spongiform
encephalopathies

Prion protein (APrP)

Intrinsically unfolded; αhelices

Brain

Parkinson’s disease

α-synuclein

Intrinsically unfolded

Substantia nigra

Amyotrophic lateral
sclerosis

Superoxide dismutase 1

β-sheet

Motor neurons

Prolactin (APro)

α-helices, 4-helical
cytokines

Pituitary

Cystatin C (ACys)

α+β, cystatin-like

Brain

Amyloid
condition
Cerebral (Localized)

Pituitary prolactinoma
Icelandic cerebral
amyloid angiopathy
(Systemic)

Peripheral – Systemic (S) or Localized (L)
AL amyloidosis –
Light chain (S,L)

Immunoglobulin light
chains (AL)

β-sheet

AH amyloidosis –
Heavy chain (S,L)

Immunoglobulin heavy
chains (AH)

β-sheet

Skin, nerves, heart, GI
tract (includes tongue),
kidney, liver, spleen,
blood vessels
Myeloma-associated
primary tumors

AA amyloidosis –
Inflammationassociated (S)

Serum amyloid A protein
(AA)

α/β

Spleen, liver, kidneys,
adrenals, lymph nodes.
vascular Secondary to
chronic infections,
reactive tumors

Familial & senile
systemic amyloidosis
(S,L)

Transthyretin (ATTR)

β-sheet

Predominately liver,
most organs & tissues

Hemodialysis
amyloidosis (S,L)

β2-microglobulin (Aβ2M)

β-sheet

Musculoskeletal, GI
tract

2

Table 1.1. Continued
Amyloid
condition

Aggregating
peptide or protein

Native structure(s)
of peptide or
protein #

Affected tissue /
Syndrome

Lysozyme
amyloidosis (S)

Lysozyme (ALys)

α+β, lysozyme fold

Visceral organs &
tissues

Familial, sporadic &
aortic (S,L)

Apolipoprotein (AApoAI,
AApoAII, AApoAIV)

α-helices

Visceral organs &
tissues

Familial amyloidosis
(S)

Gelsolin (AGel)

α+β, gelsolin-like

Eyes

Hereditary fibrinogen
α-chain amyloidosis
(S)

Fibrinogen α-chain
(AFib)

Coil?

Kidney

Familial British dementia
(S)

ABriPP (ABri)

Majority coil, some α+β

Central nervous system

Familial Danish dementia
(S)

ADanPP (ADan)

Predicted β-sheet

Central nervous system

Diabetes mellitus
type II (L)

Islet amyloid
polypeptide (AIAPP) or
amylin

Natively unfolded

Islets of Langerhans
(pancreas)

Medullary thyroid
carcinoma (L)

(Pro)calcitonin (ACal)

50% coil : 50% α-helix

C-cell thyroid tumors

Isolated atrial
amyloidosis (L)

Atrial natriuretic factor
(AANF)

50% coil : 50% α-helix

Heart

Largely α-helical

Liver, kidney, spleen,
pancreas

Iatrogenic insulindependent amyloidosis
(L)

Insulin (AIns)

Senile aortic, medin
amyloidosis (L)

Lactadherin (AMed)

Coil

Heart

Familial corneal
amyloidosis (L)

Kerato-epithelin (AKer)

Largely α-helical

Eyes

Familial corneal
amyloidosis (L)

Lactoferrin (ALac)

α+β combination

Eyes

#

Based on the Structural Classification of Proteins (SCOP), Protein Data Bank (PDB), or
Advanced Protein Secondary Structure Prediction Server (APSSP).
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A natively folded protein can become pathogenic for a variety of reasons,
including posttranslational processing or the improper trafficking of the protein [Chai et
al. 1999; Amaral 2004; Lee et al. 2004; Gunawardena and Goldstein 2005; Luo et al.
2005]. The majority of conformational disorders, however, occur as a result of a change
in the protein from a normally soluble state into an aggregated state, where the aggregates
range from soluble, oligomeric structures to large, insoluble, ”amyloid” or amyloid-like
fibrils. This aggregation is normally associated with a conformational change.
Aggregated proteins either accumulate within the cell (examples are inclusions of
huntingtin and neurofibrillary tangles of tau) or outside the cell (amyloid plaques in
Alzheimer’s disease, amyloid fibrils in other amyloid diseases, diffuse, non-amyloid
deposits in AD). The overall effect is that there is a reduction in the amount of the
normal protein and an increase in the misfolded protein. While some aggregation diseases
may exhibit a component of a loss of function phenotype (generally intracellular
aggregation disorders), due to the reduction in normal protein levels, for many of these
diseases the principle effects appear to be due to toxic gains of function.

AMYLOID STRUCTURE
Amyloid fibrils, by classical definition, are extracellular protein aggregates
[Pepys 2006] that: (a) exhibit a cross-β structure (β-sheets run parallel to the fibril axis,
and the β-strand components run perpendicular to the axis) as demonstrated by x-ray
diffraction (see Figure 1.1) [Sunde et al. 1997]; (b) that specifically bind Congo red (CR)
dye, which is thought to bind between β-strands, with a green birefringence that is
4

A

B

C

DD

Figure 1.1: Proposed β-strand structures. (A) Cross-β spine structure of amyloid fibrils
(Taken from [Nelson et al. 2005]). Carbon atoms are colored purple or gray/white,
oxygen is red, and nitrogen is blue. The backbone of each β-strand is represented as an
arrow with protruding side chains. The “dry” interface (composed of side chains Asn2,
Gln4, and Asn6) is located between the two sheets, while the solvated surfaces are
exposed. (B) Ribbon diagram and detailed conformational views of the human
monomeric β2-microglobulin (Taken from [Trinh et al. 2002]). (C) Model of a single
strand of residues 15-36 of the amyloid fibril core β-sheet cross-section (Adapted from
[Shivaprasad and Wetzel 2004]). Model was created by J.T. Guo and Y. Xu based on
cysteine accessibility and disulfide cross-linking [Shivaprasad and Wetzel 2006]. Carbon
backbone is colored green, hydrogen is gray/white, oxygen is red, nitrogen is blue, and
yellow is sulfur. (D) Cartoon depiction of antiparallel β-sheets of Abeta fibril. Residues
12-21 are red and residues 30-40 are blue. (Taken from [Tycko 2006]).
5

observed under polarized light microscopy [Puchtler 1962]; and (c) that bind the yellow
fluorescent dye thioflavin T (ThT), another molecule thought to bind to β-sheets [Sunde,
Serpell et al. 1997]. Actual amyloid deposits have also been shown to contain glycan
molecules, such as heparan sulfate [Nelson et al. 1991] and to bind serum amyloid P
(SAP) component [Pepys et al. 1994]. In contrast to the above restrictive definition of
amyloid, the term has been adopted by the protein structural and biophysical community
to refer to a type of aggregated protein folding motif that has the structural properties of
amyloid (cross-β, dye-binding, etc.), even if the aggregate has been generated in vitro or
intracellularly. Thus, for the purposes of this dissertation, the term amyloid or amyloidlike will be used interchangeably and will refer to non-native, aggregated, β-structures
that have the ability to self-propagate.
Over the past decade, several structural models of this amyloid fibril folding motif
have been proposed. These models include the cross-β spine (Figure 1.1A) proposed by
Eisenberg and coworkers [Nelson, Sawaya et al. 2005], the polar zipper model [Perutz et
al. 1994] (discussed in Section 1.2), as well as various other antiparallel β-strand models
(Figure 1.1B-1D) [Trinh et al. 2002; Shivaprasad and Wetzel 2004; Shivaprasad and
Wetzel 2006; Tycko 2006; Bu et al. 2007]. These structures are based on data obtained
using a variety of methods including, solid-state NMR (SSNMR), hydrogen-deuterium
exchange, mutational analysis, atomic force microscopy (AFM), X-ray diffraction, and
transmission electron microscopy (TEM).
Each model has several similarities including the accepted cross-β structure, the
intermolecular packing that occurs between the β-sheets [Shivaprasad and Wetzel 2004],
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and the hydrogen bonding that occurs between the main chain and side chain amino acids
[Perutz et al. 1994; Trinh et al. 2002]. Several of the proposed models suggest that the
core region, despite differences among their primary sequences, is composed of two to
four β-sheets that intimately interact with one another [Chiti and Dobson 2006].
Despite the observed similarities, there are also numerous differences among the
various models. These differences include the nature of side chain involvement, β-strand
length and arrangement (parallel or antiparallel), the conformation of regions outside of
the core, and the number of β-sheets that comprise a protofilament (the filamentous fibril
building block of amyloid fibrils). Other factors that differ significantly are the spacing
between the β-sheets of the core and the number of peptide residues that are actually
incorporated into the core [Fandrich and Dobson 2002]. In the case of insulin amyloid
fibrils, the presence of disulfide bonds also affects the β-sheet packing [Jimenez et al.
2002]. In polyglutamine peptide amyloid, the side chains may become involved in
hydrogen bonding to each other or to the β-sheet peptide backbone [Perutz et al. 2002].
The conformation found in isolated fibrils is ultimately determined by some
combination of thermodynamics and kinetics. Protein aggregates tend to be quite stable,
so that, whether the precursor is an intrinsically unfolded protein or a stably folded
protein, fibrils occupy a lower free energy and hence are thermodynamically favored. At
the same time, reaction kinetics can determine which of the essentially equally stable
polymorphic amyloid states [Kodali and Wetzel 2007] are formed in a fibril formation
reaction. More generally, even though the fibril state exists and is thermodynamically
favored, fibrils will not form unless the reaction is kinetically feasible, for example by
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virtue of a weakening of the native state of a folded precursor, the presence of a fibril
seed, or a surmountable nucleation barrier [Kodali and Wetzel 2007].

FUNCTIONAL AMYLOID
Amyloid-like fibrils are not always associated with pathology. Some proteins
have been shown to produce amyloid fibrils not associated with tissue toxicity [Stefani
and Dobson 2003; Uversky and Fink 2004]. This type of amyloid is referred to as
functional amyloid, where the amyloid structure is found to be beneficial to the living
organism rather than associated with a disease-state. A few examples of functional
amyloid are the bacterial protein curlin [Chapman et al. 2002] that is produced by
Escherichia coli and used to mediate attachment to host proteins for colonization; the
Saccharomyces cerevisiae (yeast) prion proteins Ure2p and Sup35p [Osherovich et al.
2004] that confer alternate non-pathogenic phenotypes; and mammalian melanosomes
[Berson et al. 2003], which are lysosome-like organelles responsible for the production of
the pigment melanin. There are also amyloid deposits not known to be either pathogenic
or beneficial [Haggqvist et al. 1999].

NUCLEATION-DEPENDENT MECHANISM
Spontaneous amyloid fibril formation is normally considered to occur via
nucleation-dependent polymerization (see Figure 1.2) [Ferrone 1999] followed by
elongation or growth of the fibril. This is rather controversial, however, and in some
cases fibrils grow without a required nucleation step by a process called “downhill
aggregation” [Ferrone 1999; Modler et al. 2004].
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A
etc.

Monomer
Amyloid fibrils

B
etc.

Monomer

Nucleus
Amyloid fibrils

Figure 1.2: General schematic representations of aggregation initiation and growth
by monomer addition. (A) Downhill aggregation. In this class of aggregate assembly,
all monomers, and all aggregates, are equally capable of participating in an effective
collision to form a larger particle. There is no energy barrier to initiation of the
aggregation reaction (as indicated by the relative sizes of the arrows). (B) Nucleated
growth. In this class of aggregate assembly, the overall reaction is limited by the
energetically unfavorable formation of a critical species called the nucleus. Once the
nucleus begins to elongate by monomer addition, the aggregation reaction becomes
essentially irreversible. In this illustration, the nucleus is depicted as a special form of
the monomer, but, classically, the nucleus is conceived as an oligomer; both appear to be
possible. More complex schemes are also possible. For example, although spherical
oligomers appear to form by downhill aggregation, their conversion to fibrils – if it
happens – could be considered to be the nucleation event for amyloid formation,
effectively drawing components of both A and B. These schemes ignore the further
complexity that aggregation reactions often require an initial misfolding of the monomer.
This is not a concern for amyloidogenic peptides like Aβ and polyglutamine, however,
since they have no stable folded structure in solution.
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The conversion of the protein into a fibril can be monitored by many means,
including light scattering, ThT fluorescence, atomic force microscopy (AFM), electron
microscopy (EM), and centrifugation coupled with high performance liquid
chromatography (HPLC) (which is useful for following the disappearance of the
monomeric species). Fibril formation is often preceded by a lag phase associated with the
formation of a nucleus or other, oligomeric states. Once the nucleus has been established
(rate-limiting step), the growth (elongation) of the fibril, by addition of either monomers
[Lomakin et al. 1996; Lomakin et al. 1997; Collins et al. 2004; O'Nuallain et al. 2005] or
oligomers [Kumar et al. 2007; Vestergaard et al. 2007] , occurs very rapidly. Whatever
the mechanistic source of the lag phase (nucleus formation, oligomer formation), it may
be eliminated by the addition of preformed fibrillar seeds [Naiki et al. 1997; Serio et al.
2000; O'Nuallain et al. 2005]. Experimental conditions as well as certain kinds of
mutations have also been shown to decrease the lag phase [Uversky et al. 2002; Pedersen
et al. 2004].

AGGREGATE MORPHOLOGIES
As mentioned above, there are a variety of aggregate types and morphologies that
go well beyond the amyloid designation. Morphologies of protein aggregates in the
literature include amyloid fibrils of various polymorphic states, spherical oligomers of
various diameters, and linear and annular protofibrils.

The word ‘amorphous’ is

sometimes applied to protein aggregates that do not easily fit into previously described
definitions or exist in highly variable structures or which maintain their native-like state
in the aggregate. Proteins capable of making amyloid fibrils are often also capable of
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making other aggregate morphologies, and it is frequently assumed – but rarely if ever
proved – that there are precursor-product relationships between these forms.
In 1996, Wood and colleagues discussed the effects of pH on the ability of the
amyloid beta peptide to form aggregates [Wood et al. 1996]. Their results demonstrated
that aggregates grown at physiologically relevant pH (7.4) exhibit characteristics of
standard amyloid fibrils, i.e. a high affinity for Congo red, possessed twists along the
longitudinal axis, were approximately 100 Å in width, as evidenced by EM, and were
excellent seeds for fibril elongation. In contrast, aggregates produced at a more acidic pH
(5.8) did not bind CR, were thicker and shorter (Figure 1.3), and were also poor seeds for
further fibril formation.
In another example, IAPP (a 37aa peptide associated with the amyloid found in
patients with Type II diabetes), amorphous aggregates were observed to form in vitro via
EM from a full-length synthetic human IAPP peptide [Higham et al. 2000]. Within 24
hours, these structures had completely converted into amyloid fibrils, which were
confirmed not only by EM but also by ThT response, thus demonstrating the complicated
nature of fibril formation.
Within the last decade, new aggregate species have been identified. One of these
species was named protofibrils by the authors who first described them [Harper et al.
1997; Walsh et al. 1997]. Protofibrils are small, filamentous aggregates that appear early
in fibril formation reactions. Their role in the mechanism of mature amyloid fibril
assembly remains controversial, and may vary depending on the peptide involved [Kodali
and Wetzel 2007]. Protofibrils are different from protofilaments, which are the actual
11
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B

Figure 1.3: Electron micrographs of Aβ aggregates. (Images taken from [Wood,
Maleeff et al. 1996]). (A) pH 7.4 Aβ(1-40) fibrils. 230µM peptide was incubated for 48
hours at 37°C in phosphate buffered saline. (B) pH 5.8 Aβ(1-40) aggregates. 230µM
peptide was incubated for 48 hours at 37°C in 50mM 2-(N-morpholino)ethanesulfonic
acid (Mes).
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components of mature fibrils and not intermediates observed during fibril assembly.
Some protofibrils are annular in shape, and this has suggested a particular hypothesis for
their cytotoxicity [Harper et al. 1997; Walsh et al. 1999; Lashuel et al. 2002].
Another recently described aggregate is the class called spherical oligomers
[Kayed et al. 2003]. These are sometimes referred to as ADDLs (Aβ diffusible ligands)
[Lambert et al. 1998] or Aβ56* [Cheng et al. 2007]. The presence of various kinds of
small, non-fibrillar Aβ aggregates in vivo has also been described [Roher et al. 1996;
Cleary et al. 2005]. Oligomers and protofibrils have been identified in vitro in a host of
protein systems, such as β-amyloid [Harper et al. 1997; Walsh et al. 1997; Kheterpal et
al. 2003; Williams et al. 2005], α-synuclein [Conway et al. 2000], transthyretin [Quintas
et al. 2001], polyGln proteins [Poirier et al. 2002], β2-microglobulin [Gosal et al. 2005],
and immunoglobulin light chain [Ionescu-Zanetti et al. 1999]. Although they have a
distinct, non-amyloid morphology, some oligomers/protofibrils give a ThT response and
have significant β-structure (but not so much as mature fibrils) [Kodali and Wetzel 2007]
(See Figure 1.4). The identification of such species has led to the idea that these smaller
structures are responsible for the toxicity observed in neurodegenerative disorders
[Conway et al. 2001; Klein et al. 2001; Bucciantini et al. 2002; Walsh et al. 2002;
Schaffar et al. 2004; Malisauskas et al. 2005; Glabe and Kayed 2006]
Although it is well documented that protofibrils exist, a question remains whether
they are “on-pathway” [Harper et al. 1999; Serio et al. 2000; Plakoutsi et al. 2005;
Ellisdon et al. 2006] or “off-pathway” [Collins et al. 2004; Gosal et al. 2005]
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A

B

Figure 1.4: Electron micrograph images of Aβ arctic mutant protofibrils and fibrils.
(Images adapted from [Kheterpal et al. 2003]). (A) Aβ arctic mutant protofibrils obtained
16 hours post-incubation at room temp. (B) Negatively stained electron micrograph of
mature Aβ arctic fibrils. The arctic mutant is an Aβ peptide mutation at E22G that is
responsible for an early onset familial Alzheimer’s disease.
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intermediates during the formation of fibrils. Several experiments conducted support both
hypothesis (reviewed in [Kodali and Wetzel 2007]).
A particular example supporting an “on-pathway” role of oligomers in fibril
formation was demonstrated in a yeast prion model [Serio et al. 2000; Serio et al. 2001]
where the Lindquist group showed that fluid oligomeric intermediates underwent a
“conformational conversion” upon association with the nucleus. Once the interaction had
been established, rapid assembly of an amyloid fibril ensued. Other evidence for “onpathway” fibril formation was demonstrated in the protein α/β acylphosphatase in
Sulfolobus solfataricus [Plakoutsi et al. 2005] where early, enzymatically active
aggregates were observed that had secondary structure but did not exhibit any β-structure
by circular dichroism (CD) or fourier transform infrared spectroscopy (FTIR). As time
progressed, these aggregates slowly converted to more amyloid-like structures: loss of
enzymatic activity, contained extensive β-sheets, and were ThT and CR positive.
Transmission EM also revealed that these latter aggregates contained structures
reminiscent of spherical oligomers and protofibrils.
Two other pieces of evidence that suggest that oligomer/protofibrils are “onpathway” intermediates come from polyglutamine diseases: Machado-Joseph Disease
(MJD) [Ellisdon et al. 2006] and Huntington’s disease (HD) [Poirier, Li et al. 2002]. In
the first example, MJD, it was shown that the ataxin-3 protein formed fibrils through a
two-step mechanism [Ellisdon, Thomas et al. 2006], and that fibril formation was
nucleation-dependent [Ellisdon et al. 2007]. The first step involved the formation of a
protofibril within the Josephin domain of the protein, and the second step involved the
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conversion of the protofibril to a fibril. In the second example, HD, it was demonstrated
that recombinant htt exon-1 fragments can be induced in vitro to form aggregates similar
to the spherical oligomers and protofibrils described in other amyloid systems [Poirier et
al. 2002; Wacker et al. 2004]. As in other amyloid systems, however, the mechanistic
interrelationships between these various aggregated states and their possible roles in
pathogenesis have not been established with certainty.
Contrastingly are the reports of oligomer/protofibrils being formed “off-pathway”
[Collins et al. 2004; Gosal et al. 2005]. The Weissman group performed kinetic studies
that showed, in a yeast prion model, that amyloid formation occurred from monomer
addition to a nucleus and that this pathway was separate and competitive with the
formation of potentially toxic oligomers [Collins et al. 2004]. Other evidence supporting
an “off-pathway” mechanism was demonstrated in vitro by the use of a recombinant β2M
protein [Gosal, Morten et al. 2005] where two competing pathways were observed: a
nucleation-dependent pathway leading to amyloid fibril formation and a rapid,
nucleation-independent pathway yielding flexible “worm-like” fibrils.
As suggested in a current study, the aggregation pathway, not surprisingly, may
involve the formation of both “on-” and “off-pathway” intermediates [Thakur
unpublished data]. In recent years it has become increasingly clear that the sequences
flanking the polyGln region are very important in modulating aggregation. For example,
it has been shown that the polyproline region, C-terminal to the Gln stretch, alters the rate
of aggregate formation and destabilizes the aggregate but does not change the
aggregation mechanism, i.e. aggregation still occurs in a nucleation-dependent
16

mechanism [Bhattacharyya et al. 2006]. More recently, the effects of the first 17 aa on htt
aggregation have also been explored [Rockabrand et al. 2007; Thakur unpublished data].
Our group has found that the presence of htt’s first 17 aa rapidly accelerates polyGln
aggregation, alters the aggregate morphology, and changes the aggregation mechanism
(non-nucleated) [Thakur unpublished data]. For example, at least four morphologically
different aggregates are formed. The earliest species appear to be recruitmentincompetent oligomers/protofibrils, while the later species that are formed are
recruitment-competent fibrils (reminiscent of the fibrils produced from synthetic peptides
containing only polyGln or polyGln and polyproline). The mechanistic relationship
between the various types of aggregates is not clear; however, the data suggest that some
of the observed aggregates may be “on-pathway”, while other species may be “offpathway”.
The exact role(s) that oligomers, “off-pathway” aggregates, and protofibrils play
in disease pathogenesis is contentious and unresolved. As alluded in the previous
paragraph, perhaps, there are multiple pathways by which amyloid fibrils can form, some
directly producing amyloid from monomers, and some involving on-pathway
intermediates like protofibrils. Some may involve toxicity, while others do not. Indeed,
accessibility to these pathways may even be protein specific. Further research is needed
to address these critical questions.
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1.2 Polyglutamine diseases:
OVERVIEW
The term neurodegenerative disease refers to any condition in which brain and/or
spinal cord cells die or become dysfunctional.

These diseases are comprised of a

multitude of illnesses involving, but not limited to, dementia and/or the loss of motor
skills (ataxia). In the early 1990s, it was found that the expansion of an unstable
trinucleotide repeat was associated with several related neurological disorders [Fu et al.
1991; La Spada et al. 1991; Fu et al. 1992]. To date, at least 15 neurological disorders
ranging from Huntington’s disease to forms of mental retardation occur due to a triplet
codon (trinucleotide) expansion (Table 1.2). Each of the trinucleotide repeat disorders
can occur in either the coding exon sequences (such as in the polyglutamine repeat
diseases), spliced out of the intron sequences (such as in Friedreich’s ataxia), or in the 5’
or 3’ untranslated regions (as found in fragile X syndrome or myotonic dystrophy). A
summary of these gene mutations are shown in Figure 1.5. Each mutation confers a
different toxic effect, which will be discussed later in the chapter.
Of these trinucleotide repeat disorders, at least nine are caused by an expansion of
a polyglutamine sequence (polyGln) within their respective proteins (Table 1.3), with
Huntington’s disease (HD) being the most common in the population. The remaining
CAG repeat diseases are spinobulbar muscular atrophy (SBMA), dentatorubralpallidoluysian atrophy (DRPLA), and the spinocerebellar ataxias (SCA) 1, 2, 3, 6, 7 and
17.
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Table 1.2: Trinucleotide repeat disorders.
Triplet expansion
Disease

Clinical features upon expansion
Normal

Fragile X syndrome
(FRAXA)
Fragile XE mental
retardation (FRAXE)
Friedreich’s ataxia
(FRDA)

(CGG)n
6-60

4-39

6-32

Huntington diseaselike 2 (HDL2)

200, 1700

50-10,000
(CGG)n
60-200
(CTG)n

16-34

> 74
(CTG)n

7-28

66-78
(CAG)n

SCA12
7-45
Polyglutamine repeat
diseases (CAG)

Mental retardation

(CTG)n

6-60

Mental retardation, enlarged testes,
connective tissue defects,
behavioral abnormalities

200-900
(GAA)n

5-37

Spinocerebellar ataxia
8 (SCA8)

> 200
(CCG)n

Myotonic dystrophy
(DM1)

Fragile X-associated
tremor ataxia
syndrome (FXTAS)

Pathological

Sensory ataxia, cardiomyopathy,
diabetes
Myotonia, weakness, cardiac
conduction defects, insulin
resistance, cataracts, testicular
atrophy, and congenital mental
retardation
Ataxia, tremor, Parkinsonism,
dementia
Ataxia, slurred speech, involuntary
eye movements
Chorea, dystonia, cognitive deficits,
psychiatric problems (similar to
HD)
Ataxia, seizures

55-78
(CAG)n

Various

Varies per disease
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TAA

ATG

5’

3’

(CGG)n
(CCG)n
(CAG)n

(CAG)n

(GAA)n

Friedrich’s ataxia
Fragile X syndrome
FRAXE
FXTAS
SCA12

(CTG)n

Myotonic dystrophy

Huntington’s disease
DRPLA
SMBA
SCA1
SCA2
SCA3
SCA6
SCA7

Figure 1.5: Gene location of trinucleotide expansions. Green represents the start codon
(ATG) at the beginning of an exon (gray). Red is representative of a stop codon (TAA)
signaling the end of the coding region. The purple areas represent untranslated regions,
and the dark blue represents non-coding intron regions. Huntington’s disease-like 2 (SCA
12) is not shown; however, the mutation occurs in a non-coding spliced exon of the
junctophilin 3 gene.
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Table 1.3: Polyglutamine neurodegenerative diseases.
Disease

Gene
locus

CAG repeat length
Normal

Pathological

Clinical features upon
expansion

Spinobulbar
muscular atrophy
(SBMA) –
Kennedy’s
disease

Xq13-21

9-36

38-62

Motor weakness,
swallowing, male breast
enlargement, decreased
fertility

Huntington’s
disease (HD)

4p16.3

6-34

36-121

Chorea, dystonia, cognitive
deficits, psychiatric
problems

39-82

Ataxia, slurred speech,
spasms, cognitive
impairments

Spinocerebellar
ataxia 1 (SCA1)

6p23

6-44

SCA2

12q24.1

15-31

36-63

Ataxia, polyneuropathy,
decreased reflexes, infancy
variant with retinopathy

SCA3 –
Machado-Joseph
Disease (MJD)

14q32.1

12-41

62-84

Ataxia, Parkinsonism,
spasms

SCA6

19p13

4-18

21-33

Ataxia, difficulty in
articulating, involuntary
eye movements, tremors

SCA7

3p12-21.1

4-35

37-306

Ataxia, blindness, infancy
variant with cardiac failure

SCA17

6q27

25-42

47-63

Ataxia, cognitive decline,
seizures, psychiatric
problems

Dentatorubralpallidoluysian
atrophy (DRPLA)

12p13.31

6-36

49-84

Ataxia, seizures,
choreoathetosis, dementia
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For these expanded CAG repeat diseases, longer repeat expansions lead to earlier
ages of onset and increased disease severity (Figure 1.6) [Gusella and MacDonald 2000].
In the remainder of this chapter, the polyGln diseases will be discussed with a particular
emphasis on Huntington’s disease, the proposed mechanisms of cell dystrophy, and the
model systems that have been created in order to study these devastating diseases.

POLYGLUTAMINE DISEASE CHARACTERISTICS
There are many similarities and differences among the various polyglutamine
diseases. This section will summarize some of the characteristics found among these
diseases. For instance, all of the polyglutamine diseases, except spinobulbar muscular
atrophy (SBMA), which is X-linked recessive [Belsham et al. 1992; Ferlini et al. 1995],
are dominantly inherited [Wilmot 1998]. Also the diseases generally occur during midlife and are progressive (see review by [Fischbeck 2001]), causing neuronal dysfunction
and eventually neuronal death [Ross 1995; Taylor et al. 2002; Bates 2003]. The
instabilities observed in these diseases occur in both germline and somatic cells
(reviewed by [Bates 2002]). Especially in the case of HD, DRPLA, SCA1, and SCA3,
somatic instabilities are generally higher in the central nervous system than in peripheral
tissues [Telenius et al. 1994; Chong et al. 1995; Ueno et al. 1995; Lopes-Cendes et al.
1996; Tanaka et al. 1996; Hashida et al. 1997; Cancel et al. 1998]. As repeat length
increases, the disease progresses more rapidly and onset appears earlier (see review by
[Gusella and MacDonald 2000]).
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Age of onset
B

Disease severity
of penetrance
B

AG
GA

Repeat expansion

B

Figure 1.6: Observed inverse correlation between trinucleotide repeat expansion
and age of onset. (A) The longer the glutamine repeat the more complete penetrance and
earlier onset. (B) Data compiled from the literature (Figure and Legend from [Gusella and
MacDonald 2000]) were used to calculate the mean age at onset (denoted by ‘+’)
associated with various CAG repeat lengths and the best-fit curve (denoted by a smooth
line), using a simple exponential decay model for the relationship, in each of the
polyglutamine disorders. The age of onset of homozygotes for the various disorders is
also shown (filled circles), plotted according to the longer of their two expanded CAG
repeats. (DRPLA, dentatorubropallidoluysian atrophy; HD, Huntington’s disease; MJD,
Machado-Joseph disease; SBMA, spinal and bulbar muscular atrophy; SCA,
spinocerebellar ataxia.)
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Interestingly, the proteins produced in each disease are expressed ubiquitously
throughout the brain and other tissues; however, only a subset of neurons appear to be
affected (Figure 1.7 for selective summary) [Young 1998; Bates 2002]. Some of the
diseases share overlap of the affected regions; however, there are also differences in the
areas attacked. Table 1.4 summarizes the proteins produced, the cells affected and the
area(s) of the cell where detectable aggregates accumulate. Similar pathological
thresholds are observed for the CAG repeat disorders (~35-40 Gln repeats), excluding
SCA-6, which has a slightly lower threshold [Bates 2002]. Because of these very similar
expansion-threshold lengths, a common pathogenic mechanism involving the polyGlnrich region has been suggested for these disorders [Cha and Dure 1994; Paulson and
Fischbeck 1996].
Another major characteristic shared by the polyGln disorders is the formation of
insoluble nuclear and/or cytoplasmic aggregates, which exhibit a fibrillar morphology
[DiFiglia et al. 1997] and can be detected with antibodies to the disease protein [Davies et
al. 1997; Scherzinger et al. 1997], ubiquitin, or polyGln (1C2). 1C2 is an antibody that
was originally raised against TATA binding protein (TBP) and selectively recognizes
polyGln stretches on Western blots [Trottier et al. 1995].
As mentioned in the preceding section, expansion of the polyglutamine sequence
in the CAG trinucleotide diseases occurs in the coding region of the genes, resulting in
the transcription and translation of the gene into the protein product, which then becomes
misfolded and prone to aggregate. It is widely accepted that the mechanism by which the
polyGln expansion causes diseases is by imparting a toxic “gain of function” (GOF)
24

Figure 1.7: Depiction of the brain pathology in five of the polyGln diseases. Darker
shaded areas represent severe pathology where the lighter shaded areas indicate varying
degrees of intermediate pathology. (Image taken from [Bates 2002]).
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Table 1.4: Polyglutamine localization.
Disease

Protein product

Expanded protein
localization

Affected cells

SBMA

Androgen receptor
(AR)

Nuclear /
cytoplasmic

Anterior horn and bulbar
neurons, dorsal root
ganglia, brainstem

HD

Huntingtin (htt)

Nuclear /
cytoplasmic

Striatum, cerebral cortex,
caudate-putamen, globus
pallidus, hippocampus,
thalamus

SCA1

Ataxin-1 (At1)

Nuclear /
cytoplasmic

Cerebellar Purkinje cells,
dentate nucleus, inferior
olive, brainstem

SCA2

Ataxin-2 (At2)

Cytoplasmic

Cerebellar Purkinje cells,
brainstem, fronto-temporal
lobes, substantia nigra,
inferior olive and pons

SCA3 –
MJD

Ataxin-3 (At3)

Nuclear /
cytoplasmic

Cerebellar dentate neurons,
basal ganglia, brainstem,
spinal cord

SCA6

Calcium channel
(CACNAIA)

Cytoplasmic/ cell
membrane

Cerebellar Purkinje cells,
dentate nucleus, inferior
olive, cerebellar granule
cells

SCA7

Ataxin-7 (At7)

Nuclear /
cytoplasmic

Cerebellum, brainstem,
macula, visual cortex,
inferior olive

TATA box-binding
protein (TBP)

Nuclear

Caudate nucleus, putamen,
thalamus, frontal cortex,
temporal cortex, Purkinje
cells

Atrophin (drplap)

Nuclear /
cytoplasmic

Cerebellum, cerebral
cortex, basal ganglia, Luys
body (subthalamic nucleus)

SCA17

DRPLA
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mutation to the affected protein [Wilmot 1998; Bates 2002] that increases with longer
Gln repeats [Ross 1997; Klockgether and Evert 1998; Evert et al. 2000]. Evidence
suggests that the gain of function is the ability of the protein to access a non-native state
that is toxic to neurons. Supporting evidence for this discovery was presented by Ordway
and

colleagues

who

demonstrated

that

in

an

unrelated

protein,

hprt

(hypoxanthine/guanine phosphoribosyltransferase), which exhibited an abnormal CAG
expansion of 150 repeats, the polyGln tract was directly responsible for generating a
similar late-onset, progressive, neurodegenerative disorder [Ordway et al. 1997]. This
suggested that the polyGln tract was responsible for causing neuronal dysfunction and
subsequent neurodegeneration and that the protein context played a role in defining other
characteristics of the disease. Some groups interpret their data as indicating that toxicity
is caused not by a gain of function but by the loss of normal protein function (LOF); this,
however, is a much less widely-accepted theory [Zhuchenko et al. 1997; Cattaneo et al.
2001; Katsuno et al. 2004].

COMMON AMYLOID FEATURES
Polyglutamine proteins possess many of the same features as other amyloidogenic
proteins (see Figure 1.8). Polyglutamine aggregates formed at 37°C have been shown to
exhibit fibrillar morphology by EM that is comparable to an amyloid fibril [Scherzinger
et al. 1997; Thakur and Wetzel 2002]. Earlier studies revealed huntingtin aggregates
expressed in patient brains exhibited an apple green birefringence when stained with
Congo red and examined using polarized light microscopy [Huang et al. 1998; McGowan
et al. 2000], while other groups have found htt inclusions to be CR negative
27
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Figure 1.8: Common amyloid features exhibited by polyglutamine peptides/proteins.
(A) Electron micrographs of Q37 synthetic aggregates grown in PBS at 37 °C. (B) Aβ(140) fibrils grown in PBS at 37 °C. A Hitachi 500 electron microscope was used to obtain
images. Samples were adsorbed onto mica grids and stained with 0.05% potassium
phosphor-tungstate (KPTA) solution. (Adapted from [Chen et al. 2002].) (C) Congo red
birefringence of isolated Huntington’s disease frontal cortex. (D) Congo red
birefringence of Alzheimer’s disease frontal cortex. C,D images were obtained via crosspolarizers and light microscopy. (Taken from [Huang et al. 1998]). Both types of images
represent the fibrillar morphology and presence of cross β-sheets.
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[Karpuj et al. 1999]. However, other data has shown that many aggregates generated
from a synthetic polyglutamine peptide, while efficient in binding Congo red, are much
less efficient in displaying the green birefringence seen in other amyloid fibrils [Chen,
Berthelier et al. 2002]. Polyglutamine aggregates (synthetic, fusion, or natural) also
exhibit a ThT response [Chen et al. 2002; Ellisdon et al. 2006]. Another commonality
between aggregates of simple polyGln peptides and other amyloid fibril systems is the
presence of a lag phase during fibril growth (see above) (Figure 1.9) that can be
shortened or eliminated by the addition of pre-formed fibrillar seed [Chen et al. 2002;
Thakur and Wetzel 2002; Bhattacharyya et al. 2005]. Amyloid-like character is also
suggested by the microstructure EMs of neuronal inclusions [DiFiglia, Sapp et al. 1997]
and the abilities of aggregates in brain tissue and transformed cells to recruit monomeric
polyglutamine molecules [Osmand et al. 2006]. Finally, the most important similarity is
that polyglutamine aggregates also exhibit a cross-β structure, which is the hallmark of all
amyloid proteins (Figure 1.10) [Perutz et al. 1994; Thakur and Wetzel 2002; Sharma et
al. 2005].

HUNTINGTON’S DISEASE
Huntington’s

disease

(HD)

is

a

progressive

autosomal

dominant

neurodegenerative disorder that was first characterized in the late 1800s by Dr. George
Huntington and is the most common of the nine CAG repeat diseases. Dr. Huntington
published the seminal manuscript entitled On chorea [Huntington 1872] in 1872 that
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Figure 1.9: Polyglutamine nucleation-dependent polymerization by monomer
addition. ([Bhattacharyya et al. 2005]) An unfavorable folding event (nucleation) occurs
with monomeric polyGln. Elongation occurs after an initial binding step to an extended
conformational monomer. Subsequent monomer additions to the altered conformation
result in elongation.

A
B

Figure 1.10: Proposed structural models for polyglutamine proteins are comparable
to amyloid proteins. (A) Computer-generated structure of two paired anti-parallel βstrands of polyGln linked together by main chain and side chain hydrogen bonds. (Taken
from [Perutz, Johnson et al. 1994]). (B) β-sheet β-turn model of expanded polyGln. Light
blue – carbon, dark blue – nitrogen, red – oxygen. (Taken from [Ross et al. 2003]).
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described the clinical manifestation of an illness (“hereditary chorea”) he observed
among three families residing in New York. Patients with the illness were described as
having involuntary, jerky movements (chorea) and significantly retarded voluntary
movements (bradykinesia), combined with cognitive impairment, and which had adult
onset and an advancing development that was eventually fatal.

He also noted the

hereditary nature of the disease. Among people of European descent, the prevalence of
the disease is 3-4 per 100,000 people, and it’s estimated that another 15-30 out of
100,000 of the Caucasian population are at risk of developing the disease [Harper 2002].
In 1983, the HD gene (interesting transcript, IT15) was mapped near the vicinity
of a DNA marker, D4S10, located on chromosome 4p16.3 [Gusella et al. 1983]. The
gene contains 67 exons and spans ~180 kb (Figure 1.11). After 10 years of research, the
genetic defect responsible for HD was found to be localized in the first exon of the IT15
gene, which encodes a 350-kDa protein, huntingtin [Group 1993]. The disease-causing
mutation is the expansion of an unstable, polymorphic CAG trinucleotide repeat within
exon 1 of the HD gene. This CAG repeat (found in the N-terminus) translates into a
polyGln tract that is expressed in the huntingtin (htt) protein. Located just downstream of
the polyGln region there is also a proline-rich stretch containing approximately 21
prolines.

The

sequence

of

htt

exon

1

is

MATLEKLMKAFESLKSF(Q)n

(P)11QLPQPPPQ AQPLLPQPQ(P)10GPA VAEEPLHRPKK. As discussed above for
expanded CAG repeat diseases in general, polyGln repeat length is directly correlated to
disease severity [Gusella and MacDonald 2000]. People who have a repeat length of
<Q35 do not develop the disease; whereas, people who have >Q40 will invariably develop
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Figure 1.11: Structure of HD gene and translated protein.
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HD (See Figure 1.6 and 1.12). There is an ambiguous CAG repeat length, 36-40, where
some people develop the disease and others do not [Myers 1998]. As with the other
polyGln diseases, there is an inverse correlation between repeat length and age of onset,
where the longer the CAG repeat, the earlier the age of onset [Duyao et al. 1993] (see
Figure 1.6).

CHARACTERISTICS OF NORMAL AND EXPANDED HUNTINGTIN
Huntingtin is a highly conserved protein that is expressed throughout the body
and which has no functional homology to any known protein. However, it has been
shown that wildtype htt plays important roles in embryonic development including
gastrulation [Duyao et al. 1995; Nasir et al. 1995; Zeitlin et al. 1995; Dragatsis et al.
1998], neurogenesis [White et al. 1997; Reiner et al. 2003], and formation of
extraneuronal tissue [Dragatsis et al. 1998]. In recent years, there has been growing
evidence that normal htt is also involved in RNA biogenesis [Faber et al. 1998; Boutell et
al. 1999; Passani et al. 2000; Takagaki and Manley 2000; Strehlow et al. 2007],
membrane association and vesicle/protein trafficking [Li et al. 1995; Kalchman et al.
1997; Wanker et al. 1997; Truant et al. 2006; Truant et al. 2007], and iron homeostasis
[Hilditch-Maguire et al. 2000].
Even though htt is ubiquitously expressed, the only known pathological changes
that occur in HD are specific to the brain and are characterized by selective neuronal
degeneration and loss [Ross 1995; Huq 1998; Bates 2002]. The most striking atrophy
occurs in the caudate nucleus and putamen, which together form the neostriatum within
the basal ganglia. A secondary effect due to caudate atrophy is an enlargement in the
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Figure 1.12: Distribution of HD CAG repeat lengths on normal and HD chromosomes. Histogram plot of HD CAG repeat
sizes found on the1212 normal chromosomes (black bars) and 1212 HD chromosomes (red bars), from the same individuals,
largely of western European ancestry [MacDonald personal communication].
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lateral ventricles. Other than these major affected areas, there is 10-20% overall
deterioration of the brain.

The reduction occurs in the cerebral hemispheres, the

cerebellum, the brainstem, the diencephalons, and the spinal cord [Forno 1979].
Loss of neurons in both the putamen and caudate show a gradient correlating to
disease progression [Bruyn 1979; Roos et al. 1985; Vonsattel et al. 1985; Myers et al.
1988; Heinsen et al. 1994]. To determine the severity of neurodegeneration, a grading
scale of 0 to 4 (mild to severe), based on microscopic and gross deterioration of the basal
ganglion, was created so that a patient could be graded semiquantitatively on the severity
of the disease (Figure 1.13) [Vonsattel et al. 1985; Myers et al. 1988]. Also, there is a
severe loss in the medium-sized spiny neurons (MSNs) but a preservation of the large
striatal neurons [Cicchetti et al. 2000]. MSNs are inhibitory projection neurons that
encompass more than 95% of the neuronal cells in the striatum and use γ-aminobutyric
acid (GABA) as their neurotransmitter. Other than the basal ganglion, the next most
severely affected region is the cerebral cortex, with the greatest loss in layer VI and
significant loss in layers III and V [de la Monte et al. 1988].
At the subcellular level, normal length huntingtin is most often localized in the
cytoplasm as a soluble protein; however, aggregates arising from the expanded form are
often found in the nucleus as well as the cytoplasm. As mentioned previously, the
expanded protein accumulates into insoluble, fibrillar aggregates [Davies et al. 1997;
Scherzinger et al. 1997] that primarily contain N-terminal htt fragments that leads to
pathology [DiFiglia et al. 1997; Sapp et al. 1997; Gutekunst et al. 1999]. A hallmark of
HD is the appearance of protein aggregates as neuronal intranuclear inclusions (NII)
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A

B

C

D

Figure 1.13: Huntingtin accumulation causes neurodegeneration of the brain. (A)
Normal brain section of the caudate nucleus, nucleus accumbens, and putamen. (B-D)
Progressive neuronal loss of HD patients’ brain sections as graded via the Vonsattel
method. (B) early HD grade 2, (C) mid HD grade 3, (D) late HD grade 4. (Images taken
from [Myers 1998].)
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[Davies et al. 1997; DiFiglia et al. 1997; Gutekunst et al. 1999; Sieradzan et al. 1999;
Wheeler et al. 2000].

NII have been found in the MSNs of the striatum but are most

prevalent in the large striatal neuron, which do not undergo neurodegeneration
[Kuemmerle et al. 1999]. Moreover, NII are rarely observed in neurons of the globus
pallidus and cerebellum [Gutekunst et al. 1999]. In general, NIIs range from 3 – 5µm in
diameter and generally adopt one of two shapes: the majority are spherical (55%); while
the remainder are elliptical (ovoid) [DiFiglia et al. 1997; Becher et al. 1998; Gutekunst et
al. 1999].
Other aggregated states of huntingtin, besides NII, have been described. Neuropil
aggregates (NA) localize in the white matter outside of discernable cell bodies and are
assumed to be located in the axons, dendrites, and synapses. They tend to be round to
oval in shape [DiFiglia et al. 1997; Gutekunst et al. 1999] and are typically larger than
NII. Both NII and NA have been shown to stain positively for ubiquitin (an indication
that the protein has been targeted for degradation [Alves-Rodrigues et al. 1998; Sieradzan
et al. 1999]) and CREB binding protein (CBP) (which also contains a polyGln tract and
therefore indicates that huntingtin inclusions can sequester other polyGln-containing
proteins) [DiFiglia et al. 1997; Preisinger et al. 1999; Nucifora et al. 2001]. Another class
of aggregates, often seen in conjunction with NII, is perikaryal aggregates. This type of
aggregate is generally smaller (0.3 – 1.5µm) than the NII and exhibit a round to oval
appearance [Gutekunst 2002]. However, these structures are found in a perinuclear
location [Huang et al. 1998; Heiser et al. 2000]. Each of these types of aggregates have
been shown to exihibit Congo red blue-green birefringence, again suggestive of an
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amyloid-like structure [McGowan et al. 2000]. In vitro data have shown that it is possible
to produce both detergent-soluble [Muchowski et al. 2000] and detergent-resistant htt
aggregates [Cooper et al. 1998; Kazantsev et al. 1999; Chen et al. 2001], with the latter
representing end-stage aggregates.
It has long been recognized that the aggregation and deposition of misfolded
proteins are the pathological hallmarks for many neurodegenerative diseases [Ross and
Poirier 2005]. However, the presence of these inclusion bodies correlate poorly with
other neurodegenerative characteristics [Terry et al. 1991; Tompkins and Hill 1997],
especially in HD [Gutekunst, Li et al. 1999], introducing questions about the role of
aggregates in the disease process. It has been hypothesized that inclusion bodies may
represent an end stage structure in a multi-step aggregation process [Ross and Poirier
2005] and that early events, including the formation of misfolded monomers [Weissmann
2005; Nagai et al. 2007] or soluble oligomeric/protofibrillar intermediates [Poirier et al.
2002; Bucciantini et al. 2004; Katsuno et al. 2004; Wacker et al. 2004; Mukai et al.
2005], which directly arise from the presence of an expanded polyGln sequence, may be
responsible for cellular toxicity. However, there is no consensus on what the toxic species
is, whether the intermediates are “on-pathway” or “off-pathway”, or the precise role of
aggregation in the disease mechanism.
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1.3 Disease Mechanisms in Huntington’s Disease:
OVERVIEW
Despite the fact that the genetic abnormality is well characterized, the underlying
mechanism of neurodegeneration in Huntington’s disease has not yet been unequivocally
elucidated [Ross et al. 1999; Ross 2002; Ross 2004; Bett 2006].

A schematic

representation of the proposed pathogenic mechanisms is shown in Figure 1.14. The
widely accepted view is that the HD mutation causes a toxic gain of function, where the
aberrant protein inherits additional properties that render it cytotoxic [Ross 1997; Wilmot
1998; Bates 2002]. Alternatively, there may be a loss of normal htt functionality that
results in neurodegeneration [Cattaneo et al. 2001]. In support of a loss of function
mechanism, huntingtin gene expression must be required for normal development, since
huntingtin knock-out mice die early in embryogenesis [Duyao et al. 1995; Jones 2002].
At the same time, several lines of evidence argue against loss-of-function being the major
disease mechanism. Patients homozygous for the HD mutation are not more severely
affected than patients who are heterozygous for the mutation [Wexler et al. 1987; Myers
et al. 1989], and a patient with only one viable copy of the normal polyGln length htt
gene did not develop HD [Ambrose et al. 1994]. Several gain of function hypotheses are
described in greater detail in this section.
Compounding the difficulty in identifying the toxic species is the critical issue of
establishing the nature of the cellular events that are associated with HD symptoms.
Should we be looking for overt cell death, or for more subtle sub-lethal dystrophic events
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Figure 1.14: Model representing modes of HD cellular pathogenesis. (Taken from
[Ross 2004]).
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that are more difficult to observe and quantify? The brain atrophy evident at autopsy is a
clear indication that cell death occurs during the development of HD, but does this
account for early symptoms or is it only an end-stage event? Is the loss of cell mass
really due to cell death or to cell shrinkage? Are there earlier events in HD progression,
such as synaptic loss and neurite retraction that are responsible for disruptions in
neuronal circuitry associated with abnormal motor neuron function? Clearly, identifying
and validating the molecular species responsible for HD requires a correct perspective on
the abnormal biology behind the disease symptoms and progression, and the lack of
certainty on these central questions contributes to our inability to define the key
molecular players.

EXPANDED HUNTINGTIN AGGREGATE FORMATION
Many researchers believe that some aspect of polyGln protein misfolding and
aggregation is an early, necessary event in HD pathogenesis. It has been shown that
directing the aggregate to the nucleus by introducing a nuclear localization signal (NLS)
causes cellular toxicity [Cooper et al. 1998; Hackam et al. 1999; Yang et al. 2002].
Furthermore, numerous experiments have demonstrated that a reduction in aggregate
burden can rescue neuronal damage [Yamamoto et al. 2000; Kazantsev et al. 2002]. In
contrast, several lines of evidence suggest that protein aggregation is not directly linked
to disease pathogenesis, in that aggregate burden does not always correlate well with cell
death [Cummings and Zoghbi 2000; Tobin and Signer 2000]. It is possible, however,
that good correlations are not always observed because the genuinely toxic aggregate
species are not observable or quantifiable. Furthermore, it is possible that htt inclusions
41

offer protection against neurotoxic effects by sequestering smaller, potentially more toxic
oligomers [Kopito 2000]. A number of mechanisms of aggregate toxicity have been
postulated, and these will be reviewed below. The strong indications of a central, early
role for htt aggregates in the disease mechanism argues for a closer look at the nature of
the aggregated species in the cell. In addition, regardless of their role in pathogenesis,
aggregates are a hallmark of HD and deserve attention on that basis alone.

TOXIC FRAGMENT HYPOTHESIS
One theory regarding the pathogenic mechanism of HD is the “toxic fragment
hypothesis”, which suggests that following proteolytic processing, full-length mutant htt
generates N-terminal fragments that accumulate and aggregate in the nucleus leading to
toxicity [DiFiglia, Sapp et al. 1997; Martindale et al. 1998; Saudou et al. 1998]. Fulllength htt contains several proteolytic cleavage sites within the first five exons (Figure
1.15) [Li and Li 2004], which are sensitive to caspase-3, calpain, and aspartic
endopeptidase cleavage. Caspases are enzymes that play essential roles in apoptosis and
inflammation. Calpains are a group of calcium-dependent cysteine proteases. Aspartic
endopeptidases are another class of intracellular proteases. Recently, it was shown that
mutation of two calpain cleavage sites in mutant htt renders the protein less susceptible to
proteolytic cleavage and reduces cell toxicity in an in vitro cell culture model [Gafni et al.
2004]. N-terminal mutant htt fragments have been shown to be more toxic in model
systems than their full-length protein counterpart [Hackam et al. 1998; Lunkes and
Mandel 1998; Martindale et al. 1998; Lunkes et al. 2002]. It has been proposed that the
generation of such htt fragments favors the formation and deposition of insoluble
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Figure 1.15: Proteolytic processing of full-length mutant huntingtin generates
polyGln expanded N-terminal htt fragments.
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aggregates in the nucleus [Lunkes and Mandel 1998; Martindale et al. 1998; Hackam et
al. 1999; Li et al. 2000]. This hypothesis, as far as it goes, accounts for the localization
of aggregates in the nucleus, but does not offer any clues to why aggregates might be
toxic. The remaining portions of this section deal with this issue.

TRANSCRIPTIONAL DYSREGULATION / RECRUITMENT-SEQUESTRATION
It is known that expanded htt aggregates can recruit proteins, such as certain
transcription factors and co-factors, in a polyGln-mediated manner (See Table 1.5)
[Davies, Turmaine et al. 1997; DiFiglia, Sapp et al. 1997; Scherzinger, Lurz et al. 1997;
Jiang et al. 2003], thus sequestering them and compromising their ability to function
normally.

This recruitment and sequestration provides an attractive mechanism for

cellular dysfunction. PolyGln-specific sequestration is likely mediated by the ability of
amyloid-like polyGln aggregates to highly selectively elongate via recruitment of other
polyGln sequences into the growing aggregate [Chen et al. 2001]. This model is the basis
of the recruitment-sequestration hypothesis. In the past decade, it has also become
increasingly clear that several transcriptional pathways are altered in mouse models of
HD as well as patients with Huntington’s disease [Cha 2000; Luthi-Carter et al. 2000;
Luthi-Carter et al. 2002], and recruitment of transcription factors is one mechanism by
which this might occur.
Two well characterized examples where polyGln-containing transcription factors
have been shown to be sequestered by htt aggregates will be discussed. In the first
example, TATA binding protein (TBP), an essential polyGln containing transcription
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Table 1.5: Huntingtin-interacting proteins.
Protein

Possible cellular role

Reference

TBP, CBP, and
p300/CBPassociated

Transcription factors. Colocalization with NIIs

[Huang et al. 1998; Boutell
et al. 1999; Kazantsev et al.
1999; Steffan et al. 2000;
Nucifora et al. 2001]

P53

Transcription factor. Repressed by
mutant N-terminal htt

[Steffan et al. 2000]

Nuclear receptor
co-repressor and
mSin3A

Transcriptional repressor complex.
Cellular localization altered in HD
brain

[Boutell et al. 1999; Jones
1999]

SP1 and TAFII130

Transcriptional activator and coactivator

[Dunah et al. 2002]

BDNF
HAP1

Neurotrophic factor required for
striatal neuronal survival
Cytoskeletal, microtubule, and
vesicle functions

[Zuccato et al. 2001]
[Li et al. 1995]

Cytoskeletal, microtubule, and
vesicle functions

[Kalchman et al. 1997;
Wanker et al. 1997;
Singaraja et al. 2002]

Caspase-3

Cytoskeletal, microtubule, and
vesicle functions
Apoptotic pathway

[Faber et al. 1998; Gusella
and MacDonald 1998]
[Goldberg et al. 1996]

HIP2

Ubiquitin-conjugating enzyme

[Kalchman et al. 1996]

GAPDH

Glycolytic enzyme

[Burke et al. 1996]

Cystathionine β
synthase

Amino acid metabolism

[Boutell et al. 1999; Jones
1999]

HIP1
α-Adaptin

Calmodulin
HYP A, B, and C

Intracellular calcium binding and
sensing
Non-receptor signaling, protein
degradation, and pre-mRNA
splicing. Interaction enhanced by
lengthening of polyGln tract
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[Bao et al. 1996]
[Faber et al. 1998; Passani
et al. 2000]

factor involved in the separation of double stranded DNA, was found to interact with
mutant N-terminal htt in a polyGln-dependent manner and was recruited into the
polyglutamine aggregates [Schaffar et al. 2004]. In vivo, TBP has also been shown to be
present in HD inclusions [Huang et al. 1998].
Secondly, cAMP response element (CRE)-regulated genes have been implicated
in HD pathogenesis [Wyttenbach et al. 2001; Sugars et al. 2004]. The cAMP response
element-binding protein (CREB) binds the CRE promoter, and upon phosphorylation,
recruits the polyGln-containing co-activator CBP. This is an essential process in genetic
transcription. It has been shown that CBP can be recruited into polyglutamine aggregates
in multiple model systems, as well as in HD patients [Kazantsev et al. 1999; Steffan et al.
2000; Nucifora et al. 2001]. Therefore it is easy to imagine how aberrant interactions with
such vital transcription factors can lead to cellular dysfunction. For example, it was
demonstrated that mutant N-terminal htt directly interacts with and inhibits the
acetyltransferase activity (responsible for histone acetylation) of CBP and p300/CBPassociated factor. Furthermore, the reduction can be reversed by treatment with histone
deacetylase (HDAC) inhibitors [Steffan et al. 2001; Bodai et al. 2003]. In an elegant
demonstration of the important role of CBP sequestration in cell death, the Ross group
showed that recruitment of endogenous CBP into exon1 aggregates killed cells, but that
over-expression of a CBP molecule lacking the polyGln stretch protects cells from this
recruitment, presumably by being impervious to recruitment and by providing the
functions of the recruited endogenous CBP [Nucifora et al. 2001].
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Another transcriptional pathway that has been shown to be dysfunctional in HD
involves the interaction of normal htt and repressor element 1 transcription factor–
neuron-restrictive silencer factor (REST-NRSF) [Boutell et al. 1999; Holbert et al. 2001;
Zuccato et al. 2001; Dunah et al. 2002], which is a transcriptional repressor responsible
for binding neuron-restrictive silencer elements (NRSEs) in the nucleus. This pathway is
implicated in the transcription of neuroprotective proteins such as brain-derived
neurotropic factor (BDNF) [Zuccato, Ciammola et al. 2001]. When htt becomes
expanded, it fails to bind properly, resulting in the accumulation of REST-NRSF in the
nucleus, and the transcriptional repression of genes regulated by NRSEs [Zuccato et al.
2003]. This further supports the hypothesis that mutant htt can interfere and dysregulate
normal transcriptional processes leading to pathology and ultimately toxicity.
The recruitment-sequestration mechanism is a favored explanation to describe the
interference of mutant htt in various transcriptional processes, where the expanded
protein is thought to play a role in recruiting vital proteins from their normal locations
and depositing them either in htt inclusions or other abnormal cellular locations thereby
rendering them unable to perform their normal functions. It is easy to imagine how these
interactions can contribute to cellular dysfunction.

TOXICITY DUE TO COMPROMISING PROTEIN QUALITY CONTROL
Chaperones
The dominating presence of htt inclusion bodies throughout brains of various HD
model systems suggests that the aggregated protein somehow escapes the many quality
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control systems within a cell. The first of those mechanisms is chaperone proteins.
Chaperone proteins are known to assist proteins in folding to their native conformations,
help to refold abnormally folded proteins, and to liberate proteins from an aggregated
protein in both normal and stress conditions [Hartl 1996]. Many molecular chaperones
are also heat shock proteins (Hsps), which are expressed in response to an environmental
stress [Lodish 2004]. Two major classes of molecular chaperones are Hsp70 and Hsp40,
which jointly act in an ATP-dependent manner to properly fold misfolded proteins [Bett
2006].
Chaperone proteins are often found localized within polyGln aggregates in HD
transgenic mice [Jana et al. 2000; Hay et al. 2004] as well as brains of patients with
polyGln diseases [Alves-Rodrigues et al. 1998; Cummings et al. 1998; Chai et al. 1999;
Schmidt et al. 2002]. These findings indicated that aggregated polyGln proteins were
recognized as misfolded, and therefore, much attention was given to understanding the
roles of molecular chaperones in the disease process. The two most studied chaperones in
HD are Hsp70 and Hsp40. Several studies have been performed in which these two
molecular chaperones were overexpressed [Cummings et al. 1998; Warrick et al. 1999;
Chan et al. 2000; Jana et al. 2000; Kobayashi et al. 2000; Sittler et al. 2001; Zhou et al.
2001]. The results indicate that the overexpression of the Hsp70 and Hsp40 combination
in cell cultures profoundly inhibited polyGln aggregation and that this correlated with a
decrease in cellular toxicity [Cummings et al. 1998; Jana et al. 2000; Kobayashi et al.
2000; Sittler et al. 2001; Zhou et al. 2001]. It was also shown that overexpression of
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Hsp70 in Drosophila suppressed neurodegeneration [Warrick et al. 1999], and the effect
was more dramatic when both Hsp70 and Hsp40 were overexpressed [Chai et al. 2001].
Another interesting observation was that Hsp40 and Hsp70, when expressed in
cell-free and yeast systems, altered the biochemical properties of mutant polyGln
proteins, rendering the aggregates more soluble than previously described as well as
delayed the formation of ordered-amyloid fibrils [Muchowski, Schaffar et al. 2000].
Furthermore, addition of the chaperones to in vitro polyGln aggregation reaction was
only effective when they were added during the lag phase, suggesting that chaperones
were most active on earlier forming species rather than the inclusions themselves
[Muchowski et al. 2000; Wacker et al. 2004]. Yet further data suggesting the importance
of molecular chaperones in the disease mechanism was provided by the Hartl group in
2004. They showed that in vitro the Hsp70/Hsp40 combination was effective in inhibiting
the negative interactions of expanded htt and TBP [Schaffar et al. 2004]. With the
substantial data presented, one can see the importance of molecular chaperones in HD.

Ubiquitin-Proteasome System
The ubiquitin-proteasome system (UPS) is responsible for regulating protein
turnover and is vital for many cellular processes, including differentiation, antigen
presentation, cell survival, cell cycle control, as well as the elimination of misfolded or
damaged proteins [Ciechanover 1994]. The proteasome is barrel-shaped multiprotein
complex that is responsible for the breakdown and clearance of short-lived nuclear and
cytosolic proteins as well as ubiquitin-tagged misfolded proteins [Ciechanover 2006].
Degradation by the UPS involves many successive steps. First, the misfolded proteins are
49

tagged for clearance by the covalent attachment of a polyubiquitin chain. This
conjugation is ATP-dependent and typically involves three enzymes: ubiquitin-activating
enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin-protein ligase (E3).
Together these enzymes compose the ubiquitin ligase system [Hershko and Ciechanover
1998; Taylor et al. 2002]. With the linkage of four or more ubiquitin molecules to the
substrate, a recognition signal is generated that allows the substrates to be shuttled to the
proteasome, via escort and chaperone proteins, where they are degraded [Hershko and
Ciechanover 1992; Jentsch 1992; Richly et al. 2005; Weihl et al. 2006].
HD inclusion bodies have been shown to be ubiquitinated, suggesting that the
UPS has targeted the aggregated proteins for degradation [Alves-Rodrigues et al. 1998;
Cummings et al. 1998; Chai et al. 1999; Sieradzan et al. 1999; Waelter et al. 2001]. Both
Hsp40 and Hsp70 chaperones have been shown to be involved in the clearance of
misfolded proteins via the UPS [Bercovich et al. 1997]. However, once the polyGlncontaining proteins have appreciably aggregated, they appear to be resistant to
degradation by the UPS [Cummings et al. 1999; Verhoef et al. 2002]. It has been
suggested that impairment may be a direct result of the misfolded polyGln proteins
getting ‘trapped’ within the proteasome [Jana et al. 2001; Holmberg et al. 2004] or the
inability of the proteasome to cleave between successive Gln residues [Goellner and
Rechsteiner 2003; Holmberg et al. 2004; Venkatraman et al. 2004], therefore limiting its
normal activity. However, data have shown that impairment of the proteasome can occur
in the absence of visible aggregates, suggesting other factors, such as the presence
soluble, potentially toxic species, also contribute to this impairment [Bennett et al. 2005].
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Other supporting evidence for the impairment of the UPS by polyGln aggregates
was provided by the Kopito lab, in which they used two non-related aggregating proteins
(Q103-GFP and CFTR-GFP) [Bence et al. 2001]. In both instances, they utilized a
fluorescence-based measurement for UPS activity, where higher fluorescence intensities
indicated a more severe disruption of UPS activity. In each case, protein aggregation led
to the accumulation of intracellular ubiquitin and, thus, cell cycle arrest. This impairment
yielded an increase in aggregate production, which was suggested, may result in the
increase of the ubiquitin conjugates [Mayer et al. 1989] and other UPS substrates that are
aberrantly expressed in diseased neurons [Raina et al. 2000]. Therefore, as more protein
accumulated, the UPS became more impaired.

Autophagy-Lysosome Pathway
Another commonly proposed mechanism by which aggregate-prone proteins are
removed is through the autophagy-lysosome pathway, which is induced by a stress
response. Autophagy is a process that involves bulk degradation of the cell’s own
components through encapsulation and enzymatic processing. There are three primary
forms of autophagy: macroautophagy, microautophagy, and chaperone-mediated
autophagy. Macroautophagy, typically referred to as autophagy, is the most common
form and occurs after an induction signal (often stress) when a flat membrane cistern
engulfs a portion of the cytoplasm, forming a double membrane vacuole
(autophagosome) [Williams et al. 2006]. After vacuole formation, the autophagosome
fuses with a digestive lysosome, which is responsible for the breakdown. Ultimately, the
breakdown products are returned to the cytoplasm [Klionsky and Ohsumi 1999;
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Stromhaug and Klionsky 2001; Mizushima 2004]. Microautophagy, which has been
characterized the least, involves the invagination of the lysosomal membrane to sequester
portion of the cytoplasm for degradation [Kim and Klionsky 2000]. Chaperone-mediated
autophagy, in contrast to the other two forms, is more selective and involves the direct
translocation of cytosolic proteins containing a specific pentapeptide sequence motif to
the lysosome [Massey et al. 2004].
Because it was demonstrated that aggregated htt is inefficiently degraded by the
UPS [Verhoef et al. 2002], it was proposed that the autophagy-lysosome pathway may be
responsible for the clearance of aggregated polyGln proteins [Qin et al. 2003; Ravikumar
et al. 2003; Webb et al. 2003; Iwata et al. 2005; Berger et al. 2006; Shibata et al. 2006].
Clearance by this pathway is proportional to polyGln repeat length, and wild-type
proteins are less susceptible to autophagy than the mutant form [Ravikumar et al. 2002;
Webb et al. 2003; Berger et al. 2006]. It was shown that inhibiting autophagy increased
the accumulation of aggregates thereby inhibiting the clearance of mutant htt [Qin et al.
2003; Ravikumar et al. 2004], and enhancing autophagy resulted in the more rapid
clearance of both soluble and aggregated species of expanded htt [Williams, Jahreiss et
al. 2006].

Aggresomes
When aggregated proteins are unable to be degraded or refolded by the normal
quality control mechanisms, the cells can sequester aggregates by a microtubulemediated process and transport them to a cytoplasmic site near the centrosomes [Johnston
et al. 1998; Ross and Poirier 2005]. These structures are referred to as aggresomes.
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Clearance of the aggresomes is often accomplished through autophagy. The protein
within an aggresome is largely surrounded by a structural protein known as vimentin
[Johnston, Ward et al. 1998]. Aggresome formation involves the trafficking of mutant
proteins and the rearrangement of intermediate filaments around the perinuclear inclusion
[Kopito 2000].
Data suggests that inclusion body formation, containing htt and molecular
chaperones, primarily occurs due to this inability to be degraded by the normal protein
quality control systems. It has been suggested that these inclusions, aggresomes, which
generally have a perinuclear location, are similar in structure to cystic fibrosis
transmembrane conductance regulator (CFTR) aggresomes [Johnston, Ward et al. 1998]
that occur when the proteasome’s degradative capacity is exceeded. Aggregates
expressed in transiently transfected cell models of HD have many characteristics
reminiscent of aggresomes [Qin et al. 2003]. Several groups have shown that inhibiting
microtubule polymerization inhibits the formation of aggresomes [Johnston et al. 1998;
Garcia-Mata et al. 1999; Webb et al. 2004]. One interesting possible mechanism of cell
dysfunction caused by aggregation involves the normal cellular trafficking of aggregates
to the perinuclearly located aggresome [Chang et al. 2006].

Thus, the inability of

mitochondria to be correctly trafficked through the neuronal processes along
microtubules, which are also involved in shuttling aggregates, could lead to energy
starvation at the synapse and synaptic retraction.
Whether or not the aggregates themselves are toxic remains to be answered.
However, a substantial amount of evidence has shown that aggregates are both handled
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by, and can impair, normal protein quality control mechanisms [Hartl 1996; Cummings et
al. 1998; Johnston et al. 1998; Chai et al. 1999; Jana et al. 2001; Waelter et al. 2001;
Ravikumar et al. 2002; Verhoef et al. 2002; Qin et al. 2003; Holmberg et al. 2004;
Schaffar et al. 2004]. It is therefore important to continue the search for the toxic species
and to investigate each of their roles in cellular dysfunction and death.

TOXICITY BY AXONAL TRANSPORT IMPAIRMENT
Another important development in unfolding the mystery of HD pathogenesis,
was the discovery that htt localizes with microtubules and synaptic vesicles suggesting a
role in vesicle trafficking by axonal transport [Gutekunst et al. 1995; Lee et al. 2004;
Webb et al. 2004; Gunawardena and Goldstein 2005; Truant et al. 2006]. Axonal
transport is a microtubule-dependent system that is responsible for the movement of
various cargo, such as mitrochondria, proteins, lipids, and synaptic vesicles, to and from
the cell body [Feany and La Spada 2003; Chang et al. 2006].
Pertinent to this idea, was the detection of two significant cytoskeletal associated
proteins that interact with htt, huntingtin-interacting protein (HIP1) and huntingtinassociated protein (HAP1) [Li, Li et al. 1995; Kalchman et al. 1997]. It has been reported
that mutant htt binds antagonistically to synaptic vesicles decreasing the association of
HAP1 resulting in a decrease in glutamate release in HD mouse brain sections [Li et al.
2003]. It was also shown that HIP1 has a decreased affinity for htt with expanded
polyGln suggesting that HIP1 and htt interactions may be crucial for cellular function
[Kalchman, Koide et al. 1997]. Data available on both of these interacting proteins
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suggest a loss of function mechanism and will not be further addressed in this
dissertation.
The presence of htt inclusion bodies are well documented in human HD patients
[DiFiglia et al. 1997; Gutekunst et al. 1999] as well as in various other models of HD
[Lunkes and Mandel 1998; Hollenbach et al. 1999; Kazantsev et al. 1999; Bates 2002;
Rubinsztein 2002; Bates 2003; Feany and La Spada 2003; Marsh et al. 2003; Thompson
and Marsh 2003; Gunawardena and Goldstein 2005; Chang et al. 2006]. Often these
inclusions are found associated with microtubules [Tukamoto et al. 1997; Muchowski et
al. 2002; Trushina et al. 2003; Webb et al. 2004; Iwata et al. 2005; Chang et al. 2006;
Truant et al. 2007], suggesting a role for the impairment of axonal transport in HD.
It has been shown that in a Drosophila model expressing N-terminal htt
fragments, inclusion bodies are formed in axonal processes and organelle accumulation is
also present, suggesting a blockage of axonal transport [Gunawardena et al. 2003], which
may be a direct result of the presence of the large aggregates and their ability to sequester
vital polyGln-containing proteins necessary for axonal transport [Lee et al. 2004]. It was
also recently shown, in a primary neuronal culture, that the presence of expanded htt
aggregates was responsible for impairing mitochondrial trafficking, causing an
accumulation of mitochondria, while aggregate-free sites were unaffected [Chang et al.
2006]. Thus, the concept of impaired axonal transport by the presence of htt inclusions
can undoubtedly be imagined.
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TOXICITY CAUSED BY EXCITOTOXICITY AND OXIDATIVE STRESS
It has also been suggested that calcium-dependent, glutamate-mediated
excitotoxicity plays a pivotal role in HD pathogenesis [Greene and Greenamyre 1996;
Tabrizi et al. 1999]. This mechanism will not be described in significant detail. Briefly,
this theory proposes that subpopulations of striatal neurons (MSNs) become sensitive to
glutamate release due mainly to changes in N-methyl-D-aspartate (NMDA) receptors
[Freese et al. 1990], which can be correlated to neuronal death [Olney et al. 1971].
There has been a tremendous amount of data that demonstrates mitochondria
dysfunction in HD (reviewed in [Lin and Beal 2006]). For example, htt has been shown
to be associated with mitochondria in both truncated and full-length mutant htt models
[Gutekunst et al. 1998; Panov et al. 2002; Yu et al. 2003; Choo et al. 2004], thus
suggesting another impairment of normal cell processes by the presence of these
inclusions.
This section has addressed the various mechanisms by which Huntington’s
disease pathogenesis is thought to occur. Some central questions surrounding HD are
whether or not the aggregated proteins are themselves toxic, if the aggregation process is
responsible for toxicity, or if early or later cellular events trigger dystrophy. While many
theories have been posed, the exact mechanism is still unknown and the toxic species
have not been identified. However, the disease mechanism is likely to involve several
factors and multiple pathways that ultimately lead to cellular dysfunction and death.
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1.4 Model Systems:
OVERVIEW
HD is a late-onset disorder, and therefore, the changes that are observed in the
patients’ brains are likely representative of late-stage pathological events or in
combination with some early-stage pathogenesis. However, the limited availability of
pre-symptomatic and early-stage HD patient material has made it difficult to study the
exact causes of neurodegeneration in situ. Considering HD lesions are localized in the
brain, tissue samples can only be feasibly obtained post-mortem. For these reasons, it was
important to develop alternative model systems that recapitulate the deleterious effects
seen in HD. With the identification in 1993 of the IT15 gene responsible for HD, it has
been possible to create both synthetic and genetic variations of the htt protein product.
Through the years, there have been many model systems created that include
virtually every phylum, including in vitro synthetic peptide models, cell and yeast
models, invertebrate models, and vertebrate models. Although there isn’t a perfect model
for HD, the hope is that collectively the information gained from each model will provide
new insights into the mechanism(s) of disease. The goal of this section will be to provide
a summary of the various model systems created and a brief synopsis of the results and
limitations associated with each.
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IN VITRO MODELS
The use of chemically synthesized polyGln peptides and recombinant fusion
proteins have been particularly important models for studying the biochemical,
biophysical, and structural characteristics of polyGln-containing proteins [Scherzinger et
al. 1997; Chen and Wetzel 2001; Wetzel 2005] because they bypass many complications
that can arise due to studying whole animal systems. In synthetic models, various length
polyGln peptides can be solubilized by exposure to disaggregating solutions, subjected to
ultracentrifugation in order to remove any small oligomeric species, and then
resuspended in physiological solutions [Wetzel 2005].
Aggregation kinetics and thermodynamics have been thoroughly studied in these
models, and a great deal of knowledge has been acquired about the folding properties of
these proteins as well. These accomplishments were made using various techniques, such
as ThT and Congo red birefringence, which shed light on the β-sheet structure of the
fibrillar protein [Scherzinger et al. 1997; Huang et al. 1998; Chen et al. 2002]. Dynamic
light scattering, which increases as particles increase in size and number, has been used to
measure the kinetics of aggregation; however, this method is generally used in
conjunction with one or more methods due to the problem of larger aggregates
dominating the signal [Lomakin et al. 1999].
Another important observation from in vitro models is the ability of polyGln
proteins to exhibit recruitment-competency [Berthelier et al. 2001; Berthelier and Wetzel
2003]. Data from in vitro models reveal that simple polyGln sequences can self-assemble
into aggregates and that this process is nucleation-dependent [Chen et al. 2001; Chen et
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al. 2002; Ross et al. 2003]. At the same time, studies on larger fragments that include
flanking sequences to polyGln indicate more complex aggregation mechanisms that
include initial rapid formation of amyloid-like aggregates [Ellisdon, Pearce et al. 2007] or
non-amyloid oligomeric aggregates (huntingtin; [Thakur] involving the flanking
sequences.

CELL MODELS
There have also been many yeast and mammalian cell models developed that have
had great impacts in the HD field. Such models are simpler than animal models but at the
same time, compared to in vitro models, allow a better understanding of how the
misfolded proteins behave in a more complex mixture of other cellular components.

Yeast model
Saccharomyces cerevisiae has often been used to explore the relationship between
polyGln aggregation and toxicity and other cellular components including chaperones.
Yeast models are relatively simple to generate and study and do not feature huge cell-tocell variations of the total proteome as is evident in mammalian cell culture models. Most
commonly these yeast models are designed to express variant htt exon 1 constructs. As
seen in other eukaryotic systems, the polyGln repeat length is directly correlated to
aggregate formation. While yeast cells do not appear to be actually killed by expanded
polyGln aggregates, their growth is retarded, and it is in this context that expanded
polyGln is said to be toxic in yeast.

After some confusion about the yeast strain

dependence of this toxic effect, it was shown that Rnq1, a yeast prion, is required for
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polyGln aggregation, which directly correlates with cellular toxicity, and that upon
deletion of Rnq1, aggregation and toxicity were both suppressed [Meriin et al. 2002].
The overexpression of both Hsp40 and Hsp70 have been found to attenuate polyGln
aggregation and alleviate cellular toxicity [Muchowski, Schaffar et al. 2000].
Interestingly, it has also been observed that the molecular chaperone Hsp104 is required
for polyGln aggregation [Krobitsch and Lindquist 2000], and upon its deletion, virtually
none of the detected protein is found in an aggregated form. A similar counter-intuitive
ability of Hsp104 to promote the formation of a yeast prion was described previously
[Schirmer and Lindquist 1997].
More recently, the role of the polyGln flanking sequences have been found to
have a profound influence on the toxicity in yeast associated with the protein [Dehay and
Bertolotti 2006; Duennwald et al. 2006; Duennwald et al. 2006]. Introduction of a htt
construct containing the proline-rich region of exon 1 creates morphologically different
aggregates, which are generally smaller than the well-described insoluble polyGln
aggregates [Dehay and Bertolotti 2006; Duennwald et al. 2006]. Next, deleting this
polyproline region slowed aggregate formation [Dehay and Bertolotti 2006]. Also, the
deletion of this region created a more insoluble aggregate compared to a construct that
includes the polyproline region. Furthermore, yeast expressing the proline flanking
sequences in htt exhibited less toxic effects than cells expressing a htt construct lacking
the proline-rich region [Dehay and Bertolotti 2006].

The ability of a proline-rich

sequence to suppress polyGln aggregation and weaken aggregate structure can also be
observed in vitro using simple polyGln peptides (Bhattacharyya et al 2006).
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Mammalian cell models
There have been a host of transient and stably transfected mammalian cell culture
models developed that constitutively or inducibly overexpress fusion proteins of either
truncated or full-length huntingtin DNA constructs (See Table 1.6 for a summary of the
various models and the major findings associated with each model) [Lunkes and Mandel
1998; Martindale, Hackam et al. 1998; Saudou, Finkbeiner et al. 1998; Li et al. 1999;
Preisinger et al. 1999; Sanchez et al. 1999; Wellington et al. 2000; Apostol et al. 2003;
Aiken et al. 2004]. In transient expression models, plasmid DNA is introduced into the
cells by various delivery methods, usually via a lipid-mediated carrier, and expression is
only detectible for up to one week. This effect is due to the fact that a majority of the
DNA introduced to the cells does not make it into the nucleus for transcription. The DNA
that manages to get into the nucleus becomes diluted with the dividing cells until it is no
longer observable. The transient effect is solely due to the lack of integration of the
plasmid DNA into the genome of the dividing cell line.
In contrast, stably transfected models depend on the recombination of a delivered
transgene into the model system’s genome. This technique involves introducing the
plasmid DNA, which spontaneously inserts itself into the genome of the model organism,
and selecting for this rare event by the use of drug resistance or a phenotypic alteration.
Once incorporation occurs, the transgene will replicate in synchrony with the dividing
cell, theoretically creating a stable, long-lasting genotype. Addition of an inducible
promoter to a stable transfectant creates a stable genotype in which transgene expression
is controlled by the addition or removal of an inducing (suppressing) agent.
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Table 1.6: Cellular models of Huntington’s disease.
Cell Line

Expression

Htt
fragment*

Findings

Reference

Cos-7,
SK-N-SH

Transient

Full-length
Q21, 72

Wildtype htt protective
against mutant htt

[Ho et al.
2001]

Cos-1

Transient

N-terminal
fragments
Q20-51

Mutant htt aggregate
formation dependent on
repeat length, concentration,
& time

[Scherzinger
et al. 1999]

Cos-7,
SK-N-SH

Transient

Exon 1
Q23, 53, 74

Mutant htt increased
reactive oxygen species

[Wyttenbach
et al. 2002]

Transient

Exon 1
fragments
Q25-103

Cleavage of mutant htt
results in N-terminal
fragments localization to
nucleus: recruitmentsequestration

[Steffan et
al. 2000]

Stable,
inducible

Exon 1
fragments
Q20, 51, 83

Mutant htt form detergentresistant aggresome
inclusions. Inhibition of
proteasome results in further
accumulation

[Waelter et
al. 2001]

Transient

Exon 1
fragments
Q25-103

PolyGln aggregates are
detergent-resistant, located
perinuclear, and interact
with other polyGlncontaining proteins

[Kazantsev
et al. 1999;
Preisinger et
al. 1999]

Exon 1
Q20, 150

Benign htt diffuse in the
cytoplasm; mutant htt
diffuse in the nucleus and is
susceptible to stress

[Li, Cheng
et al. 1999]

Drug screen coupled with
Drosophila: disruption of
aggregation correlates with
reduces neurodegeneration
in Drosophila

[Apostol,
Kazantsev et
al. 2003]

Drug screen showed caspase
inhibitors protected against
cell death

[Aiken,
Tobin et al.
2004]

HEK293

HEK293

PC12

PC12

Stable,
inducible

PC12

Stable,
inducible

PC12

Stable,
inducible

Exon 1
Q25, 47, 103
Exon1
fragments
Q25, 103
Exon 1 Q103
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Table 1.6. Continued

Cell Line

Expression

Htt
fragment*

Findings

Reference

PC12,
Cos-7

Stable,
inducible

Exon 1
Q23, 74

Mutant htt formed
cytoprotective aggresomes
that are formed via
microtubule-dependence

[Webb et
al. 2004]

Transient

N-terminal
fragments
Q23, 75

Nuclear localization of
mutant htt important for
toxicity

[Peters et
al. 1999]

Exon 1
Q16, 60, 150

Increased polyGln
expression = decreased
proteasomal processing,
mitochondrial membrane,
activated caspases

[Jana et al.
2001]

Mutant htt more resistant to
proteolysis than normal. Nterminal cleavage products
sequestered by full-length
htt

[Dyer and
McMurray
2001]

N2a

N2a

Stable,
inducible

IMR

Transient

Full-length
Q82

Primary
striatal /
hippocampal

Transient

Exon 1
Q17, 68

Nuclear localization
important for cell death,
not aggregation

[Saudou,
Finkbeiner
et al. 1998]

Full-length
Q15, 44, 128

Increasing Gln length and
truncation = increased
toxicity

[Hackam et
al. 1998;
Martindale
et al. 1998]

Primary
cortical

Transient

* N-terminal fragments = various shortened Exon 1 fragments that do not necessarily
contain the first 17 amino acids (region preceding Gln stretch). Exon 1 differs from exon
1 fragments in that “fragments” represents truncation after the Gln sequence. Synthetic
indicates only the Gln sequence was used. N2a, IMR and SK-N-SH cells are
neuroblastomas.

63

The rat pheochromocytoma cell line, PC12, is one of the most commonly used
mammalian cell lines to study neurodegenerative diseases [Warren and Chute 1972;
DeLellis et al. 1973; Greene and Tischler 1976; Schubert and Whitlock 1977; Chai et al.
1999; Li et al. 1999; Wyttenbach et al. 2001; Apostol et al. 2003; Aiken et al. 2004]. Like
neurons, PC12 cells synthesize and store dopamine and norepinephrine, which are
catecholamine neurotransmitters, and upon treatment with nerve growth factor (NGF) can
be transformed into a more neuronal-like appearance with long, extended neuritic
processes [Greene and Tischler 1976]. The most ideal cell models are those involving the
use of primary neuronal cultures; however, these models are not immortal and generally
more difficult to maintain.
There has been a great variety in the types of cells studied and the polyGln length
transfected. In spite of this variety, common features have emerged. There appears to be a
polyGln repeat length dependence for aggregation [Lunkes and Mandel 1998; Kazantsev
et al. 1999]; toxicity requires nuclear localization of the aggregate [Saudou et al. 1998;
Yang et al. 2002]; and the overexpression of chaperone proteins reduces aggregate
burden and/or toxicity [Cummings et al. 1998; Sittler et al. 2001; Firdaus et al. 2006].
However, these findings appear to indicate cell background independence because a
number of models have utilized the non-neuronal-like cell lines [Cooper et al. 1998;
Zeron et al. 2001; Skinner et al. 2002; Firdaus et al. 2006]. Regardless of the simple
eukaryotic model used, yeast or mammalian cells, these systems provide the framework
for addressing key questions about disease mechanism.
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INVERTEBRATE MODELS
Invertebrate models, such as Caenorhabditis elegans (worm) and Drosophila
melanogaster (fly), are also now being used to study neurodegenerative diseases (See
Table 1.7) [Jackson et al. 1998; Satyal et al. 2000; Link 2001; Driscoll and Gerstbrein
2003; Marsh et al. 2003; Marsh and Thompson 2006; Slepko et al. 2006; Brignull et al.
2007]. These models are important because they represent simple multicellular organisms
and have a greater rank than in vitro systems, yeast, and cell cultures. Both the worm and
the fly have been utilized for studying neurodegenerative disorders largely because of
their rapid generation times and fully functional nervous systems, which are absent in the
above presented models. In both models, many neuronal dysfunction characteristics are
exhibited. For instance, in Drosophila, a commonly used, easily measured assessment of
dysfunction is the degree of climbing activity in a glass tube. Another common endpoint
used in neurodegeneration research is the loss of the photoreceptors of the eye in
response to expression of disease proteins.
Invertebrate models of HD are created from either truncated or full-length htt
constructs. Simple glutamine sequences, without the htt context, have also been explored.
In the Drosophila models, virtually all the reported systems are placed under the control
of the upstream activating sequence (UAS), which does not express until crossed with fly
strains that express the yeast transcriptional activator GAL4. GAL4 is present in every
cell of the nervous system from embryogenesis forward [Robinow and White 1988].
Jackson’s group [Jackson et al. 1998] used gmr, which is another common
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Table 1.7: Invertebrate models of Huntington’s disease.
Model

Construct

Driver /
Promoter

Repeat
Size

Target
Cells

Mutation
phenotype

Reference

Drosophila

UAS
polyQ

gmr-GAL4

Q46

Eye retina

Retinal
degeneration

[Steffan et
al. 2001]

Drosophila

UAS
polyQ

Gmr-GAL4

Q27,
108

Eye retina

50% lethal

[Marsh et al.
2000]

Drosophila

Htt exon 1

GMR

Q2, 75,
120

Eye retina

Retinal
degeneration

[Jackson,
Salecker et
al. 1998]

Drosophila

UAS htt
exon 1
fragment

gmr-GAL4

Q20, 93

Eye retina

Retinal
degeneration /
lethality

[Steffan et
al. 2001]

C. elegans

GFP
polyQ

unc-54

Q19, 82

Body wall
muscle

Growth
retardation

[Satyal et al.
2000]

C. elegans

GFP
polyQ

myo-2

Q19, 82

Pharyngeal
wall muscle

Unreported

[Satyal et al.
2000]

C. elegans

Htt exon 1

osm-10

Q2, 23,
95, 150

ASH
sensory

Touch response
defect

[Faber et al.
1999]

C. elegans

Htt exon 1
fragment

Mec3

Q19,
88, 128

Touch
receptor
neurons

Touch response
defect

[Parker et
al. 2001]

Abbreviations: Upstream activating sequences (UAS), glass multimer reporter (gmr),
green fluorescent protein (GFP), glutamine (Q)
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driver for neurodegenerative studies that is expressed in all the cells of the eye [Ellis et al.
1993]. Regardless of the driver used, the most commonly targeted organ for
neurodegeneration is the eye. Drosophila models have shown striking neuronal
degeneration, with apoptotic hallmarks, which are highly correlated with the polyGln
repeat length, as well as the identification of chaperones that suppress polyGln-associated
toxicity [Jackson et al. 1998; Kazemi-Esfarjani and Benzer 2000]. More recently, it has
also been shown that when a Q20 sequence was co-expressed with a Q93 sequence
[Slepko et al. 2006], inclusions formed at a much faster rate than when the Q93 was
expressed alone. The observed aggregation kinetics correlated well with an increase in
toxicity, which was not seen in Drosophila expressing only Q20. Furthermore, by day 10
of the experiment, the majority of the aggregates present were found in the nucleus.
PolyGln toxicity has also been evaluated in C. elegans by expressing various Gln
constructs in the muscle or sensory neurons. As in the fly model, progressive
neurodegeneration occurs in a polyGln length-dependent manner; however, toxicity is not
observed until a second toxin is introduced [Faber, Alter et al. 1999]. In C. elegans, the
heat shock response has also been shown to be activated under the stress of expanded Gln
proteins. This effect can be alleviated by co-expression of a yeast chaperone Hsp104
[Satyal et al. 2000], which reduces the appearance of polyGln aggregates and the
associated developmental delay.
In C. elegans, behavioral assays are used to determine dysfunction in a specific
neuron [Faber, Alter et al. 1999; Parker, Connolly et al. 2001], where an unhealthy worm
is slower to respond to a touch response compared to its healthy counterpart. For
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example, worms expressing a 150 Gln repeat formed aggregates that increased as the
animal aged, which correlated with the progressive neurodegeneration of sensory neurons
[Faber, Alter et al. 1999]. In another example, worms that expressed expanded polyGln
repeats exhibited touch insensitivity, whereas worms expressing normal lengths did not
possess this characteristic [Parker, Connolly et al. 2001].
The invertebrate models share many of the same features of HD that are observed
in the human disease [Marsh et al. 2003; Brignull et al. 2006; Slepko et al. 2006], such as
the presence of polyGln aggregates and progressive degeneration. Both Drosophila and
C. elegans models provide excellent systems for combining cellular complexity and
behavioral phenotypes.

VERTEBRATE MODELS
Although the aforementioned models are well-studied, have relatively quick
generation times, are relatively easy to work with, and are readily available, they still lack
the complexity of higher eukaryotic species. Mice and rats share significant homologies
with humans, including similar proteomes and basic anatomical features. Furthermore, all
mammals share similar nervous, digestive, and circulatory systems, which stresses the
importance of developing vertebrate models depicting human disease. Finally, the Nterminal segment of mouse and rat huntingtin is very similar to the human [Barnes et al.
1994; Schmitt et al. 1995], while there is no recognizable exon1 or polyGln sequence in
Drosophila huntingtin [Li et al. 1999], and there is no huntingtin homolog at all in C.
elegans [NCBI 2007].
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Mouse models of HD can be grouped into two different categories 1) the
transgenic model, in which a portion of the mutated gene is expressed under the control
of various exogenous promoters, including bacterial and yeast artificial chromosomes
(BAC and YAC, respectively), and 2) the knock-in / knock-out models, in which an
expanded Gln repeat containing huntingtin gene is engineered at the mouse IT15 locus
(See Table 1.8 for a summary) [Sipione and Cattaneo 2001; Bao et al. 2002; Bates 2002;
Rubinsztein 2002; Levine et al. 2004].
Hdh is the mouse homolog of the human HD gene and has been shown to share a
91% identity with the human huntingtin protein [Barnes et al. 1994]. A homozygous
knock-out of this full-length murine gene results in embryonic lethality [Duyao et al.
1995], which is accompanied by an increase in apoptosis in the embryonic ectoderm
[Zeitlin et al. 1995]. These studies demonstrated the importance of htt during
development, and also proved that simply the loss of htt function could not account for
the neurodegeneration seen in HD. The lack of an HD-like phenotype in knock-out
models, is generally interpreted as proof of the expanded polyGln imparting a gain of
function activity. Furthermore, an Hdh heterozygous knock-out resulted in a normal
phenotype, reinforcing this belief [Duyao et al. 1995; Zeitlin et al. 1995].
Transgenic mouse models expressing truncated forms of mutant htt develop a
progressive neurological phenotype that includes tremors, NII, hypokinesis, failure to
gain weight, abnormal gait, a lack of coordination, limb clasping, and a reduced response
to stimuli [Bates 1998; Sipione and Cattaneo 2001]. These mice were constructed to

69

Table 1.8: Mouse models of Huntington’s disease.
Model design (Promoter / gene
size/ Gln repeat)

Neuropathology

Behavioral disorder
Inclusions

Cell loss

Reference

Transgenic Hdh models
HD promoter; exon 1 R6/2 line:
Q20, 115, 150

Onset at 2 mo. Tremors,
abnormal gait, learning
deficit, hypokinesis,
diabetes

NII and NA throughout
brain, fewer dendritic
spines

Overall atrophy. Fontal cortex,
dorsal striatum, and Purkinje
cells (late stage)

[Mangiarini
et al. 1996]

Mouse prion promoter; First 171 aa.
Q16, 44, 82

Onset 5 mo. with Q82.
Tremors, abnormal gait,
hypokinesis, weight
loss, early death

Striatum, cortex,
hippocampus,
amygdale. Diffuse
nuclear accumulation of
htt

Overall atrophy. Striatum

[Schilling et
al. 1999]

Tet-off (camKIIα-tTA) promoter;
exon 1 Q94

Onset in 50% by 2.5 mo.
late onset tremor and
abnormal gait

Striatum, septum,
cortex, hippocampus,
reactive astrocytes

Progressive striatal
neurodegeneration

[Yamamoto
et al. 2000]

HD YAC transgenic. Full-length
gene Q18, 46, 72, 128

Onset 3 mo. with Q72,
128. Hyperactive and
circling. Hyperkinesis,
progressive motor
deficit

Striatum

Striatal cell loss, cortical
atrophy with Q128

[Hodgson et
al. 1999;
Slow et al.
2003]

CMV promoter; full-length gene,
Q16, 48, 89

Onset 4 mo. with Q48,
89. Circling
hyperactivity, end-stage,
hypoactivity, and
urinary incontinence

Fewer inclusions
throughout the brain

20% cell loss in striatum of
some animals

[Reddy et al.
1998]

Rat neuron-specific enolase
promoter; 3-kb N-terminal fragment,
Q18, 48, 100

Onset 3-4 mo. with
Q100

Inclusions in Q100, few
in Q46; dystrophic
neuritis observed

20% cell loss at 8 mo. in some
animals

[Laforet et
al. 2001]

70

Table 1.8. Continued

Model design (Promoter / gene
size/ Gln repeat)

Neuropathology

Behavioral disorder

Reference

Inclusions

Cell loss

None observed

[Wheeler et
al. 1999]

Knock-in Hdh models
Endogenous mouse HD gene Hdh
promoter; Q50, 92, 111

None determined

PolyGln- and agedependent htt nuclear
relocalization at 1.5 mo.
Some inclusions >6 mo.

Neo and Hdh promoter; Q20, 111

Onset ~2 mo. and show
disorders similar to R6/2
mice

Age-dependent htt
nuclear relocalization
and inclusion

None observed

[White et al.
1997]

Hdh promoter; Q72, 80

Early onset aggressive
behavior

Late inclusions,
hippocampus, repeat
instability in striatum

Long term potentiation
impaired

[Shelbourne
et al. 1999]

Hdh promoter; Q71, 94

None determined

Striatal cell swelling in
response to NMDA

Smaller striatal cells, NMDA
sensitivity

[Levine et
al. 1999]

Hdh promoter; full-length gene,
Q80, 150

Onset 6 mo. Q150
homozygote, 15 mo.
heterozygote. Motor task
deficits, abnormal gait,
hypoactivity

NII Q150 mainly in
striatum. Htt nuclear
relocalization

Reactive gliosis

[Lin et al.
2001]
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express much larger CAG repeats than are actually seen in late-onset Huntington’s
disease. The life span is also shortened compared to transgenic mice expressing fulllength mutant htt [Bates 2002]. As is the case for the human disease, the mechanism(s)
responsible for the phenotype are unknown.
Knock-in models are an improvement over previous transgenic models because
Gln repeats can be precisely inserted into the endogenous mouse HD gene
and expression is controlled by the mouse’s own promoter. This is in contrast to the
random transgene incorporation into the mouse germline. Mild and very late onset
neuronal phenotypes have been observed in these knock-in mice; phenotypes are more
severe in homozygotes [Sipione and Cattaneo 2001].
Knock-in mice are more similar to the human disease than the other transgenic
mice expressing the truncated or full-length protein in that the expression levels are more
comparable to those of wildtype and affected tissues are more widespread in the brain
and peripheral tissues [Sipione and Cattaneo 2001]. This is due, in part to inheriting the
normal control elements that are associated with expressing the species specific gene
under the mouse promoter. A progressive neuronal phenotype and selective
neurodegeneration is also observed in transgenics (including knock-ins) expressing the
mutant full-length protein [Bates 1998].
There are many similarities among these various murine models and the human
disease. For example, a great deal of CAG repeat instability is observed both in different
vertebrate models and in humans. The largest degree of expansion, within the human
brain, was noted in the caudate and putamen, while the smallest repeats were in the
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cerebellum [Telenius et al. 1994]. CAG instability was also observed in a couple of the
knock-in models [Shelbourne et al. 1999; Wheeler et al. 1999] and in the R6 transgenic
models [Bates et al. 1997; Mangiarini et al. 1997]. Many of these models have been
reported to exhibit progressive phenotypes [Mangiarini et al. 1996; Reddy et al. 1998;
Hodgson et al. 1999; Schilling et al. 1999; Laforet et al. 2001; Lin et al. 2001], but the
majority of this type of characterization has been performed on the R6/2 mice [Carter et
al. 1999; Lione et al. 1999].
The propensity to form polyGln-containing inclusions is a hallmark of HD in
humans [DiFiglia et al. 1997; Becher et al. 1998; Gutekunst et al. 1999] that is also found
in many of the vertebrate models. PolyGln aggregate pathology similar to the inclusions
observed in humans has been described in every HD mouse model [Mangiarini et al.
1996; White et al. 1997; Reddy et al. 1998; Hodgson et al. 1999; Schilling et al. 1999;
Shelbourne et al. 1999; Wheeler et al. 1999; Yamamoto et al. 2000; Laforet et al. 2001;
Lin et al. 2001; Levine et al. 2004]; however, the precise role of these aggregates in HD
pathogenesis is still unclear.
Although there are many questions still unanswered, several important discoveries
about the molecular basis of HD have been acquired from each of these model systems.
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CHAPTER 2
PROJECT RATIONALE AND SUMMARY
The most common of a family of trinucleotide repeat neurodegenerative
disorders, Huntington’s disease is an autosomal dominant disease caused by a glutamine
expansion in the N-terminus of the gene encoding the huntingtin protein [Bates 2002].
The expanded polyGln itself is thought to be responsible for the pathogenesis of the
disease. Indeed, the severity of the disease increases with the length of the polyGln repeat.
As in all these trinucleotide repeat diseases, the expansion of the polyGln tract induces
misfolding of the protein, which then forms insoluble cytoplasmic and/or nuclear
aggregates within affected neurons [Davies, Turmaine et al. 1997; Scherzinger, Lurz et
al. 1997]. The length of the polyGln sequence (~35 Glns) associated with disease is very
similar for most of these disorders and correlates well with the length-dependent
aggregation properties observed in vitro [Harper and Newcombe 1992; Evert, Wullner et
al. 2000]. Recent experiments using cell systems support the idea that polyGln aggregates
are cytotoxic due to their ability to recruit other critical cellular proteins, via their own
polyGln components [Davies, Turmaine et al. 1997; McCampbell et al. 2000; Nucifora et
al. 2001]. In addition, it has been shown in another CAG repeat disease that some
neuronal aggregates, which are not polyGln-rich, are capable of recruiting polyGln
proteins [Takahashi et al. 2001]. On the other hand, it has also been postulated that the
formation of large, insoluble aggregates is a defense mechanism that has the beneficial
effect of sequestering smaller, more cytotoxic misfolded protein aggregates, thereby
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rendering them harmless [Klement et al. 1998; Saudou, Finkbeiner et al. 1998]. These
seemingly contradictory findings demonstrate that the aggregation phenomenon is
complex and may involve multiple discrete or interdependent pathways featuring
different misfolded and aggregated states with unique physical and biological properties.
To help distinguish different aggregated states, we have developed a cell-based
method capable of identifying intracellular aggregates based on whether or not they are
able to actively recruit biotinylated-monomeric Q28 peptide. This method was initially
developed using transiently transfected cell models in which various lengths of httpolyGln-green fluorescent protein (GFP) fusion constructs were introduced via liposomemediated delivery. The optimized biotinyl-polyGln system was then applied to a more
robust and reproducible model of stably-transfected PC12 cells capable of inducible
expression of htt with different polyGln repeat lengths. In these inducible cell models,
punctate areas were visible with the polyGln recruitment stain but not by the GFP
fluorescence typically used to discern aggregates in such models. The actively recruiting
species were designated aggregation foci (AF) [Osmand 2004; Osmand, Berthelier et al.
2006]. For reasons not entirely understood, these htt-inducible cells do not exhibit cell
toxicity due to the presence of expanded polyGln htt molecules [Apostol, Kazantsev et al.
2003], in contrast to some other models [Li, Cheng et al. 1999; Aiken, Tobin et al. 2004].
This intrinsic property of the cell line has provided a unique opportunity to dissect the
aggregation process without the complication of cell death.
The goal of this dissertation research was to: (a) develop a method for identifying
and validating the polyGln recruitment-competency within a cellular model of htt
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overexpression; (b) optimize the cells for htt-polyGln-GFP expression; (c) characterize
and investigate the potential role(s) of each of the various observed aggregated states in
aggregate propagation by examining their functionality and structure over time; and (d)
study the roles of various cellular functions in the formation and flux of AF and other
aggregates.

The

majority

of

this

characterization

was

completed

using

immunofluorescence microscopy to monitor the appearance and disappearance of AF and
htt-polyGln-GFP aggregates in a time-dependent manner. Further biochemical
characterization was achieved by isolating and examining a series of cell fractions that
contained the htt-polyGln-GFP proteins of interest. Each fraction was examined for its
reactivity with anti-GFP and 1C2-binding (anti-polyglutamine) antibodies using Western
blot assays. An attempt was also made to functionally characterize each fraction for their
abilities to support in vitro polyglutamine elongation using a microtiter plate assay
[Berthelier et al. 2001].
Finally, two compounds directed at specific cellular processes were investigated
for their ability to alter the aggregate formation pathway(s), which will be discussed in
Chapter 7. These compounds exhibit specific effects on AF and htt-polyGln-GFP
aggregates in the inducible cell system. These data suggest several possible modes for
aggregate formation in cells, which are addressed in greater detail in the Discussion and
Conclusions sections in Chapter 9. Taken together, the data obtained from these studies
and the protocols that have been developed can be used to dissect the basic principle of
htt aggregation in vivo and provide a platform to identify and quantitatively evaluate
novel therapeutic interventions to treat patients with this devastating human condition.
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CHAPTER 3
MATERIALS AND METHODS
3.1 Polyglutamine Constructs and Synthetic Peptides:
HTT DNA CONSTRUCTS
The DNA constructs used for all experiments were a generous gift from Alex
Kazantsev at the Center for Aging and Neurodegeneration, Massachusetts General
Hospital, Charlestown, MA. The original DNA constructs used were all truncated htt
exon-1-polyGln-GFP fusions (htt-Qn-GFP) [Kazantsev et al. 1999; Preisinger et al. 1999;
Michalik et al. 2001]. Exon-1 of the HD gene contains the CAG repeat region, which is
translated into a polyGln stretch within the huntingtin protein. For a number of reasons,
the exon-1 fragment of htt, rather than the full-length molecule, is frequently used as a
model system for studying outcomes of expanded polyGln expression. Truncated htt
constructs were initially used because it has been shown in a mouse model that the HD
inclusions contain processed N-terminal htt fragments [Martindale, Hackam et al. 1998],
and that these fragments were more toxic than the mutant full-length protein [Hackam et
al. 1998; Lunkes and Mandel 1998]. More recently, N-terminal fragment models have
been further validated with evidence that caspase release of an N-terminal portion of htt
is likely to be a critical step in the disease mechanism [Sawa et al. 2005; Maglione et al.
2006].
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The truncated constructs were composed of the first 17 amino acids (aa) of htt
exon 1, followed by the Gln repeat expansion with alternating CAG/CAA for added
stability [Michalik et al. 2001], and an in frame fusion with GFP at the C-terminus of
truncated htt exon 1 (htt-Qn-GFP, Q25, 47, 65, and 103) (see Figure 3.1B).
Complete htt exon 1 GFP constructs were used to create a stable htt-inducible cell
line (generously supplied by Leslie Thompson at the University of California, Irvin, and
Aleksey Kazantsev at Massachusetts General Institute for Neurodegenerative Disease
[Apostol, Kazantsev et al. 2003]), which will be discussed in detail in Section 3.2. These
constructs also contained the first 17 aa of huntingtin exon 1, the Gln repeat stretch, the
polyproline region, and the GFP tag, as indicated in Figure 3.1A. Cells containing these
constructs were available in 25, 47, and 103 Gln repeat lengths. The cells expressing
complete htt exon 1 constructs will be designated as 25QP, 47QP, and 103QP. Also for
the htt-inducible cells, we had one cell line expressing a truncated form of htt exon 1
(Figure 3.1B). This cell line will be referred to as Q103.

POLYGLUTAMINE PEPTIDE PREPARATION
Synthetic polyGln peptides were utilized for the polyGln-recruitment stain
(Section 3.3) and as control samples for the polyGln microtiter plate elongation assay
(Section 3.7), see Figure 3.1C. All peptides were prepared by custom solid-phase
synthesis

from

the

Keck

Biotechnology

Center

at

Yale

University

(http://info.med.yale.edu/wmkeck). The polyGln sequences were flanked by pairs of
lysine (Lys or K) residues to enhance solubility by conferring a net positive charge on the
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(A) Complete exon 1 constructs: 25QP, 47QP, and 103QP
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Q25

Q47 Q65
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(B) Truncated exon 1 constructs: Q25, Q47, Q65, and Q103
K2 -

Q47

- K2

Biotin-PEG-K2

Q28

- K2

(C) Synthetic polyGln peptides: K2Q47K2 and biotin-PEG-K2Q28K2

Figure 3.1: PolyGln constructs and peptide sequences. (A) Complete htt exon 1
constructs. (B) Truncated htt exon 1 constructs. (C) Synthetic polyGln peptides.
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peptide at a neutral pH [Chen and Wetzel 2001]. We utilized biotinylated peptides as
well, which were created by an N-terminal derivatization during the synthesis. The
biotinylated peptide was enhanced by the addition of a polyethylene glycol (PEG) spacer
between the biotin moiety and the polyGln peptide [Osmand, Berthelier et al. 2006].
Peptides were purified by disaggregation and HPLC [Berthelier et al. 2001; Chen and
Wetzel 2001], and stored at -80°C in 1- or 5-ml aliquot stock solutions in extension
buffer (1X phosphate buffered saline (PBS) and 0.01% Tween® 20) with 5% dimethyl
sulfoxide (DMSO) or PBS alone.

Solubilization and Disaggregation of Peptides
Peptides were dissolved at 0.5mg/ml in a 1:1 mixture of trifluoroacetic acid (TFA,
#28901, Pierce, Rockford, IL) and 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, #52517,
Sigma-Aldrich, St. Louis, MO) for 24 hour. The solvents were evaporated in a fume hood
under a stream of argon and further lyophilized under a vacuum for one hour. The peptide
residue was resuspended in an equal volume of cold water, adjusted to pH 3.0 by TFA,
and allowed to dissolve for at least 15 minutes at 4°C. The sample was then subjected to
ultracentrifugation at 100,000xg overnight at 4°C to remove any aggregate contaminants.
All but the bottom 10% of the supernatant was carefully removed and stored at 4°C while
the exact peptide concentration was determined by reverse-phase high-performance
liquid chromatography (RP-HPLC, Hewlett-Packard, Palo Alto, CA) fitted with a Zorbax
SB-C3

column. Biotinylated-PEG-K2-Q28-K2 peptides were diluted to a final

concentration of 500nM in extension buffer, aliquoted, flash frozen, and stored at -80°C.
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A more complete description of the disaggregation protocol has been published
[O'Nuallain et al. 2006].

Preparation of Polyglutamine Aggregates
K2Q47K2 peptides were subjected to the above disaggregation protocol; after
which, the concentration was adjusted to 10µM (44µg/ml) in 1X PBS. The peptide
solution was then incubated at 37°C for 24 hours, snap frozen, and subjected to an
additional 24 hour incubation at -20°C [Berthelier, Hamilton et al. 2001]. Aggregates
were aliquoted, snap frozen, and stored at -80°C.

3.2 Cell Culture and Treatment:
MAINTENANCE
PC12 Cells
Two cell lines, PC12 and SH-SY5Y cells, were utilized for the transient
expression model systems. Rat pheochromoctyoma (PC12) cells are an adherent cell line
that were established in the 1970s to provide a model system that displayed neuronal
characteristics but was easier to work with than primary neuronal cultures [Warren and
Chute 1972; Greene and Tischler 1976]. For these reasons, PC12 cells are commonly
used as mammalian cells to study neurodegenerative diseases [Li, Cheng et al. 1999;
Apostol, Kazantsev et al. 2003; Aiken, Tobin et al. 2004]. PC12 cells were graciously
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donated by Erik Schweitzer in the Department of Physiological Science and Neurology at
the Brain Research Institute, University of California, Los Angeles, CA.
PC12 cultures were maintained in Dulbecco's Modification of Eagle's Medium
(DMEM) supplemented with 5% fetal bovine serum (FBS), 5% horse serum (HS), and
penicillin/streptomycin antibiotics (complete growth medium). Media and supplements
were purchased from MediaTech, Inc. (Herndon, VA), Hyclone, (Logan, UT), and
Calbiochem (San Diego, CA) unless otherwise noted. All cells were grown at 37°C in
5.0% carbon dioxide (CO2) and at 98% relative humidity. The media was changed every
third day, and the cultures were passaged weekly.

SH-SY5Y Cells
To create an even more physiologically relevant mammalian culture, a human
neuroblastoma cell line, SH-SY5Y (American Type Culture Collection (ATCC) – #CRL2266, Manassas, VA) was used. These cells are a third generation clone that was
established from the parental SK-N-SH cells. Although SH-SY5Y cells grow as a
mixture of adherent and floating cells, they can be differentiated with 10µM retinoic acid
(RA) to generate a more adherent phenotype. Like the PC12 cells, SH-SY5Y cells exhibit
many neuronal characteristics. These cells, irrespective of differentiation, actively
produce many neurotransmitters that are found in the normal human brain. Although SHSY5Y cells are less commonly used than PC12 cells (probably because they are more
difficult to maintain) there have been several reports of their use in neurodegenerative
disease research [Grierson et al. 2001; Ho, Carmichael et al. 2001; Wyttenbach,
Sauvageot et al. 2002; Olivieri et al. 2003]. SH-SY5Y cells were cultured in a 1:1
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mixture of DMEM and Ham’s F12 Medium supplemented with 10% FBS and
penicillin/streptomycin antibiotics.

Stable, htt-inducible PC12 Cells
We also had available several htt-inducible PC12 cell models that expressed
various polyGln lengths (25QP, 47QP, 103QP, and Q103; detailed in Section 3.1)
[Apostol, Kazantsev et al. 2003]. Protein expression within these cells was controlled by
an ecdysone-inducible promoter and was regulated by Ponasterone (#H101-01,
Invitrogen, Carlsbad, CA), an insect steroid. The htt-inducible PC12 cells were cultured
in DMEM supplemented with 10% HS, 5% FBS, 15mM HEPES (4-(2-hydroxyethyl)-1piperazineethanesulfonic acid) buffer, and antibiotics. Dilution cloning on these cells will
be discussed in the next subsection.
The ecdysone-inducible mammalian expression systems were created using a cotransfection of a vector (pVgRXR) containing a heterodimer receptor that would bind to a
hybrid ecdysone response element and a vector containing the cDNA of interest (pIND)
(see Figure 3.2). In the presence of the inducing agent (Ponasterone), a stable transfectant
can be established. Selection for this stably incorporated transgene was maintained with
concurrent treatment of 100µg/ml G418 (#11811-023, Invitrogen) and 200µg/ml Zeocin
(#R250-01, Invitrogen) antibiotics. These cells maintain their stability for at least 1.5
years when stored in liquid nitrogen; furthermore, the transgene is stable up to passage 25
once reconstituted.
The day prior to transfection, induction or differentiation (in the case of SHSY5Y cells), cells were seeded onto poly-D-lysine coated glass coverslips and allowed to
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Figure 3.2: Ecdysone-inducible mammalian expression system. This is a schematic
representation of how the htt-inducible cells were generated (Taken from [Invitrogen
2002]).
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adhere for a minimum of 16 hours. PC12 cells were plated at a density of 150,000 cells/
cm2 in either 6-, 12-, or 24-well microplates. SH-SY5Y cells were seeded at 50,000
cells/cm2 density in 24-well microplates. SH-SY5Y cells were differentiated with 10µM
RA for seven days prior to transfection. Htt-inducible PC12 cells were plated at a density
of 50,000 or 100,000 cells/cm2, depending on the length of time in culture, into a 24-well
microplate.

DILUTION CLONING
We received four htt-inducible PC12 cell lines: 25QP, 47QP, 103QP, and Q103.
Although all these cells were expressing the selectable marker, they were not uniform cell
lines. In general, only a small percentage of these cells exhibited good expression of the
transgene, as indicated by GFP fluorescence. To obtain a more uniform cell line, it was
necessary to subclone. As received from the Thompson lab, only the Q103 cells had
been subjected to subcloning and hence were enriched for a high percentage of httpolyGln-GFP expressing cells. These cells had been subcloned, pooled, and flow sorted
(MoFlo cell sorter, Cytomation, Fort Collins, CO) [Apostol, Kazantsev et al. 2003]. The
other three cell lines were not of very high clonal integrity and needed to be enriched.
Dilution cloning, or subcloning, is a process by which a polyclonal cell population
is serially diluted until a population of one or two cells has been achieved. This
population, a subclone, is then plated and allowed to reach confluency. Ideally during
cellular division, the characteristics of the original one or two cells will be passed on to
the next generation of cells. By performing this technique, one should be able to achieve
a fairly homogenous monoclonal population of cells.
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Dilution cloning was performed as described in “Culture of Animal Cells. A
Manual of Basic Technique” [Freshney 1987]. Cells were treated with Cellstripper (#25056-CI, MediaTech) to detach the culture. Cells were resuspended in complete growth
media (described in Section 3.2), counted, and serially diluted to achieve approximately
one cell/100µl of media (10 cells/1ml of media). Once the correct dilution had been
found, 100µl/well of cells were plated into 96-well plates and cultured until ~80%
confluency had been achieved.
When the cells had reached this confluency, the cultures were detached and
divided between a well in a 96-well microtiter plate and a well in a 24-well plate. The
sample in the 24-well plate was maintained for continual growth. The sample in the 96well plate was subjected to induction with 5µM ponasterone, and htt-polyGln-GFP
expression was monitored for several days beginning 24 hours post-induction. Clones
were chosen based on their percent GFP expression, and presumably percent htt-polyGln
expression. The highest percentage of expressing cells was chosen as the most optimal
clones.
Ideally, to match the Q103 cells, the samples should have also been flow sorted,
which would have allowed for an even purer population of cells. This was not possible;
however, even without the use of a flow cytometer, we were able to achieve a high clonal
integrity with our cell lines.

TRANSFECTION
PC12 and RA differentiated SH-SY5Y cells were transiently transfected with the
htt-Qn-GFP constructs using the liposome-mediated LipofectAMINE PLUSTM reagent
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(#18324-012 and 11514-015, Invitrogen), according to manufacturer’s instructions. In
this method of transfection a cationic lipid is mixed with the DNA to produce a positively
charged liposome. The net positive charge of the liposome/DNA complex is attracted to
the negatively charged plasma membrane. Upon their fusion, the liposome becomes
engulfed by the cell where the DNA is then deposited and travels to the nucleus. It is
unclear the exact mechanism that allows the DNA to cross the nuclear membrane
[Felgner et al. 1987].
The day prior to transfection, PC12 cells were plated on poly-D-lysine coated glass
coverslips at a density of 150,000 cells/cm2. SH-SY5Y cells were plated at a density of
50,000 cells/cm2 and differentiated for seven days with 10µM retinoic acid. In both cell
lines, the DNA was complexed with the PLUS reagent at a ratio of 2µg DNA to 10µL
PLUS reagent in 100µl of serum- and antibiotic-free media for 15 minutes at room
temperature. During incubation, 10µl of LipofectAMINE reagent was diluted in 100µl of
serum- and antibiotic-free media. The two mixtures were then combined and incubated
for an additional 15 minutes at room temperature. Complete media was replaced by
serum- and antibiotic-free media in each well prior to the addition of the liposome/DNA
complexes. After the 15 minutes of incubation, the liposome/DNA complexes were
gently mixed into each well and incubated at 37°C in 5% CO2 for 5 hours; after which,
fresh media containing twice the normal serum was added to each well. Coverslips were
removed at 16, 24, 48, and 72 hours post-transfection, fixed and permeabilized (Section
3.2), and subjected to the polyGln-recruitment stain discussed in Section 3.3.
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INDUCTION
At least 16 hours prior to induction, stable, htt-inducible PC12 cells were detached,
counted, and plated at a density of 50,000 – 100,000 cells/cm2 on poly-D-lysine coated
glass coverslips located in 24-well microplates. Just prior to the addition of inducing
agent, the growth media was exchanged for 1ml/well of fresh complete growth media. To
each well, 5µM ponasterone (stock = 1.1mM in absolute, ethanol) was added. Cells were
maintained under constant induction for 16, 24, 48, 72, 96, 120, 144, or 168 hours, with
the induction media being changed every day. At each time point, the cells were fixed
and permeabilized (Section 3.2) and subjected to the polyGln-recruitment stain discussed
in Section 3.3.

Compound Treatment
In experiments where stable htt-inducible cells were treated with inhibitory
compounds, the compounds were introduced simultaneously with the ponasterone.
Curcumin has been shown to be an effective for its anti-inflammatory, anti-oxidant, antitumor, and most importantly, anti-amyloid compound [Kelloff et al. 1996; Lim et al.
2005; Yang et al. 2005]. The stock solution of curcumin was prepared at a concentration
of 10mM in absolute ethanol. The day of induction curcumin was diluted into complete
growth media to concentrations of 0.1, 1, or 10µM. Cells were treated for 24 hours; after
which, they were fixed, permeabilized (Section 3.2), and subjected to the polyGlnrecruitment stain (Section 3.3).
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Two antimitotic compounds were also tested: nocodazole and demecolcine. These
compounds have been shown to depolymerize microtubules [Luduena and Roach 1991;
Nishiyama and Fujii 1992; Wang et al. 1998]. Demecolcine was dissolved in absolute
ethanol to a concentration of 10mg/ml (27mM) then further diluted in ethanol to 2µg/ml.
Prior to induction and compound treatment, dilutions were made in complete growth
media to the final concentrations of 50, 200, 400, and 1000ng/ml. Treatment was
continued for 24 hours then the cells were fixed, permeabilized, and stained for polyGlnrecruitment competency and cell nuclei (Section 3.3).
Nocodazole was resuspended in ethanol to a concentration of 10mg/ml (33mM)
and further diluted to 2µg/ml in ethanol. Before the cells were treated, dilutions were
again made in complete growth media to concentrations of 50 and 400ng/ml. Cells were
fixed, permeabilized, and stained with 100µg/ml Hoechst 33342 (stock solution was
10mg/ml diluted in water, #H-3570, Molecular Probes, Eugene, OR) for 30 minutes at
37°C. Hoechst fluorescent dye is a nucleic acid specific reagent that exhibits blue
fluorescence upon excitation.

FIXATION AND PERMEABILIZATION OF COVERSLIPS
At the specified time points, coverslips with the attached transfected or induced
cells were subjected to fixation and permeabilization. The process of fixation halts the
life processes taking place within the culture; thereby preserving a snapshot of the culture
for microscopic analysis. Permeabilization is necessary to gain access into the
intracellular structures.
89

There are two widely accepted protocols for the fixation and permeabilization of
cell cultures: 1) subquential treatments with acetone and methanol and 2) the use of a
cross-linking

reagent,

such

as

paraformaldehyde,

followed

by

a

detergent

permeabilization [Melan and Sluder 1992; Allan 2000]. Each method has been reported
to stabilize both soluble and insoluble proteins in their native cellular locations [Melan
and Sluder 1992].
In initial transient transfection experiments, coverslips were washed with 1X PBS,
immediately fixed in acetone for 10 minutes, and allowed to air-dry overnight. The
coverslips were permeabilized the following day by incubating in cold methanol (100%)
for 5 minutes; after which, the coverslips were washed in Tris-buffered saline containing
0.01% Tween® 20 (TBST). This method, however, proved inefficient in our system due
to the leaching of the GFP from the cellular cytoplasm [Kalejta et al. 1999]. All data
shown were therefore obtained from cells fixed using a paraformaldehyde solution and
permeabilized using 0.2% Triton® X-100 detergent.
Coverslips were washed with 1X PBS and fixed for 15 minutes at room
temperature with Cytofix buffer (#554655, BD Biosciences, Rockville, MD), a neutral
pH-buffered solution containing 4% paraformaldehyde. The coverslips were washed
again with 1X PBS and permeabilized with cold 0.2% Triton® X-100 for 5 minutes. After
permeabilization, the coverslips were washed with 1X TBST and subjected to the
polyGln-recruitment stain detailed in Section 3.3.
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3.3 Polyglutamine-recruitment Stain:
Upon fixation and permeabilization, the coverslips were subjected to the polyGlnrecruitment stain (Figure 3.3), which relies on the specific ability of amyloid-like polyGln
proteins to recruit biotinylated Q28 monomeric protein. After each addition or incubation,
the coverslips were washed extensively with 1X TBST. Prior to incubation with the
biotinylated monomer, coverslips were blocked with streptavidin / biotin (#SP2002,
Vector Laboratories, Burlingame, CA) to eliminate any non-specific biotin binding.
Briefly, cells were incubated with cold (4°C) streptavidin for 15 minutes followed by 15
minutes of incubation with cold (4°C) biotin.
After the blocking step was complete, cells were incubated with 100nM of
biotinylated Q28 monomer (stock solution was 500nM) for 2 hours at room temperature.
Several incubation times and temperatures were explored; however, the 2 hour, room
temperature incubation provided the most consistent results with the lowest background.
The coverslips were then incubated with 100µg/ml Hoechst 33342 (Molecular Probes) for
30 minutes at 37°C, washed, then incubated with a 1:200 dilution of a red streptavidinconjugated Alexa Fluor® 594 (stock solution was 2mg/ml, #S-32356, Molecular Probes)
for 1 hour at room temperature. This dye was used for the detection of the incorporated
biotinylated monomer. Coverslips were washed exhaustively with 1X TBST followed by
an extensive wash with distilled water to remove any salt precipitation from the previous
buffer.
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Figure 3.3: Schematic representation of polyGln-recruitment staining protocol. Transfected / induced cells were removed
at various time points and subjected to the above staining protocol. Blue fluorescence represented cell nuclei (stained with
Hoechst), green fluorescence was indicative of htt-polyGln-GFP expression, and red fluorescence represented polyGln
recruitment-competent foci.
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Coverslips were mounted onto slides with the cell-side up using an aqueous
fluorescent mounting medium (#S3023, DakoCytomation, Carpinteria, CA), and a cover
glass was applied for microscopic analysis. Green fluorescence was indicative of the httpolyGln-GFP fusion constructs, blue fluorescence represented cell nuclei, and red
fluorescence corresponded to polyGln recruitment-positive regions.

3.4 Microscopy and Flow Cytometry:
IMMUNOFLUORESCENCE MICROSCOPY
Images were obtained using a Leica DMRB fluorescent microscope equipped
with a SPOT RT color camera (Diagnostic Instruments, Inc., Sterling Heights, MI) and
SPOT Advanced, version 3.5.2 imaging software (Diagnostic Instruments). Data was
analyzed using Image-Pro Plus software (Windows version 4.5, Media Cybernetics, Inc.,
Silver Springs, MD) or Adobe Photoshop 5.5 (San Jose, CA). The microscope was fitted
with a brightfield differential interference contrast (DIC) analyzer, a DAPI/blue
fluorescent protein (BFP) filter (excitation 360/40nm, emission 460/50nm, with a
bandwidth 400nm), a Texas red filter (excitation 560/40nm, emission 630/60nm,
bandwidth 595nm), and a FITC/GFP filter (excitation 480/30nm, emission 535/40nm,
bandwidth 505nm).

DIC microscopy utilizes the contrast between background and

specimen to generate an image of the unstained structures. The DIC analyzer was used in
conjunction with all experiments to observe overall cell morphology.
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FLOW CYTOMETRY
Transient transfection efficiencies were initially confirmed using a FACScan
(Becton-Dickinson, San Jose CA). Htt-Qn-GFP expression was monitored by the
excitation of the GFP fusions at 488nm (FL-1, 530nm emission). At least 10,000 events
were collected for each sample. Data was analyzed using Cell Quest software version 1.2
(Becton-Dickinson).

3.5 MTS Reduction Assay:
Cell viability was determined using the CellTiter 96® AQueous One Solution Cell
Proliferation Assay (#G3580, Promega, Madison, WI) according to manufacturer’s
instructions. CellTiter 96® is a colorimetric assay that contains a tetrazolium compound
MTS

(3-(4,5-demethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-

2H-tetrazolium) and PES (phenazine ethosulfate, an electron coupling reagent), which is
converted to water-soluble formazan by NADH- or NADPH-, presumably.

The

formazan product can then be quantified by measuring the absorbance at 490nm.
Absorbance is directly proportional to the number of viable cells [Promega 2005]. MTS
reduction is generally considered to be an indication of the health of cell mitochondria
[Gschwind 1997]. When used previously to observe the response of PC12 cells to
polyGln aggregates, MTS reduction gave a read-out entirely in agreement with other
assays for cell viability, eg., lactate dehydrogenase release and propidium iodide
exclusion [Yang et al. 2002].
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Briefly, cells were detached, counted and seeded into 96-well microplates at least
16 hours prior to induction and/or compound treatment. Cells were induced with 5µM
ponasterone as previously described (Section 3.2, Cell Culture and Treatment, Induction).
At the appropriate time point, the inducing medium was exchanged for 100µl of complete
growth medium/well. To each well, 20µl of CellTiter 96® AQueous One Solution reagent
was added, and the plate was incubated at 37°C for 4 hours. After incubation, absorbance
readings were taken at 490nm on a SynergyTM HT multi-detection microplate reader
(BioTek Instruments, Inc., Winooski, VT). Data were analyzed using Microsoft Excel
2000 (Microsoft Corporation).

3.6 Preparation and Fractionation of Cell Lysates:
PREPARATION OF CELL LYSATES
There are two common techniques for the lysis of cells: 1) physical means or 2)
the use of detergents. Lysis by physical means employs a method that physically ruptures
the cell membrane. Sonication, freeze/thawing, and grinding are a few examples of
physical lysis. There are some drawbacks associated with this technique. Often during
physical disruption, a localized heating may occur, which can lead to the denaturation or
aggregation of cellular proteins[Alberts 1994]. Another problem is the lack of
consistency with making lysates. Cells are not homogenous and will therefore dissociate
at various rates. Because of this, there is little control over the rate and extent of cellular
components being disrupted[Alberts 1994].
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The other means of lysing a cell is by the use of detergents. Detergents disrupt the
lipid barrier surrounding the cells by solubilizing the proteins and interfering with the
interactions that hold them together. This type of lysis is generally milder than physical
disruption. However, detergent lysis is often used in conjunction with sonication for a
more complete means of releasing cellular proteins. There are several detergents
available: ionic, zwitterionic, and nonionic. The latter two types are less denaturing than
the ionic detergents, which tend to destroy protein activity. Various detergents have been
shown to have different capabilities of dissolving aggregates. For example, SDS (sodium
dodecyl sulfate) treatment has been shown inefficient at dissolving late-stage fibrillar htt
aggregates [Davies et al. 1997; DiFiglia et al. 1997; Kazantsev et al. 1999]; whereas,
early forming htt exon-1 aggregates have been found susceptible to treatment with the
detergent [Poirier, Li et al. 2002]. Although there are no formal guidelines for choosing
the proper detergent for studying aggregates, we tried to choose a detergent that has not
been shown to have solubilizing effects on polyGln aggregates.
We chose to use detergent lysis followed by sonication in order to release the
cellular proteins. Triton® X-100 is a nonionic detergent that is commonly used for the
isolation of proteins [Barbero et al. 1984]. Triton® X-100 was chosen largely because it
was also used we used during our polyGln recruitment stain. Cell lysates were prepared
from htt-inducible cells using a balanced salt solution containing the following
constituents: 150mM sodium chloride (NaCl), 0.1% Triton® X-100, 50mM Tris, 50mM
HEPES, 1mM EDTA (ethylenediamine tetraacetic acid ), and a cocktail of inhibitors of
various classes of proteases (#P8340, Sigma-Aldrich). The addition of protease inhibitors
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was necessary to prevent the unwanted proteolytic degradation of the sample [Roskams
2002].
At specified time points that correlated with the microscopic data, i.e., 24-72
hours post-induction, cells were detached, counted, and disrupted using the lysis buffer.
Cell lysates were prepared at a density of ~2.0x107 cells/200µl of lysis buffer. Whole cell
lysates were sonicated for 20 seconds and divided into two portions, one of which was
retained for analysis at a later time. The other portion was subjected to fractionation by
either centrifugation or gel filtration.

Lysates were prepared, snap frozen, and stored at

-80°C for future analysis. Protein concentrations were determined using the Coomassie
Plus – Better Bradford Assay (#23236, Pierce, Rockford, IL).

FRACTIONATION BY GEL FILTRATION
Two separate methods were used to isolate the observed polyGln species: 1) size
exclusion chromatography (gel filtration) and 2) differential centrifugation. Gel filtration
is used to separate proteins based on their size, where larger proteins elute faster than
smaller proteins.
Q103 lysate samples were sonicated briefly, and 200µl (~8mg/ml) of the total
sample was loaded onto a Sephacryl® S500HR resin (#S500HR-100ML, Sigma-Aldrich).
The same buffer used for cell lysis was also used for protein elution. Fractions were
collected immediately and until triple the bed volume (10ml) had been achieved. A total
of 67 fractions were collected in 500µl volumes each. After the fractions had been
collected, absorbance readings at 280nm (wavelength specific for proteins) and protein
concentrations were obtained for each sample.
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FRACTIONATION BY DIFFERENTIAL CENTRIFUGATION
Differential centrifugation relies on the fact that there are many proteins with
different masses within the cell suspension that will separate at different rates. For this
reason whole cell lysates (W) were subjected to two centrifugation speeds: a slower
speed to pull down the larger particles and a higher speed to collect the smaller
aggregated species (refer to Figure 3.4). The samples were briefly sonicated and
centrifuged at 15,000xg for 30 minutes at 4°C. The supernatant (S1) was transferred to a
new tube, and the pellet was washed twice with lysis buffer. The combined washes and
supernatant (S1) from the first centrifugation was subjected to a 100,000xg spin for 30
min at 4°C. Both the pellet from the 15,000xg (P1w) and the pellet from the 100,000xg
(P2) were resuspended, separately, in lysis buffer. Protein concentration was determined
on each fraction (W, P1w, P2, and S2 – final supernatant fraction) before further analysis.
Our hypothesis was that the P1w fraction would contain the largest aggregates; the P2
fraction would contain the smaller, nuclear aggregates and aggregation foci; and the S2
fraction would contain monomeric protein. Fractionation by differential centrifugation
provided a good way for separating the large aggregates from the smaller aggregates and
monomeric protein. Several wash steps had to be introduced in order to release the sticky
proteins from cellular debris. However, this method proved useful for the crude
separation of proteins.
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Cell lysate preparation
Sonicate
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Pellet washed 2X
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Induced cells
Supernatant 1 (S1)

Pellet 2 (P2)
resuspended
in lysis buffer
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Figure 3.4: Schematic representation of polyGln aggregate isolation protocol by differential centrifugation. Cell lysates
are prepared from cells 24-72h post-induction. The lysates were subjected to a medium and low speed centrifugation step. Both
pellet (P1w and P2 – aggregated species) and supernatant (S2 – monomeric species) fractions were analyzed for protein
content.
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3.7 Protein Gel Electrophoresis and Western Blot Analysis:
PROTEIN GEL ELECTROPHORESIS
The fractionated cell lysates were then subjected to protein gel electrophoresis (a
technique used for separating proteins according to their net charge: smaller proteins
migrate faster than large ones) and Western blot analysis. Commonly, protein separation
is performed on polyacrylamide gels [Laemmli 1970]. Proteins are often found in
complexes or aggregated states. When the goal of an experiment is to study individual
proteins or gain information about the non-aggregated state, it is important to denature
the protein prior to loading the sample onto the gel. SDS is an ionic detergent that is
commonly used for this purpose. SDS treatment abolishes the effects of any differences
in shape, so proteins are separated solely on their masses.
Two gels were loaded with equal amounts of material (~9µg/well prepared from
~2x107 cells) were loaded into a 10-well pre-cast NuPAGE® (polyacrylamide gel
electrophoresis) 4-12% Bis-Tris gel from Invitrogen Corporation (#NP0321BOX) and
subjected to electrophoresis under denaturing conditions (according to manufacturer’s
instructions). After which, one gel was stained with Coomassie Blue (a protein specific
dye) and the proteins from the other gel were electrotransferred onto 0.2µm nitrocellulose
membranes (#LC2000, Invitrogen) using the XCell II Blot Module (#E19051,
Invitrogen). Transfer of the proteins took ~2 hours at 35 Volts.
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WESTERN BLOT ANALYSIS
Nitrocellulose membranes containing the cell lysate proteins were analyzed for
their reactivities to anti-GFP (#sc-8334, Santa Cruz Biotechnology, Santa Cruz, CA) and
1C2 (#MAB1574, Chemicon, Temecula, CA) (anti-polyglutamine) antibodies. Briefly,
each membrane was blocked with 1% Casein (in TBST) for 1h and exposed to either the
1C2 or anti-GFP antibody at a 1:1,500 or 1:150 dilution, respectively, for 1 hour at room
temperature. The membranes were washed with 1X TBST and then exposed to a
horseradish peroxidase (HRP) conjugated goat-anti-mouse or rabbit secondary antibody
(depending on the primary antibody) at a 1:10,000 dilution (Jackson Laboratories, Bar
Harbor, ME) for 1 hour. After thoroughly washing the membranes with 1X TBST,
Luminol (#sc-2048, Santa Cruz), a chemiluminescent product, was used to detect 1C2
and anti-GFP reactive protein bands. The membranes were exposed to autoradiography
film and developed using Kodak supplies.

3.8 Microtiter Plate Extension Assay:
Centrifuged fractions of htt-inducible cell lysates were examined for their ability
to support polyGln recruitment as measured by the microtiter plate polyGln extension
assay [Berthelier, Hamilton et al. 2001]. Cell lysate material (~9µg/well) was coated into
the wells of a 96-well plate and allowed to air dry overnight at 37°C. As a positive
control for polyGln extension, synthetic K2Q47K2 aggregates (80ng/well) were also
immobilized in the microplates. The plates were thoroughly washed with extension buffer
(1X PBS with 0.01% Tween® 20) and blocked for 1 hour in a 0.3% Gelatin solution. The
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plates were again washed and incubated with 100µl/well of either extension buffer
(negative control) or 100nM biotinylated Q28 monomer (the same concentration as used
in the microscopy experiments) for 1-3 hours.
After monomer incubation, the plates were washed then incubated with
100µl/well of a 100ng/ml streptavidin-labeled Europium (Eu) solution (0.5% bovine
serum albumin (BSA)) for 1 hour. The plate was again washed, and europium released by
the addition of 100µl/well of an enhancement solution (#1244-105, PerkinElmer,
Waltham, MA). Eu-incorporation was measured by time-resolved fluorescence in a
Victor2 1420 Multi-label Counter (EG&G Wallac, Gaithersburg, MD). Europium counts
were converted to femtomoles using a determined standard curve.
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CHAPTER 4
FLUORESCENCE METHODS FOR AGGREGATE DETECTION
4.1 Rationale:
It is well documented that polyGln aggregates are present in HD disease tissue,
and in various models of HD and other CAG repeat diseases [DiFiglia et al. 1997; Ross
1997; Lunkes and Mandel 1998; Hackam et al. 1999; Kazantsev et al. 1999; Bates 2002;
Marsh et al. 2003]; however, it is unclear the precise role they play in the disease
mechanism. There have been much evidence supporting a toxic role of the aggregates
themselves [Cooper et al. 1998; Hackam et al. 1999; Yamamoto et al. 2000; Kazantsev et
al. 2002; Yang et al. 2002]; conversely, there is also speculation that the aggregates are
not directly linked to toxicity [Cummings and Zoghbi 2000; Tobin and Signer 2000]. It
has also been proposed that aggregates represent an end stage in an aggregation process
with multiple steps [Ross and Poirier 2005]. This is suggestive that early events,
including the formation of misfolded monomers [Weissmann 2005; Nagai et al. 2007] or
soluble oligomeric/protofibrillar intermediates [Poirier et al. 2002; Bucciantini et al.
2004; Katsuno et al. 2004; Wacker et al. 2004; Mukai et al. 2005] accelerated by the
expansion of the polyGln sequence, may actually be responsible for cellular toxicity.
Nevertheless, there is not an agreement on which species actually exist in the cell and
which are toxic; furthermore, it is also not known whether the intermediate species are
“on-” or “off-pathway” in aggregate formation.
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In vitro, polyGln proteins have been shown to form a host of aggregate types with
different sizes, shapes, and functional characteristics [Wetzel 2006]. Among these,
amyloid-like fibrils are highly ordered structures that are capable of growth by monomer
addition [Lomakin et al. 1996; Lomakin et al. 1997; Berthelier et al. 2001; Chen et al.
2002; Collins et al. 2004; O'Nuallain et al. 2005]. Smaller polyGln aggregates were more
potent, on a weight basis, than larger aggregates at recruiting biotinyl-monomer [Chen,
Berthelier et al. 2001]. Currently, aggregate detection methods are not optimal and often
rely on the fluorescence associated with fusion proteins for identification or antibodies
that recognize the presence of polyGln sequences. Methods such as these may not be
sufficient to recognize every aggregated species that might be present and may not be
specific enough to distinguish among aggregate types and to detect the most toxic
species. Therefore, much attention has been given to the need for more sensitive
detection methods, which should help reveal the aggregation pathway.
In vitro discoveries in our lab [Berthelier et al. 2001; Chen et al. 2001; Chen et al.
2002] led to the development of a highly sensitive stain that recognizes areas active in
recruiting free polyGln monomer [Osmand, Berthelier et al. 2006], allowing for the first
time a functional staining method for better characterizing aggregated species. Initially,
this stain was developed using HD patient and animal brain tissue, but its success in these
settings raised the possibility that such an assay may also be beneficial in characterizing
aggregates in cell culture. The polyGln recruitment stain was adapted and applied to
various cell culture models. In this chapter, we will discuss the optimization of the new
detection method, the problems and limitations of the technique, and the caveats of the
microscopic evaluations.
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In our cell models, htt-polyGln expression was monitored by the presence of a
GFP-fusion tag. The GFP fluorescence yields two expression patterns: diffuse and
punctate. Diffuse fluorescence, in such models, is assumed to be representative of
monomeric species [Lunkes and Mandel 1998; Preisinger et al. 1999; Apostol et al.
2003], and punctate fluorescence is always used synonymously with the term “aggregate”
[Fink 1998; Johnston, Ward et al. 1998; Lunkes and Mandel 1998; Garcia-Mata et al.
1999; Kazantsev, Preisinger et al. 1999; Preisinger, Jordan et al. 1999; Apostol,
Kazantsev et al. 2003]. It must not be overlooked that punctate centers of fluorescence
may also represent a collection of monomers trapped in an organelle, such as a lysosome,
proteasome, or aggresome. However, for the purposes of this dissertation, this
terminology will be adopted; therefore, “diffuse fluorescence” and “monomer” will be
used interchangeably, as will “punctate fluorescence” and “aggregate”. As will be seen
later, this usage is validated by our experimental results. Aggregation foci (AF), which
were identified using the new functional stain, are punctate sites found within the cell that
actively recruit externally added polyGln monomer. AF and polyGln recruitmentcompetency will be used equivalently.

4.2 Detection by Fluorescence:
As mentioned above, the AF stain was originally developed in using HD patient
and animal autopsied brains [Osmand, Berthelier et al. 2006]. This method was modified
for the use in cell cultures (see Section 3.3). One modification to the original protocol
was the method of detection. The preferred method for visualizing AF in cell cultures
was fluorescence. Some major reasons for this was because our protein of interest already
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had a fluorescent tag associated with it, and the use of fluorescence allowed for the ability
to incorporate multiple colors (theoretically, as many as four) within the same
experiment. For our experimental purposes, three fluorescent labels were utilized: 1)
green – expressed upon transfection / induction of htt-polyGln-GFP fusion proteins, 2)
blue – Hoechst dye used to stain the cell nuclei, and 3) red – streptavidin-conjugated
Alexa Fluor® 594 dye used to detect biotinylated polyGln monomer (see Section 3.3).
These three fluorescent labels were chosen for their different absorption properties, which
made it possible for the simultaneous detection of multiple events / species (Figure 4.1).

4.3 Determination of the Correct Incubation Conditions:
The polyGln recruitment stain was optimized primarily in the transiently
transfected

cell

models

expressing

htt-Q47-GFP

constructs.

Various

concentrations of biotinylated polyGln monomer (10nM, 50nM, 100nM, and 500nM)
were incubated with fixed and permeabilized cells for 16 hours at room temperature
(Section 3.3). The concentration that gave the most consistent results and the best
fluorescence signal, while keeping the background to a minimum, was 100nM. After the
optimal concentration had been decided, incubation times (1 hour – 16 hours) and
temperatures (room temperature, 4°C, and 37°C) were varied. Incubation at room
temperature provided the best signal-to-noise ratio, while incubation at 37°C provided
excessive background, presumably due to the self-aggregation of the monomer.
Irrespective of temperature below 25°C, incubation for 16 hours with the biotinylated
monomer provided the best conditions for visualizing AF. These conditions were double-
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(percentage of maximum value)

Wavelength (nm)

Figure 4.1: Absorption spectra of fluorescent dyes used for detection. Dashed lines
represent the excitation spectra, while solid lines represent the emission spectra. Blue
color is for Hoechst dye, green color is for GFP fusion proteins, and red color is for
Alexa Fluor 594® streptavidin-conjugated dye. (Created using Spectra Viewer from
Molecular Probes – http://probes.invitrogen.com/servlets/spectraviewer?fileid1=11005p72).
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checked with the stably transfected PC12 cells, and polyGln recruitment competency was
slightly diminished after prolonged incubation (16 hours) with 100nM of the biotinylated
monomer; therefore, the protocol was modified such that incubation with 100nM
biotinylated polyGln monomer was carried out at room temperature for 2 hours prior to
staining (Figure 3.3). Figure 4.2 shows the optimal conditions for both the transiently
transfected cells and the stably transfected PC12 cells.

4.4 Image Exposure Time Variations:
When working with different fluorescence entities, one problem that is often
encountered is the various camera exposure times that are required for each fluorescent
dye and for varying degrees of fluorescent intensities using the same fluorochrome. An
example of the latter is the situation in which both monomer and aggregate were present
within the same microscopic field. Monomeric expression had much less fluorescence
intensity than an aggregated structure. This is probably due to the concentration of the
protein at any one location or the compact folding of the htt- polyGln-GFP protein, which
presumably brings many GFP into close proximity creating a much more intense object.
In order to collect interpretable data, two exposure times of the green image
where taken so that both types of species could be more properly characterized (Figure
4.3). The first exposure was taken at 500 milliseconds (msec) to capture the diffuse
entities, while the second image was exposed using the automatic / default exposure time
(< 1 msec). Images taken from both exposure times are necessary so that all species can
be accounted for. Exposure times for red images also had to be modified from the normal
default settings of the camera. All red images were photographed first in the series and
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A

B

C
Figure 4.2: Optimal AF staining conditions in a transient and stable htt exon-1 cell
models. (A) Transiently transfected PC12 cells expressing htt-Q47-GFP constructs. (B)
SH-SY5Y cells transiently transfected with htt-Q47-GFP constructs. 100nM biotinylated
monomer was incubated for 16 hours at room temperature before staining in each of the
transient models. (C) Stable 47QP PC12 cells. 100nM biotinylated monomer was
incubated for 2 hours at room temperature prior to staining. Fluorescence color is blue for
cell nuclei, green for htt-polyGln-GFP proteins, and red for AF.
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A

B

Figure 4.3: Various exposure times needed to photograph different fluorescence
entities. Both images are of the same field of stable 103Q cells 24 hours post-induction.
(A) 500 msec exposure time. (B) <1 msec exposure time. Blue color is cell nuclei and
green color is htt-polyGln-GFP protein. The white box shows that diffuse protein was
photographed only when the longer exposure time (A) was utilized, which caused the
aggregated species to be overexposed. Therefore, two exposures of such images were
necessary to account for all species present.
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captured at a 1 second exposure time to account for the diminished fluorescence intensity
and the photobleaching of the Alexa Fluor 594® dye. Blue images were exposed to the
camera using the default settings and were the last fluorescence images taken in the series
because of the high stability of the fluorochrome.
Development and optimization of the AF stain allowed, for the first time in cell
cultures, the observation of a class of aggregates capable of further growth by monomer
addition, as is especially evident in Figure 4.2C. This new technique promised to be very
beneficial in characterizing multiple aggregated species and their roles in the aggregation
pathway.

4.5 Fluorescence Microscopy Caveats:
As will be shown later, we identified a number of morphological forms of htt
exon-1 in our cell models, including dispersed fluorescence normally interpreted as
monomeric protein, as well as several different types of aggregates. It is appropriate in
this discussion of the fluorescence microscopy to include some caveats and rationales for
some of the assumptions we make in the interpretation of our microscopy data.
There were limitations to the types of analysis that could be performed using a
two dimensional imaging system. For example, subcellular localization of the protein
(nuclear/cytoplasmic or co-localization) could not be irrefutably confirmed. In many
images presented throughout this dissertation, there will be an apparent co-localization of
the different polyGln species. The only thing that can be said for certain is that, in the
case of co-localization, the two species, were in the same cellular location (Z-plane), and
without the use of a three dimensional imaging system, such as confocal microscopy, we
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could not exclude the possibility that the two species were, perhaps, independent and not
co-localized. The same is true for the question of nuclear vs. cytoplasmic localization.
The appearance of nuclear accumulation may actually be cytoplasmic accumulation
located in the volume above or below the nucleus. More images will be presented
throughout this dissertation that appear to exhibit co-localization or nuclear distribution,
but when interpreting the data, one cannot must consider the alternative interpretations.
This problem is more difficult to resolve in the case of determining with certainty
whether aggregates are in the nucleus. In contrast, when a cell contains a limited number
of punctuate green objects, and the only red objects observed are found to exactly colocalize with them, it seems unlikely that these objects are not truly co-localized;
however, the possibility remains that they are distinct.
Another limitation of the imaging method is the question of whether diffuse green
fluorescence is actually indicative of monomer. As stated earlier, a diffuse staining
pattern, like as observed in our cells, is often interpreted as monomeric species [Lunkes
and Mandel 1998; Preisinger et al. 1999; Apostol et al. 2003].

However, in our

experiments at least, the “diffuse green” areas often have a speckled appearance and
don’t always provide a uniform distribution. It might thus be argued that the granular
appearance of these “diffuse green” areas might arise from a field of microaggregates ( or
htt-polyGln-GFP in organelles/lysomes/proteasomes) rather than monomeric protein.
However, this granular appearance most likely is a consequence of the camera exposure
time needed to capture the diffuse pattern (Section 4.4). This question could not be
addressed by fluorescence microscopy – at least not with the available equipment – but
instead was addressed by other, biochemical experiments (presented in Chapter 8).
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CHAPTER 5
DEVELOPMENT AND EVALUATION OF CELL MODELS EXPRESSING HTT
EXON-1 CONSTRUCTS
5.1 Rationale:
Implementation and optimization of the AF stain were explored in two types of
cell models: transient and stable. Transient models were explored first, as the most
straightforward approach, while stable, htt-inducible models were utilized in later
experiments and were found to be the superior model system. In this chapter, we will
discuss the development of each of these cell model systems (transient and stable)
expressing htt exon-1 constructs, the limitations, and the problems encountered along the
way.

5.2 Transient Cell Models Expressing Htt Exon-1:
For these experiments, PC12 and SH-SY5Y cells were transiently transfected
with truncated htt exon-1 constructs expressing Q25, 47, 65, and 103 (as described in
Sections 3.1 and 3.2). Protein expression was monitored by virtue of the GFP tag
associated with the htt exon-1 constructs and was calculated at 24 hours post-transfection.
Therefore, no matter the expression pattern, diffuse, punctate, or AF, the images were
scored the same: expression or no expression. Total htt-polyGln expression was similar
for each cell line (Figure 5.1) and aggregation occurred in a polyGln length-dependent
manner (Figure 5.2). Data obtained from the flow cytometer was a measure of cells
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Figure 5.1: PolyGln expression was similar by flow cytometry and
immunofluorescence. Flow cytometry data are shown in the left panels. M2 represents
polyGln expression. Right panels are fluorescence microscopy images: blue – nuclei,
green – htt-polyGln-GFP. Top row is data from PC12 cells transiently transfected with
htt-Q65-GFP at 24 hours post-transfection. Bottom row is SH-SY5Y cells transiently
transfected with htt-Q47-GFP at 24 hours post-transfection.
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Figure 5.2: Aggregation occurs in a polyGln-length dependent manner. PC12 cells
were transiently transfected for 24 hours with various lengths of htt-polyGln-GFP
constructs. (A) Q25, (B) Q47, (C) Q65, (D) Q103. Fluorescence color is blue for cell
nuclei and green for GFP fusion constructs. Cells were exposed to the AF staining
procedure as well but exhibit no red AF above background. Aggregation was faster when
cells expressed longer polyGln repeats.
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exhibiting GFP fluorescence and did not necessarily reflect any species that exhibited
AF, while microscopic measurements were calculated by counting cells that exhibited all
types of htt-polyGln fluorescence (red and/or green) and dividing by the total number of
cells in the microscopic field.
For microscopic experiments, SH-SY5Y cells were differentiated in order to aid
in cellular attachment. However, experiments involving PC12 cells were performed
without differentiation because the cells did not possess the same detachment properties
that were observed with SH-SY5Y cells (Section 3.2). Figures 5.3 and 5.4 show a
temporal progression of polyGln expression in transiently transfected PC12 and SHSY5Y cells, respectively.
Cells expressing htt exon-1-Q25-GFP exhibited a faint, diffuse green fluorescence
throughout the cytoplasm (PC12 and SH-SY5Y cells) and/or the nucleus (SH-SY5Y
cells) at all time points studied and never showed any aggregation foci. In contrast, cells
transfected with htt exon-1-Q47, 65, or 103-GFP produced two types of aggregates
(Figure 5.5). One class consisted of punctate green-fluorescent aggregates that developed
by 24 hours and whose numbers correlate with polyGln-repeat length (Figure 5.6). These
aggregates were primarily located just outside the cell nucleus (perinuclear) in the PC12
cells with some apparent localization in the nucleus for SH-SY5Y cells. The second class
of aggregates were recruitment-competent but at the same time not observable by GFP
fluorescence. These were more evident in cells expressing htt exon-1-Q47 and Q65-GFP,
and tended to form at early time points (Figure 5.6). Aggregates that exhibited GFP
fluorescence appeared to be coincident with AF at early time points (Figures 5.3 – 5.6),
but, as the cells aged, less co-localization was observed.
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Figure 5.3: Transiently transfected PC12 cells expressing various polyGln-length
constructs. Blue – nuclei, Green – htt exon-1-Qn-GFP, Red – aggregation foci. (a)
Columns from left to right represent the various lengths of polyGln constructs expressed
in PC12 cells. Rows from top to bottom show the temporal progression of polyGln
expression from 16 hours to 72 hours post-transfection. A magnification for observing
specific detail will be provided for pictures of particular interest. For example, at 16
hours and 12 hours post-transfection with htt-Q47-GFP and htt-Q65-GFP, respectively, a
class of aggregates form that are recruitment-positive but do not exhibit green
fluorescence (b). GFP aggregates are often found superimposed on AF in the same focal
plane, yielding a yellow color mix which represent co-localization, as shown in cells
transfected with htt-Q65-GFP for 24 hours (c).
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Figure 5.3. Continued.
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Figure 5.4: Transiently transfected retinoic acid differentiated SH-SY5Y expressing
various htt exon-1-Qn-GFP constructs. Blue – nuclei, Green – htt exon-1-Qn-GFP,
Red – aggregation foci. (a) Columns from left to right show the different polyGln lengths
expressed in cells. Rows from top to bottom show the time-dependent manner of polyGln
expression. At 24 hours post-induction, SH-SY5Y cells transitioned from a mostly
adherent cell line to a mostly floating cell line. A magnification for observing specific
detail will be provided for pictures of particular interest. At 12 and 16 hours posttransfection with htt-Q47-GFP AF were the predominant species (b). GFP aggregates are
often found in the same focal plane as AF, which represent co-localization, as shown in
cells transfected with htt-Q65-GFP for 16 hours (c)
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Figure 5.4. Continued.
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Figure 5.5: Aggregated species observed in transiently transfected PC12 cells. (A)
htt-Q103-GFP at 16 hours post-transfection. (B) htt-Q47-GFP at 16 hours posttransfection. (C) htt-Q103-GFP at 72 hours post-transfection. Blue – cell nuclei, green –
htt-polyGln-GFP constructs, red – AF.
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Figure 5.6: Percentage of cells exhibiting different polyGln expression patterns in transiently transfected PC12 cells.
Data were obtained from microscopy images. At least two independent fields were counted within a single experiment. No AF
or punctate green aggregates were observed in cells expressing htt-Q25-GFP constructs (data not shown). Red bars represent
AF, green bars represent punctate htt-polyGln-GFP aggregates, red/green stripped bars indicate the aggregates that exhibit both
green and red species.
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Interestingly, PC12 and SH-SY5Y cells expressing htt exon-1-Q47 exhibited an
abundant population of AF at 16 hours post-transfection, prior to the formation of
punctate polyGln aggregates detected by GFP fluorescence (Figures 5.3, 5.4, and 5.6).
AF diminished with increasing transfection times as the larger, GFP polyGln aggregates
became more abundant. The implications of the timing of appearance of these two
classes of aggregate will be considered in a later chapter.
As expected, cells expressing the hyperexpanded htt exon-1-Q103-GFP construct
were more aggressive in the formation of polyGln aggregates. Interestingly, there was a
mixture of both recruitment-competent and recruitment-inert GFP-positive aggregates
(Figure 5.6). The small number of AF observed only briefly exhibited coincidence with
the punctate polyGln aggregates. At later stages of cell growth, green fluorescent
aggregates inefficient at polyGln recruitment became more dominant.
We observed inconsistencies in the expression patterns for both cell lines in
multiple experiments, irrespective of the polyGln length (Figure 5.7). For example, one
experiment would yield polyGln expression of 35%, while another experiment (following
the same protocol) would yield an expression of 18%. These data were again confirmed
by flow cytometry (Figure 5.8). The inconsistencies observed did not appear to correlate
with the passage number of the cells before transfection.
Regardless of the cell line, htt exon-1-Qn-GFP protein expression was never more
than 35% at 24 hours post-transfection, and cells with aggregation foci numbered far less
than that (21% maximal expression), and these upper limits placed a number of
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Figure 5.7: Inconsistencies observed in percentage of polyGln expression. Data was
obtained from at least 4 independent experiments. PolyGln expression was calculated at
24 hours post-transfection as the percentage of cells expressing any detectible form of htt
exon1: diffuse green, punctuate green, or red AF. This total expression figure was never
more than 35%, and the numbers varied, in most cases, by at least 10%.
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18.24%

16.5%
Figure 5.8: Transfection efficiency varied between experiments. SH-SY5Y cells were
transiently transfected for 24 hours with htt-Q47-GFP. Left panel: flow cytometry. Right
panel: immunofluorescence, blue – nuclei, green – htt-polyGln-GFP. Expression levels
decreased from 35% as is shown in Figure 5.1.
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restrictions on the kinds of experiments we could do and the kinds of interpretations we
could make. With such low expression levels and the transient time frame in which AF
were present; characterization of the various aggregates would have been challenging and
not very fruitful. For example, in a cell population expressing only a handful of
aggregates, as is evident in Figures 5.2 – 5.4, it is very difficult to make global
interpretations from extracts of the entire population, especially when this population of
cells is the minority. The above limitations led us to investigate an alternative model
involving stably transfected cells engineered for inducible expression, described next.

5.3 Stable PC12 Model Expressing Various Htt Exon-1 Constructs:
Although the work on the transient protein expression systems provided the
groundwork for the dissertation research, the majority of the experiments and the most
exciting data were obtained from PC12 cells stably transfected for inducible expression
of htt exon-1 (see Sections 3.1 and 3.2). This section will provide the details pertaining to
the creation a viable cell model system that exhibited a high percentage of polyGln
expressing cells and the troubleshooting that was addressed along the way.
For these experiments, stable PC12 cells expressing complete htt exon-1
constructs (Gln repeats: 25, 47, and 103) and truncated htt exon-1 fragments (Q103) were
induced for 24 hours, as described in Section 3.2, to determine the initial polyGln
expression levels in each of the cell lines. As with the transient models, polyGln
expression was monitored by following the green fluorescence of the attached GFP
molecule. Given that we found an excellent correlation between the quantitative flow
cytometry data and qualitative immunofluorescence images in all our transient expression
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experiments (Figures 5.1 and 5.8), in subsequent experiments only the microscopy data
was used to determine levels of expression. As received from the Thompson lab, the
25QP and 103QP cells had initial GFP expression levels of ~32%, while the 47QP cells
had a beginning expression level of ~22%. Q103 cells, on the contrary, exhibited a high
number of cells the expressed htt-polyGln-GFP (~65%).
Considering the relatively low percentages of protein expression in the cells
expressing the complete htt exon-1 constructs, these three cell lines were subcloned with
selection for high htt-GFP expression (Figure 5.9 for representative) (see Section 3.2)
[Freshney 1987]. After the cells had been subcloned, percent expression increased to
~56% in each cell line. While the 25QP and 103QP cell lines after subcloning maintained
these expression levels, a stability issue arose with the cell line expressing the
physiologically relevant Gln repeat (47QP). Following a freeze/thaw cycle of the 47QP
cells, polyGln expression reverted back to the observed basal expression levels of ~22%
(Figure 5.10). Furthermore, the intensity at which the polyGln species were observed in
the subcloned cells prior to the freeze/thaw cycle was vastly superior to those seen
afterwards. Repeated attempts at subcloning the parental 47QP cells did not yield
satisfactory results. Finally, our collaborators kindly supplied a new parental vial of cells
from an earlier passage and a separate clone. Upon subcloning these cells, we were able
to achieve and maintain 47QP cells that exhibited high clonal integrity for exon-1
production, irrespective of the amount of times they were subjected to freezing and
thawing (Figure 5.11).
Considering polyGln expression was stabilized after receiving the new vial of
parental 47QP cells, the problem we encountered using the original lot of cells was
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Figure 5.9: Representative sample of cells before and after clonal dilution. Top
panel: 103QP cells prior to enrichment. Bottom panel: 103QP cells after selection for a
high percentage of htt-polyGln-GFP expressing cells. (A & C) Phase contrast microscopy
image. (B & D) Fluorescence images taken using a FITC filter.
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A

B

Figure 5.10: Stable PC12 cells expressing 47QP were unable to maintain high clonal
integrity once subjected to a freeze/thaw cycle. (A) Cells were photographed at 48
hours post-induction and exhibited ~56% htt-polyGln-GFP prior to being frozen. (B)
Cells were thawed and induced for 48 hours. Expression levels dropped to ~20% after
the cultures had been thawed. Blue – nuclei, green – htt-polyGln-GFP, red – AF.

Figure 5.11: New 47QP parental cell line generated stable expression after repeated
freeze/thaw cycles. Photograph was taken 48 hours post-induction. Blue – nuclei, green
– htt-polyGln-GFP, red – AF.
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probably due to poor stability of the inserted transgene into that particular parental clone.
Obtaining a different clone of the 47QP parental cells appeared to resolve the problem,
and additional subcloning provided a population with high clonal integrity that was
unaltered by successive freeze/thaw cycles.
Other complications arose during experiments with the stable PC12 cells. A
reoccurring obstacle that was addressed in many ways but was never quite resolved was
the issue of cell detachment. Irrespective of the incorporated htt construct and inducing
agent, each cell line had a tendency to lift from the coverslips on which the cells were
grown. As mentioned with the transient cell lines (Section 3.2), this phenomenon limited
cell numbers at later growth points and introduced the possibility that selective
detachment might skew results. Several steps were taken to address this issue including
the use of poly-D-lysine, a common attachment factor used in cell culture, as a coating
agent. Another change that was integrated into the protocol was the use of the pH
buffering agent HEPES. While these efforts yielded some improvement, the most useful
change was to the seeding density of the cells. These cells had a very quick doubling time
(32-36 hours). Once the cultures became slightly overgrown, the cells began to detach;
this may be due to a depletion of nutrients in the culture medium, but detachment seemed
to occur regardless of how often the media was changed. In any case, decreasing the
density at which the cells were plated provided the most beneficial results and decreased
the detachment rate, which was especially evident in the later time points. Prior to these
changes, an estimated 50% of the plated cells lifted from the coverslips; however, after
the changes were incorporated, we estimated that <10% of the culture had detached. We
also examined the detached cells, and found that the cells that had lifted from the
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coverslips were a mixed population of cells that expressed the GFP transgene and those
that did not. Thus, the detachment problem was not a direct effect of the incorporated htt
transgene, and it is clear that detachment is not an indication of polyGln-dependent cell
death or dystrophy.
One of the biggest obstacles encountered was the inability to view polyGln
recruitment via live cell microscopy. A drawback to the current staining technique is that
in order for the cells to take up free monomeric peptide, the cells must be permeabilized.
For this reason, there was no feasible way to view polyGln incorporation in real-time. In
principle, this might be done by co-expression of an appropriately tagged short polyGln
substrate, analogous to our biotinylated polyGln peptide; however, the problem of
peptide uptake would have still been present.

PRESENCE OF INDUCIBLE-HTT DOES NOT CAUSE CYTOTOXICITY
Many cell models have shown reduced viability when cells express an expanded
polyGln protein [Lunkes and Mandel 1998; Chai et al. 1999; Li, Cheng et al. 1999;
Wyttenbach et al. 2001; Yang et al. 2002; Aiken, Tobin et al. 2004], while other groups
have found contradictory results [Ding et al. 2002; Apostol et al. 2003; Webb, Ravikumar
et al. 2004]. Prior to aggregate characterization (discussed in Chapter 6), we wanted to
confirm whether or not the htt constructs were causing cell death. As discussed earlier,
while cell death might in some sense validate these cells as a valid model for HD, the loss
of cells and their contents during the experiment – and before analysis – would clearly
have complicated the interpretation of data. Microscopically, it did not appear that the
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presence of the htt insert was causing cell death. However, it was imperative to determine
whether or not this was true.
We performed an MTS reduction assay (Section 3.4) to determine the number of
proliferating cells within each induced culture at 24 hours post-induction. We found that,
irrespective of the polyGln length insert, overt cytotoxicity was not detected (p>0.2,
Figure 5.12). As is evident by the absorbance values in Figure 5.12, each cell line was
plated at different seeding densities. Regardless of the plating density, polyGln
expression had no effect on cell viability.
It has been shown that, for reasons not entirely understood, these particular cell
lines are not susceptible to polyGln-induced cytotoxicity [Apostol, Kazantsev et al.
2003], and our data were consistent with these results. Recently, Apostol and colleagues
performed gene expression profiling on this particular cell line and showed that genes,
such as HSP27 and 70, involved in pro-survival pathways were significantly upregulated
[Apostol et al. 2006], providing a possible reason why these cells do not die even with
nuclear aggregates present.
We were successfully able to subclone three of the four received stable cell lines.
The fourth did not need further enrichment because they were initially obtained at an
already high clonal integrity. Each cell line provided consistent expression levels from
experiment to experiment, and the protein abundance (~60%) was far superior to that of
the transient models (~30%). These data will be presented in the next chapter. The use of
an inducible system was also beneficial because it provided more control of the
experimental timeline, i.e. the experiment could be conducted for longer times. The
majority of the stable cell lines were designed to produce complete htt exon-1 proteins,
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Figure 5.12: Polyglutamine expression does not cause cell death. Each cell line was
plated at different seeding densities: 25QP cells were plated at a density of ~100,000
cells/cm2; 47QP and 103QP cells were plated at a density of ~60,000 cells/cm2; and Q103
cells were plated at a density of ~200,000 cells/cm2. A cell proliferation assay (MTS
reduction) was performed to measure the number of viable cells. Although there were
slight fluctuations in the number of measurable cells, no significant change was observed
when uninduced controls were compared to the induced samples.
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which provided more physiological relevance than the truncated models lacking the
proline rich C-terminus. It has been well documented that the presence of a proline-rich
sequence following polyglutamine in huntingtin significantly decreases the rate of
aggregate formation [Bhattacharyya, Thakur et al. 2006; Dehay and Bertolotti 2006].
Inclusion of the proline-rich segment not only made the cell model more relevant to the
disease situation, it also slowed down at least some aggregation reactions, providing an
opportunity to observe the cells prior to the development of polyGln aggregates and to
monitor the aggregation pathway (discussed in Chapter 6). This was in contrast to our
transient transfection models in which aggregates developed very rapidly, making it
difficult to dissect precursor-product relationships. The fact that the cells did not exhibit
cytotoxicity was also an advantage because that allowed us to focus strictly on the
aggregation pathway without complicating the interpretation with cellular demise.
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CHAPTER 6
CHARACTERIZATION OF POLYGLUTAMINE AGGREGATES IN STABLE PC12
CELLS EXPRESSING HTT EXON-1 CONSTRUCTS
6.1 Nomenclature for Identified PolyGln Species:
With the detection of multiple polyGln species in the stable, htt-inducible PC12
cells (to be discussed later in the chapter), a simple nomenclature is clearly required.
During this section we will establish a nomenclature for the observed polyGln species,
which will be used throughout the remaining dissertation.
The species identified were categorized into four major divisions (Figure 6.1): 1)
Diffuse, monomeric protein (designated Monomer, M), 2) Aggregation foci, which were
recruitment-competent, diffusely scattered throughout the cytoplasm, and did not
demonstrate green fluorescence (designated Green- Red(Cytoplasm)+, G-RC+), 3) Aggregates
that showed GFP formation but did not exhibit recruitment-capabilities (designated
Green+ Red-, G+R-), and 4) Aggregates that were large enough to be visualized via their
GFP component but also exhibited polyGln recruitment (designated G+RC+), which
represented only a small percentage of the observed species and were observed only in
the cytoplasm.
Furthermore, the class that was designated G+R- was found in two different
cellular locations: the majority was perinuclear (designated GC for cytoplasmic
localization, Figure 6.1C), while ~5% were nuclear (designated GN for nuclear
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C
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GC+RC+

E
Figure 6.1: Distinct polyGln species identified within stable PC12 cells expressing
htt-inducible proteins. (A) Diffuse monomeric protein. M, green fluorescent protein was
found diffusely scattered throughout the cytoplasm of most cells. Diffuse staining was also
found in some cell nuclei during later time points. (B) Aggregation foci. G-RC+, polyGln
recruitment competent centers that were not detectable by the GFP component. (C) PolyGln
aggregates that did not exhibit recruitment-competency located in the cytoplasm. GC+R-. (D)
Nuclear aggregates that were recruitment-inert. GN+R-. (E) Perinuclear aggregates that were
also capable of polyGln recruitment. GC+RC+, these structures were only visualized in the
103QP cells at early time points. White inset shows that AF were coincident with GFP
aggregates. Blue – nuclei, Greene – htt-polyGln-GFP, Red – AF.
138

localization, Figure 6.1D). Perinuclear aggregates are commonly defined as an
aggregated structure that is found in the cytoplasm close to the nucleus or associated with
the nuclear membrane [Kazantsev, Preisinger et al. 1999]. These structures are also
generally quite large and even, in some instances, appear to distort the shape of the
nucleus. In the case of the stable PC12 cells, perinuclear aggregates were often 1/5 or
greater the size of the cell nucleus and were easily visualized by their fluorescent tag.
Nuclear aggregates, on the other hand, have been described to be much smaller and are
located inside the cell nucleus [Kazantsev, Preisinger et al. 1999] but can also be
observed via their fluorescent label.
The remaining chapters of the dissertation will adopt this nomenclature and will
present experiments specifically designed to provide insights into a key question that
plagues HD research: Are these small, recruitment-competent aggregates that occur early
in development precursors to the larger, recruitment-inert, GFP-positive aggregates, or do
they form via separate, parallel assembly pathways?

6.2 Microscopic Observations:
This section will present the findings of the data obtained using the stable PC12
cells expressing htt exon-1 constructs of varying polyGln repeat lengths (25QP, 47QP,
103QP, and Q103, described in Chapter 3). At least three polyGln species were
visualized during the seven days in which the replicating cells were monitored by
fluorescence microscopy (see Figures 6.2 and Figure 6.3). With respect to GFP
fluorescence, cells expressing 25QP and 47QP exhibited only diffuse green, indicative of
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Figure 6.2: Percentage of polyglutamine expression within huntingtin-inducible PC12 cells. Data were collected from at
least two separate experiments. For each time point, cells were counted from three or more independent fields. The data are
expressed as the percentage of total cells that exhibited either htt monomer ( ), htt-polyGln-GFP aggregates ( ), or
aggregation foci ( ). Data shown are from 16-168 hr. post-induction.
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Figure 6.3: Kinetic study of polyglutamine formation in huntingtin-inducible, stable
PC12 cells and uninduced controls. Fluorescent color is blue for cell nuclei, green for
GFP fusion constructs, and red for aggregation foci. Time labels indicate hours postinduction. (a) First panel: Untreated control PC12 cells. Second panel: Cells expressing
25QP. Third panel: Cells expressing 47QP. (b) First panel: Cells expressing 103QP.
Second panel: Cells expressing Q103. In each panel, the left column represents images
taken by modified differential interference contrast (DIC) microscopy. The last column in
each panel represents the red, green, and blue merged image. Where present, the middle
column(s) show a merger of only the red and green images, where the detail of AF and
htt colocalization may be more easily observed. In part b of the figure, two exposures of
the same image were taken. The second image was taken at a longer exposure so that the
monomeric species could be photographed (Section 4.3). In the 103QP cells, where htt
aggregates were also recruitment-competent, insets (solid white boxes) are included
showing the red image prior to the merger with the green image. Details of each image
can be observed at a higher magnification. (c) Diffuse fluorescence and AF were the only
species observed with 25QP and 47QP cells. Displayed images were taken at 24 hours
post-induction. (d) Punctate aggregates were present in cells expressing both complete
and truncated htt exon-1 constructs. Images were photographed at 24 hours postinduction. The amount of htt-polyGln-GFP aggregates increased with longer induction
times (Figure 6.2).
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presumably monomeric htt expression (Figure 6.3c), throughout the seven day
experiment; whereas cells expressing 103QP and Q103 developed punctate green htt
(presumably aggregates) early in development that increased in number as the cells aged
and divided (Figures 6.2 and 6.3d). In addition to green fluorescent species, a third
species, AF (red fluorescence), was present only in cell lines expressing intact htt exon-1
including the Pro-rich segment and were not observed (<3%) in Q103 cells that expressed
truncated htt exon-1 (Figures 6.2 and 6.3c-d).
All three cell lines expressing complete htt exon-1 constructs exhibited steady M
expression over the initial 72 hours (Figure 6.2). In all three cell lines, this expression
peaked at peaked at 96 hours. While 25QP cells maintained this high M expression out to
168 hrs, diffuse expression dropped somewhat after 96 hrs for the 47QP and 103QP cells.
All three cell lines also exhibited steady levels of cells expressing G-RC+ over the first 72
hrs, after which the percentage of cells with G-RC+ declined, generally by about a factor
of 2. Of these three cell lines expressing complete exon1 constructs, only the 103QP
cells exhibited any significant formation of punctate green bodies; these increased in
number from 24 to 120 hrs, after which levels remained fairly steady.
In contrast, Q103 cells expressing a construct lacking the proline-rich region
exhibited a rapid decline in M expression from 16 to 72 hours, with a commensurate
rapid rise in punctate green bodies over the same time period. By 144 hrs over 70% of
cells had punctate green bodies and no cells exhibited diffuse GFP staining.
Significantly, only a very low percentage (<3%) of G-RC+ were observed at any time
point.
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All cell lines exhibited very good homogeneity of expression, a reflection of their
being products of rigorous subcloning procedures as well as an indication of the stability
of their gene insertions. Thus, by 48 hrs, the Q103 cell line exhibited 94% of cells with
some manifestation of htt exon-1 expression. By 96 hrs, 47QP and 103QP reached
maximal expression of 84 and 66%, respectively. The 25QP cell line reached maximal
expression at 24 hrs, with 84% of cells exhibiting expression of the transgene.
The AF expression patterns in the QP cell lines is especially interesting in several
respects. First, the conventional view is that cells expressing htt exon-1 with normal
length polyGln do not make significant aggregates, and indeed this is the case if
aggregation is only detected as punctate green bodies. However, using the recruitment
stain we observe significant G-RC+ formation even at early time points and even in 25QP
cells. Second, in 103QP cells, G-RC+ form early while punctate green bodies form later,
suggesting a possible precursor-product relationship. Interestingly, at early time points in
these 103QP cells, AF co-localize with punctate GFP bodies (Figure 6.4); while at later
times, fewer punctate green bodies contain G-RC+ (Figure 6.5); this also suggests a
precursor-product relationship where AF develop first. The Q103 cells are also consistent
with a progression of AF to punctate GFP bodies; since removal of the proline rich
sequence is expected to lead to more aggressive aggregation (more than triple the number
of GC/N+R- species, see Figure 6.2), AF may progress so rapidly to punctate GFP bodies
that few G-RC+ are ever detected. However, these data alone were not sufficient to rule
out the possibility that they were forming via alternate assembly pathways. These results
will be considered further in the last chapter.
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Figure 6.4: GC+RC+ aggregates appear to co-localize with G-RC+ in cells expressing
103QP. Blue – cell nuclei, green – htt-polyGln-GFP fusions, red – G-RC+. The first and
second panels show the separate images taken with the green and red filter sets,
respectively. The third panel shows a merger of the images including the cell nuclei.
Images were taken at 48 hours post-induction of cells expressing 103QP constructs.

Percentage GFP aggregates

103QP
140%
120%
100%
80%
60%
40%
20%
0%
16

24

48

72

96

120

144

168

Time (hours)
Figure 6.5: Co-localization of G-RC+ and GC+RC+ aggregates in cells expressing
103QP diminished with time. PolyGln aggregates measurable by their GFP
fluorescence were counted and scored for their apparent coincidence with AF. Data were
collected from at least five non-overlapping fields in two independent experiments. Data
is expressed as percentage of GFP aggregates that were coincident with AF. Earlier time
points demonstrated a higher percentage of error due to the presence of fewer polyGln
aggregates.
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Another intriguing observation was noted in cells expressing Q103. These cells
exhibited small GN+-R- aggregates (Figure 6.6), which were not seen with any other cell
line. Figure 6.7 shows that the percentage of cells that contained nuclear aggregates were
far less than those that contained the larger GC+R- aggregates. Why does this cell line
uniquely produce nuclear aggregates? One possibility is that the proline rich segment is a
nuclear export signal, so that when it is present it strongly counter-balances some
intrinsic ability of htt exon-1 to enter the nucleus. Another possibility is that there is
always some cycling of htt exon-1 through the nucleus, which however normally does not
lead to accumulation because of a stronger export signal. However, with Q103, rapid
aggregation within the nucleus traps the exon-1.

Other explanations are possible.

Previously it was shown that when recruitment-positive polyGln aggregates are delivered
to the nuclei of PC12 cells, they rapidly die [Yang, Dunlap et al. 2002]. Presumably the
GN+R- aggregates observed here are not toxic because they are not recruitment positive
(i.e., are not G-RC+).
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Figure 6.6: Cells expressing Q103 exhibited GN+R- aggregates. Images were obtained
at 24 hours post induction. The left column represents green images (htt-polyGln-GFP
fusions), while the right column represents a merger of the image with the blue (nuclei).
Both top and bottom pictures are the same microscopic field. (A) Images were taken at a
longer exposure time to photograph diffuse and nuclear entities (500msec). (B)
Photographs acquired at a shorter exposure.
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Figure 6.7: GN+R- aggregates were observed but were less abundant than GC+Raggregates in cells expressing Q103 constructs. Data were obtained from two separate
experiments and from at least 3 independent microscopic fields. Data are expressed as
percentage of cells expressing either GN+R- or GC+R- aggregates.
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CHAPTER 7
MECHANISTIC STUDIES OF AGGREGATE FORMATION
7.1 Rationale:
We were successful in identifying multiple polyGln species within stable PC12
cells that are inducible for htt expression. Identification of two of those species, G-RC+
and GC+RC+, relied solely upon the development and implementation of a stain that is
based upon the ability of aggregated polyGln proteins to recruit free monomeric polyGln
[Berthelier et al. 2001; Chen et al. 2001; Chen et al. 2002; Osmand et al. 2006]. This
characteristic is similar to other amyloid diseases, in which a proposed mechanism of
fibril growth is facilitated by monomer addition [Lomakin et al. 1996; Lomakin et al.
1997; Collins et al. 2004; O'Nuallain et al. 2005]. With the identification of the various
species, the next logical step was to undertake the challenge of discerning each of their
roles in the aggregation process. This question was addressed in two manners: 1) utilizing
a compound that has been shown to inhibit amyloid formation in vivo [Yang, Lim et al.
2005] and 2) using other compounds to alter cellular processes that have been implicated
in aggregation [Johnston et al. 1998; Webb et al. 2004; Ross and Poirier 2005; Chang et
al. 2006].

7.2 Curcumin Inhibits G-RC+ Species in a Dose-dependent Manner:
Curcumin, the main ingredient in the Indian curry spice tumeric, has been used
therapeutically for its anti-inflammatory, anti-oxidant, and anti-amyloid properties [Lim
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et al. 2005; Yang et al. 2005]. Curcumin is a low molecular weight compound that has a
favorable toxicity profile and is currently being investigated as a potential
chemotherapeutic agent for cancer [Kelloff, Boone et al. 1996]. Curcumin has been found
effective at inhibiting the formation of Aβ fibrils at concentrations ranging from 0.5µM8µM. Recently, curcumin was also shown to reduce aggregate formation and ameliorate
rearing deficits in an HD mouse model [Zhu 2006]. Because of the possibility that
curcumin might selectively inhibit amyloid formation, and not other aggregation
reactions, we chose to treat our stable PC12 cells with curcumin and to monitor any
effects on the aggregation pathway.
To monitor the effects of curcumin on aggregate formation, we chose to use the
htt-inducible cells expressing 25QP and 47QP, a benign polyGln length and a diseaserelevant polyGln length, respectively. In vivo, the most common Gln repeat length is ~42
(Figure 1.12). These particular cell lines exhibited diffuse monomeric staining and never
displayed punctuate GFP-positive aggregates within a one week time frame. However,
~40% of the population expressed G-RC+ species (Figure 6.2) at any given time. The
question we wanted to answer was if curcumin inhibited or accelerated the production of
AF.
Cells were plated and maintained under the same conditions as previously
described (Section 3.2). 25QP and 47QP cells were induced with 5µM Ponasterone and
simultaneously treated with 0.1, 1, or 10µM of curcumin (10mM stock in ethanol) for 24
hours. After one day of incubation with the compound and inducing agent, the cells were
fixed, permeabilized, and subjected to the AF stain (Section 3.3).
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As shown in Figures 7.1 and 7.2, curcumin treatment decreased the formation of
G-RC+ in both 25QP and 47QP cells by >40% at all concentrations tested (p≤0.02), while
not appreciably altering the M expression. This effect was dose-dependent, with 10µM
curcumin (the highest concentration tested) showing a 75% reduction in AF, p≤0.003
(Figure 7.2). While shifting the balance of AF in the cultures, there was no alternate build
up of GFP-positive aggregates as one might expect based on other data using other
polyphenolic compounds (Figure 7.3A) [Mazzulli et al. 2006; Berthelier unpublished
data]. Our lab has shown in vitro that the treatment of Q50 synthetic aggregates with
catechols modifies polyGln aggregate morphology so that the aggregate appears more
truncated than an untreated fibril (Figure 7.3B) and are incapable of extension in a
polyGln elongation assay (Section 3.8) [Berthelier unpublished data]. These data support
other in vivo findings where catechols were found to be inhibitors of α-synuclein
aggregation while facilitating the formation of oligomeric intermediates [Mazzulli et al.
2006]. Furthermore, curcumin is similar in structure to CR in that both have charged
poles and are symmetrical with a hydrophobic spacer. CR has been shown to inhibit the
oligomerization of polyGln in cell cultures as well as had beneficial effects when
administered to mice [Sanchez et al. 2003]. Also important to note is that no visual
cytotoxic response was induced by curcumin treatment. For this reason, a cell
proliferation assay was not performed. Implications of these results will be discussed in
Chapter 9 of the dissertation.
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Figure 7.1: Effects of curcumin on aggregation foci in 25 QP and 47QP cells. Cells were simultaneously exposed to the
curcumin and inducing agent for 24 hours. Top row: 25QP cells. Bottom row: 47QP cells. From left to right cells were treated
with 0, 0.1, 1, or 10µM curcumin. Fluorescence colors: blue – cell nuclei, green – htt-polyGln-GFP fusion protein, red –
aggregation foci.

154

25QP
*p≤0.02
**p<0.0002

% Expression

100%
80%
60%

Aggregation foci
Diffuse Expression

40%

*

20%

*

**

0%
0

0.1

1

10

Concentration (uM)

47QP
*p=0.03
**p<0.003

% Expression

100%
80%
60%

Aggregation foci
*

40%

Diffuse Expression

**

20%

**

0%
0

0.1

1

10

Concentration (uM)

Figure 7.2: Curcumin inhibited G-RC+ in a dose-dependent fashion. Cells were plated
at a density of 100,000 cells/cm2 16-24 hours prior to the addition of ponasterone and
curcumin. Results are calculated from four independent fields within a single experiment.
More than 100 cells per field were counted. Data are expressed as percentage of cells
expressing either species. An unpaired Student’s t-test was used to calculate the p values.
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A
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Q50 fibrils

+10µM Myricetin

Figure 7.3: Curcumin is similar to Myricetin, which alters aggregate morphology.
(A) Curcumin and Myricetin are antioxidants that contain phenol groups. (B) Q50
synthetic fibrils untreated or treated with 10µM Myricetin. Myricetin alters aggregate
morphology. [Berthelier unpublished data]
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7.3 Demecolcine inhibits GC+R- Species:
Since similar anti-amyloid effects of curcumin are seen in vitro, the role of
curcumin in the above experiments is probably to attack the biophysical mechanism of
aggregate assembly as it would occur in a simple in vitro experiment. Another approach
would be to test a compound that interferes with a cellular mechanism potentially
involved in modulating protein aggregation.
Therefore we now describe experiments in which cells were treated with a
compound known to disrupt a vital cellular mechanism, i.e., microtubules, that are critical
in aggresome formation [Johnston et al. 1998; Webb et al. 2004; Ross and Poirier 2005;
Chang et al. 2006]. Aggresome formation is initiated in response to a cellular stress
response, such as the overexpression of an insoluble, misfolded protein. Aggresomes are
also characterized by perinuclear, large aggregates reminiscent of those seen in the Q103
expressing PC12 cells. It has been well documented that aggresome formation can be
inhibited by disrupting microtubule polymerization [Johnston et al. 1998; Garcia-Mata et
al. 1999; Dul et al. 2001; Webb et al. 2004]. It was, therefore, important to examine the
possibility that GC+R- structures might be aggresomes and whether treating the culture
with a microtubule disrupting compound might alter aggregate formation.
Demecolcine is a compound known to synchronize the cell cycle and interfere
with microtubule polymerization [Luduena and Roach 1991; Nishiyama and Fujii 1992;
Sherwood et al. 1994; Wang et al. 1998; Dul et al. 2001; Knockaert et al. 2002]. At the
same time, demecolcine has not been shown to exhibit any remarkable effects on other
biochemical events within the cell [Nishiyama and Fujii 1992].
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DETERMINATION OF THE APPROPRIATE COMPOUND CONCENTRATION
Htt-inducible cells expressing Q103, which make aggregates very aggressively,
were chosen to test the effects of the compound because of the abundance of perinuclear
Gc+R- species in these cells. The assumption was that this cell line would display the most
measurable amount of inhibition if these aggregates were formed via a microtubuledependent mechanism. Q103 cells and the 25QP control cells were subjected to the same
induction protocol as previously described (Section 3.2) with the simultaneous addition
of demecolcine for 24 hours. Percentage of htt-polyGln was calculated based on the
number of cells expressing GFP-positive monomers and/or aggregates. The data were
obtained by assessing a minimum of 200 total cells within five non-overlapping
microscopic fields.
Based on the literature, a variety of compound concentrations (70ng/ml (190nM)400ng/ml (1.1µM)) have been shown effective at inhibiting aggresome formation
[Sherwood et al. 1994; Dul et al. 2001; Knockaert et al. 2002]. For this reason, it was
important to establish an effective inhibitory dose in our inducible cell system. We tested
demecolcine in a concentration range of 0ng/ml-1,000ng/ml.
Based on an examination of diffuse staining, polyGln monomer expression (M) in
25QP cells was unaffected by the compound treatment (Figure 7.4A), suggesting the
compounds did not interfere with the normal protein production within the cells. Without
demecolcine treatment, Q103 cells yielded ~38% GC+R- species and ~5% GN+R- species
(Figure 7.3B). However, upon compound treatment, there was a significant reduction in
the percentage of cells that expressed the GC+R- species (decrease from 38% to <10%). In
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Figure 7.4: Effects of demecolcine on M and GC+R- expression. 25QP and Q103 cells
were treated with various concentrations of demecolcine. (A) Monomeric expression was
relatively unaffected by compound treatment, as indicated in 25QP cells. (B)Percentage
of Q103 cells that expressed GC+R- or GN+R- species. GN+R- species were relatively
unaffected by demecolcine treatment; however, GC+R- species were dramatically reduced.
Percent expression was calculated based on the number of GFP-positive cells/total cell
number. At least 200 cells in five non-overlapping fields were counted.
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contrast, there was no statistically significant difference in the number of cells expressing
GN+R- species (Figure 7.4B).
The effects we observed appeared to be dose-independent at the concentrations
that we tested: 50ng/ml had the same significant GC+R- reduction as the 1,000ng/ml dose
(Figure 7.4B). Figure 7.5 shows a representative image of Q103 cells prior to
demecolcine treatment and an image after 24 hours treatment with 50ng/ml demecolcine.

7.4 Use of the PolyGln-recruitment Stain on Demecolcine Treated Cells:
Initial experiments indicated that demecolcine treatment mediated a significant
reduction in GC+R- aggregates; however, it was uncertain whether the compound had any
effect on the GC+RC+ or G-RC+ species. In order to test the effects of demecolcine on each
of the polyGln species, all htt-inducible cells (25QP, 47QP, 103QP, and Q103) were
treated with 50ng/ml demecolcine; after which, they were subjected to the polyGlnrecruitment stain (Section 3.3) (Figure 7.6).
The results revealed that upon demecolcine treatment, the observed polyGln species (M,
GC+R+, and G-RC+) in 25QP, 47QP, and 103QP cells were relatively unaffected (Figure
7.7). In 47QP cells, M species remained at ~50% expression while G-RC+ species were
representative of ~30% of the expressing cells. In 103QP cells, ~25% of the polyGln
expressing cells were M and another ~20% expressed the G-RC+ species. Perinuclear
GFP-positive aggregates (GC+RC-/+) appeared unaffected in this particular cell line.
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Q103

0ng/ml demecolcine

50ng/ml demecolcine

Figure 7.5: Treatment with demecolcine effects GC+R- species in Q103 cells. Cells
were treated with 0ng/ml demecolcine and 50ng/ml demecolcine for 24 hours. Compound
treatment significantly reduced the percentage of cells that expressed GC+R- but not
GN+R-. Blue – cell nuclei, Green – polyGln-GFP fusion constructs. These images are of
cells that were not subjected to the AF stain; therefore, no red fluorescence should be
observed.
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Figure 7.6: Microscopic observations of the effects of demecolcine on htt-polyGln
species. Fluorescence color is blue for cell nuclei, green for GFP fusion constructs, and
red for aggregation foci. In each panel, the left column represents images taken by
modified DIC microscopy. The last column in each panel represents the red, green, and
blue merged image. The middle columns show a merger of the red and green images,
where the detail of AF and htt colocalization may be more easily observed. The top rows
of the cell lines are representative of untreated cells, while the bottom rows show cells
treated with 50ng/ml demecolcine for 24 hours.
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Figure 7.7: Percentage of expression of the various polyGln species after demecolcine treatment. Data were collected
from a minimum of five independent fields. The data are expressed as the percentage of total cells that exhibited either diffuse
expression ( ), GFP aggregates ( ), or AF ( ). Data shown are 24 hours post-induction and compound treatment.
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In contrast to the modest effects of demecolcine treatment of the various full
length exon-1 (“QP”) constructs, we observed a remarkable demecolcine effect in the
Q103 cell line. These cells normally aggregate very robustly yet fail to exhibit any AF.
In the presence of demecolcine, there was a significant knockdown in the number of
GC+R- species by 75% (Figure 7.7D), yet, as shown previously, GN+R- species were
relatively unaffected (Figure 7.4B). Interestingly, we observed that in addition to a
reduction in the GC+R- species, the G-RC+ species was remarkably increased (from 1% to
30% (Figure 6.2)). The total htt-polyGln protein expression (M, GC+R-, GN+R-, G-RC+),
however, was relatively unchanged.
Demecolcine treatment did not have a profound effect on any of the cells
expressing the complete htt exon-1 and was only effective in altering the polyGln
expression profile in cells expressing the truncated htt exon-1 fragment. The implications
of these data will be discussed in Chapter 9.

EFFECTS OF DEMECOLCINE ON CELL PROLIFERATION
Microscopic examination of demecolcine treated cells revealed the presence of
some (<10%) apoptotic cells (condensed or fragmented nuclei and cytoplasmic blebbing);
however, the observed amounts did not appear to be considerable. To be certain, a cell
proliferation assay was performed as described in Section 3.5 on all htt-inducible cell
lines (25QP, 47QP, 103QP, and Q103). The results indicated that the effects of
demecolcine mimicked the observed microscopic data, with the exception of the 25QP
cells (Figure 7.8). In this case, the microscopic data suggested only a slight reduction in
viability of demecolcine treated cells (Figure 7.9), but an MTS reduction assay showed
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Figure 7.8: Effects of demecolcine on cell proliferation. Cells were plated at various
densities: 25QP cells were plated at a density of ~100,000 cells/cm2; 47QP and 103QP
cells were plated at a density of ~60,000 cells/cm2; and Q103 cells were plated at a
density of ~200,000 cells/cm2. A cell proliferation assay (MTS reduction) was performed
to measure the number of viable cells. The number of viable cells is directly correlated to
the absorbance readings.
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Figure 7.9: Minimal apoptotic bodies were observed in 25QP cells treated with
demecolcine. These results were in contrast to the MTS reduction assay (Figure 7.8).
Blue – nuclei, green – htt-polyGln-GFP, red – AF.
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that demecolcine treatment significantly reduced the number of 25QP viable cells (p <
0.01) (Figure 7.8).
The reasons for the conflicting results are not clear; however, the simplest
explanation may be that when the cell proliferation assay was performed, there was an
uneven distribution of the cells such that fewer 25QP demecolcine treated cells were
plated than the untreated counterparts, which is consistent with the design of the assay
(absorbance signal is directly proportional to the number of viable cells present). Also,
considering demecoline arrests cellular division [Luduena and Roach 1991; Nishiyama
and Fujii 1992], some cell death is inevitable. An alternative rationale would be that this
particular subclone of the cell line was more susceptible to apoptotic induction (possibly
due to the randomness of transgene insertion) than a different subclone of the same cell
line. These hypotheses were not tested due to time constraints; however, additional work
should be performed to better understand this occurrence.
The positive effects seen on demecolcine treatment suggests the operation of
microtubule-dependent processes in the intracellular aggregation of these truncated exon1 proteins. M and GN+R- species were unaffected by this treatment, while G-RC+ and
GC+R- species were only affected in cells expressing truncated htt exon 1 fragments
lacking the proline-rich region. These results suggest that there are multiple aggregate
assembly pathways and that factors in the cellular environment may govern the rates at
which aggregates are formed. The implications of these results will be discussed later.
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7.5 Effects of Nocodazole on Aggregate Formation:
We wanted to confirm the observed effects of demecolcine are really attributable
to its microtubule-depolymerizing activity by also testing another compound
(nocodazole) also shown to be an effective microtubule-depolymerizing agent [Johnston,
Ward et al. 1998; Shimohata et al. 2002; Webb, Ravikumar et al. 2004]. The major
mechanistic difference between the two compounds is that the effects of demecolcine are
reported to be irreversible, while removal of nocodazole treatment allows restoration of
microtubule formation [DeBrabander 1981; Zieve 1984].

Since reversibility might

provide some unique advantages in our experiments, we also investigated nocodazole.
Like with demecolcine, a range of effective nocodazole doses have been reported
(100ng/ml (330nM) – 200ng/ml (650nM)) [Shimohata et al. 2002; Webb et al. 2004].
Therefore, we treated Q103 cells with doses ranging from 50ng/ml-400ng/ml (Figure
7.10). Treatment with nocodazole (400ng/ml) for 24 hours was effective at reducing
GC+R- species (Figure 7.11); however, we also observed a drastic reduction in the number
of attached cells, indicating that this concentration was detrimental to the cells in our
system. Because of the loss of cells observed with nocodazole and the dramatically
higher concentration needed to achieve aggregate inhibition, we terminated this line of
experiments.
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Figure 7.10: Nocodazole reduced GC+R- aggregates at a concentration of 400ng/ml.
25QP and Q103 cells were treated with various concentrations of nocodazole for 24
hours. (A) Monomeric expression was relatively unaffected by compound treatment, as
indicated in 25QP cells. (B)Percentage of Q103 cells that expressed htt-GFP aggregates.
GC+R- species were dramatically reduced. Percent expression was calculated based on the
number of GFP-positive cells/total cell number. At least 120 cells in five non-overlapping
fields were counted.
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Figure 7.11: Nocodazole effectively inhibited GC+R- species in Q103 cells but caused
a loss of cells. Blue – nuclei, green – htt-GFP fusion proteins. AF stain was not applied to
these cells; therefore, there was no red fluorescence to monitor.
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CHAPTER 8
BIOCHEMICAL CHARACTERIZATION OF OBSERVED POLYGLUTAMINE
PHENOTYPES
8.1 Rationale:
Considering a number of polyGln species have been identified in the PC12 cell
system, and some of these species were affected by compound treatment, the next logical
step was to try to gain some biochemical information about each class that corroborated
the microscopic observations. These measurements were necessary to address some key
questions that we were unable to address with the microscopic data: such as, 1) whether
the observed diffuse expression pattern actually represents monomer or microaggregate
structures, 2) whether it was possible to physically separate the observed species, and 3)
to obtain functional data, for example that might allow us to determine which species is
the most active in recruiting biotinylated polyGln monomer in vitro. In the long run, the
ability to prepare enriched cellular aggregate fractions might allow further studies, for
example to determine the non-htt-exon-1 components of these fractions.
In recent years, several groups have shown that multiple aggregated forms of
polyGln-containing proteins exist [Poirier, Li et al. 2002; Ellisdon, Thomas et al. 2006;
Wanderer and Morton 2007]. A considerable amount of effort has been spent trying to
isolate polyGln aggregates and learn more about their biochemical makeup [Scherzinger
et al. 1999; Steffan et al. 2000; Suhr et al. 2001; Webb et al. 2004; Chow et al. 2006;

172

Cong et al. 2006; Schilling et al. 2007]. Many isolation techniques have been explored.
For example, the most common isolation approach has been to utilize centrifugation
[Scherzinger, Sittler et al. 1999; Steffan, Kazantsev et al. 2000; Suhr et al. 2001; Webb,
Ravikumar et al. 2004; Schilling et al. 2007], while others have used size exclusion
chromatography [Cong et al. 2006], and immunoaffinity purification (purification by
using an antibody to the protein or to the fusion tag) [Chow et al. 2006]. Each method
was successful in the crude isolation of polyGln proteins with affinity tags proving
especially effective. This chapter will discuss the methods we evaluated for isolating the
various classes as well as the gamut of other techniques utilized to gain more information
about the observed species.

8.2 Cell Lysis:
Whole cell lysates of each cell line were prepared at 24-72 hours post-induction
as described in Section 3.6. Briefly, cells were collected by centrifugation, resuspended in
the isotonic lysis buffer containing Triton® X-100, vortexed, and sonicated resulting in
disruption of the cellular material. Cell lysates were then fractioned (via gel filtration or
differential centrifugation) and examined for the presence of the polyGln proteins of
interest by virtue of Western blot analysis and reactivity to anti-GFP (Santa Cruz
Biotechnology) and 1C2 (Chemicon) (anti-polyglutamine) antibodies.
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8.3 Gel Filtration:
We began our efforts to fractionate cell lysates using size exclusion
chromatography (gel filtration). For these studies, Q103 cells (24 hours post-induction),
which produced a high percentage of cells expressing GC+R- and some M, were subjected
to this technique (Section 3.6). Each gel filtration fraction collected was tested for the
presence of polyGln-containing proteins and reactivity with an anti-GFP antibody (data
not shown). 1C2 and anti-GFP reactivities were only detected in fractions that were
collected within 7-9 ml (less than one column bed volume). Interestingly and
contradicting our original hypothesis, we found no detectable protein (polyGln or
otherwise) in the void volume, suggesting that only soluble, low molecular weight
polyGln species were being isolated. From these results, three alternative hypotheses
were formed: 1) the lysis buffer that we used to extract the proteins was solubilizing the
aggregates, 2) the large aggregates were getting trapped in the gel filtration column, or 3)
there are no aggregates in these cells (i.e., the punctuate green staining does not indicate
aggregated material).
To address the first concern, preformed synthetic aggregates, which have been
shown to be SDS-resistant [Chen and Wetzel 2001], were treated with the lysis buffer
and subjected to SDS PAGE as described in Section 3.7. Synthetic and recombinant
exon-1 polyGln aggregates have been shown to be similar to late-stage htt aggregates
[Cooper, Schilling et al. 1998; Kazantsev, Preisinger et al. 1999; Chen, Berthelier et al.
2001] in that they are SDS-resistant. Lysis treatment did not alter the SDS solubility of
the K2Q47K2 aggregates. These aggregates remained insoluble and did not enter into the
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gel (Figure 8.1). Although this experiment was important to conduct, perhaps it did not
fully resolve the question. The purpose of conducting such biochemical experiments was
to learn more about the nature of all the aggregates and other polyGln species within the
cell culture. By only testing the lysis buffer with very stable, end-stage polyGln
aggregates, the possibility cannot be excluded that less stable, early aggregates might be
dissociated by the lysis buffer.
The second concern was addressed, by sampling the top of the column for 1C2
reactive proteins. A small portion of lysis buffer and the column bed (500µl) was
removed by a pipette, homogenized, and subjected to the SDS-PAGE protocol (Section
3.7). One set of the SDS gels were stained with Coomassie Blue, while the other set was
transferred to a nitrocellulose membrane and subjected to the Western blot protocol using
the 1C2 antibody (Section 3.7). In support of the hypothesis that polyGln aggregates did
not enter the column, the Coomassie stained gels exhibited a small amount of protein was
associated with the top of the column (Figure 8.2). However, this protein appeared to not
be related to the transgene product, since it was negative in Western blots using the 1C2
antibody. The source of the Coomassie-positive, 1C2-negative material was not clear. It
could have represented non-htt-exon-1 related high MW proteins from the cell. Failure to
detect polyGln aggregates might also be explained by a failure of the “aggregated”
protein to transfer to the membrane. To test this, the gel after electrotransfer was stained
with Coomassie and found to exhibit no residual protein staining, consistent with
complete protein transfer (data not shown).
Thus, clear results on the gel filtration fractionation of cells shown by
fluorescence microscopy to contain aggregates were unattainable. Proteins containing
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Figure 8.1: Lysis buffer does not affect SDS-resistance in K2Q47K2 synthetic
aggregates. Aggregates were subjected to SDS treatment, gel electrophoresis, and
Western blot analysis with 1C2 antibody. Irrespective of treatment, the preformed
aggregates did not migrate into the gel but remained at the top of the well, as indicated by
the black arrows.
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Figure 8.2: Material at the top of a gel filtration column was 1C2-negative. (A) Q103
fractions subjected to SDS-PAGE and stained with Coomassie blue. (B) 1C2 reactivity of
transferred gel. While there was Coomassie staining in the top of the gel, usually
suggestive of aggregates, they were not reactive with an anti-expanded polyGln antibody.
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extended polyglutamine stretches are inherently known to be very sticky molecules,
which might account for loss of protein. Alternatively, the chosen method of evaluating
the top of the column could have been better designed. Since, for whatever reasons,
isolation of the polyGln species by gel filtration was unsuccessful, we investigated an
alternative approach at fractionation: centrifugation.

8.4 Differential Centrifugation:
Cell lysates prepared as described in Section 3.6 were fractionated by the
differential centrifugation protocol shown in Figure 3.4. Four fractions were analyzed
from each cell line 24-72 hours post-induction: 1) whole cell lysate (W), 2) washed pellet
from 15,000xg spin (P1w), 3) pellet from 100,000xg spin (P2), and 4) supernatant from
100,000xg spin (S2). The hypothesis was that P1w should contain the large GC+RC-/+
species, P2 should contain the relatively small GN+R- and G-RC+ species, and S2 should
contain M species. Each fraction was subjected to electrophoresis under denaturing
conditions (Section 3.7) after which the proteins were electrotransferred to a
nitrocellulose membrane where they were probed for their reactivities with anti-GFP and
1C2 antibodies (Section 3.7). Positive antibody binding was detected using
chemiluminescence.
Initial experiments were performed to confirm that the GFP aggregates were
indeed co-localized with polyGln. GFP has been shown to self-aggregate (a rare
occurrence) in the presence of small peptides [Link et al. 2006], these aggregates
maintain there fluorescence. Therefore, we needed to be certain that the observed
fluorescence was not due to the proteolytic cleavage of GFP from htt exon-1, which then
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self-aggregated. Cell lysates from Q103 cells were tested for this occurrence.
Microscopically, these cells expressed an abundant population of cells with GC+Raggregates. Western blot analysis revealed that there was an overwhelming 1C2 antipolyGln reactivity co-localizing with the anti-GFP antibody (Figure 8.3), suggesting that
no measurable proteolysis of the construct occurred prior to aggregation.
Next, the question of whether the observed diffuse fluorescence was due to
monomeric species or microaggregates was addressed. This question was most cleanly
addressed with the 25QP cells. At 24 hours post-induction, 25QP cells have been shown
by fluorescence microscopy to have 40% of the cells expressing M and 40% of the cells
expressing G-RC+ aggregates, with no cells expressing G+R- aggregates (Figure 6.2).
Western blot analysis of lysate centrifugation fractions of these cells supported the
fluorescence microscopy in showing the htt exon-1 immunoactivity to be associated only
with the high speed centrifugation supernatant (presumably M) and pellet (presumably GRC+). The S2 fraction from the 25QP cells showed a high reactivity with both the 1C2 and
anti-GFP antibodies (Figure 8.4), suggesting that the observed diffuse green staining
pattern was due to intact (monomeric) GFP-htt-exon1 fusion proteins. The fact that there
was a quantitative difference between the gel and microscopy results for 25QP cells may be
due to the inefficient pelleting of the small G-RC+ aggregates. At the same time, there
seems to be no reason to expect quantitative agreement, given that the scoring of the
microscopy was not based on molar measurements.
While the possibility that some of the diffuse green in these and other cells may be
due to SDS-stable microaggregates cannot be eliminated, the results in Figure 8.4 suggest
that the bulk of diffuse staining is really due to M. Microscopic examinations from other
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Figure 8.3: Representative autoradiograms that show 1C2 and anti-GFP coreactivity. Q103 cell lysate samples (24h) showed that the only GFP detected runs at a
MW consistent with that of the full length exon1-GFP fusion. Abbreviations: P1w –
washed pellet from low speed centrifugation, P2 – pellet from high speed centrifugation, S2
- supernatant
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Figure 8.4: Autoradiograms of 25QP cells lysates 24 hours post-induction. The
predominant 1C2 and anti-GFP reactive bands are found in the S2 fraction; however, there
was also some GFP reactivity found in the P2 fraction. Abbreviations: P1w – washed pellet
from low speed centrifugation, P2 – pellet from high speed centrifugation, S2 - supernatant
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groups are consistent with the idea that the diffuse staining pattern is representative of
monomeric species [Lunkes and Mandel 1998; Preisinger et al. 1999; Apostol et al. 2003].
In this thesis, we will be assuming that diffuse staining comes exclusively from monomers.
Parenthetically, we also cannot formally exclude the possibility that monomer might
sometimes migrate in more dense centrifugation fractions due to association with cellular
membranes/debris.
Microscopically, the appearance and disappearance of the different polyGln species
with increasing induction times were able to be monitored. We, therefore, wanted to
examine whether or not we could develop a better understanding of the nature of these
species by analyzing cell fractions. Cell fractionation studies focused on the time period 2472 hours post induction, mainly because of the significant changes observed in the 103QP
and Q103 cells during this time frame. At each time point in these fractions, the most
reactive gel band (according to the Western blot analysis) was, as expected, our expressed
htt-polyGln-GFP constructs, which can be observed between 45-55kDa depending on the
polyGln repeat length1. Figure 8.5 shows a representative 1C2 blot from each of the cell
line lysates at 48 hours post-induction. In the Q103 blot, it is important to note that nontransformed PC12 cells as well as uninduced control samples were also assayed. The
uninduced controls had some slight reactivity with the 1C2 antibody that corresponded to
our

positive

bands

in

the

induced

1

samples.

This

was

not

unexpected

In these gels, there is a consistent discrepancy between the calculated molecular weights and the observed
molecular weights of the polyGln containing proteins (Table 8.1). These differences are routinely seen in SDS gels
of polyGln proteins by our group and by others, and can be accounted for by some not-well-understood interaction
between polyGln and polyacrylamide producing aberrant mobility of polyGln proteins in SDS-PAGE.
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Figure 8.5: 1C2 Western blot analysis of all cell line lysates at 48 hours postinduction. Lysates were fractionated by differential centrifugation. The htt-polyGln-GFP
construct of interest is denoted by a black arrow.

Table 8.1: Approximate molecular weights of polyglutamine proteins and
fragments.
Protein fragment

Calculated MW (kDa)

Observed MW (kDa) (±4kDa)

25QP

37.4

46

47QP

40

49

103QP

46.8

59

Q103

43

54

Free GFP

25.9

--

Free N1-17

2

--

Free C-Exon 1

6.5

--
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because it has been shown [Apostol, Kazantsev et al. 2003] that these cells do have some
“leaky” expression of the transgene.
Each cell line was examined independently for correlations between the microscopy
data and the cell fractionation data. Densitometry analysis was performed on each 1C2
Western blot. Protein abundance was calculated for each major fraction. The numbers
obtained from the P1w, P2, and S2 fractions are expressed as percentages of total gel
staining material, and therefore sum to 100%. In contrast, the microscopy data was
normally expressed as the percentage of cells containing each manifestation of htt exon-1.
Since 10-30% of cells generally exhibit no expression of the transgene, the data were
normalized to 100% in order to put the microscopy data on an equal footing for
comparisons.
As mentioned previously, cells expressing 25QP exhibited a population expressing
an equal mixture (±10%) of about 40% diffuse protein and 40% AF, which was relatively
unchanged over the 24-72 hours period (Figure 8.6A). Densitometry analysis of the 1C2
Western blots revealed a similar trend, with fractions representing the soluble protein
remaining at ~60% and the P2 fraction, which we interpret as AF, remaining at ~40%
(Figure 8.6B) during the 3 time points.
Cells expressing 47QP produced similar data to 25QP cells (Figure 8.7). Both
microscopic results and densitometry analysis revealed 40% expression of AF or P2 and
60% expression of diffuse or S2 at the 24 hour and 48 hour time points. There was,
however, a slight discrepancy at 72 hours post-induction. Microscopic analysis showed that
60% of the cells were expressing AF and 40% of the cells were expressing monomer,
whereas densitometry analysis revealed 5% of the protein was found in the P1w fraction
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Figure 8.6: Microscopic and densitometry comparison of 25QP cells. (A) Microscopic
analysis of 25QP cells from 24-72 hours post-induction. Percentage of cells expressing
each species was normalized to 100% expression. (B) Densitometry analysis of 25QP cell
lysate fractions from 24-72 hours post-induction. P1w- washed pellet from 15,000xg, P2
– pellet from 100,000xg, S2 – supernatant.
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Figure 8.7: Microscopic and densitometry comparison of 47QP cells. (A)
Microscopic analysis of 47QP cells from 24-72 hours post-induction. Percentage of cells
expressing each species was normalized to 100% expression. (B) Densitometry analysis
of 47QP cell lysate fractions from 24-72 hours post-induction. P1w- washed pellet from
15,000xg, P2 – pellet from 100,000xg, S2 – supernatant.
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(normally associated with larger aggregates), 45% of the protein was found in the P2
fraction, and 50% of the protein was found in the S2 fraction. The small portion of material
pelleting at low centrifugation speed found in these cells may be due to some aggregates
not detected in the microscopy, or to M that is physically associated with cell debris and
was not dislodged by washing.
103QP cells, which exhibited all the observed polyGln species, appear to be a
more complex situation (Figure 8.8). At the 24 hour time point, it appeared that the
major species by microscopic examination were G-RC+. According to the densitometry
data at this same time, the P2 fraction also represented the most abundant species. At 48
hours, the microscopic and densitometry analyses correlate fairly well, with 10% of the
protein being large aggregates, 40% being smaller aggregated material, and ~50% of the
protein being monomeric. By 72 hours, however, there was a small disagreement
between the two data sets. Microscopically, we saw that 20% of the population had large
GC+RC+ aggregates; however, the densitometry analysis revealed the P1w fraction
represented only ~10% of the protein abundance. It is possible that the larger aggregates
may be partially broken down by the detergent treatment used to prepare the lysate (see
below). Even considering the slight disagreement at 72 hrs, the match between the
centrifugation data and the microscopy data is striking.
Finally, microscopy showed that in Q103 cells there is a time-dependent increase in
GC+R- species that we interpret as large exon-1 aggregates (Figure 8.9A). Consistent with
this, densitometry of the 1C2 stained gel on Q103 cells shows a corresponding timedependent increase in the P1w fraction that was expect to contain large aggregates (Figure
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Figure 8.8: Microscopic and densitometry comparison of 103QP cells. (A)
Microscopic analysis of 103QP cells from 24-72 hours post-induction. Percentage of
cells expressing each species was normalized to 100% expression. (B) Densitometry
analysis of 103QP cell lysate fractions from 24-72 hours post-induction. P1w- washed
pellet from 15,000xg, P2 – pellet from 100,000xg, S2 – supernatant.
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Figure 8.9: Microscopic and densitometry comparison of Q103 cells. (A) Microscopic
analysis of Q103 cells from 24-72 hours post-induction. Percentage of cells expressing
each species was normalized to 100% expression. (B) Densitometry analysis of Q103 cell
lysate fractions from 24-72 hours post-induction. P1w- washed pellet from 15,000xg, P2
– pellet from 100,000xg, S2 – supernatant.
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8.9B). However, inconsistent with the microscopic data is the relative abundance in which
this species was found. The microscopy data revealed an increase from 40% GC+R- species
to >80% GC+R- species from 24-72 hours; however, the densitometry data showed only an
increase from 20% to 40% in the P1w fraction. Additionally, while the densitometry data
shows that 40% or greater of the protein population was collected in the P2 fraction,
microscopy found none of the G-RC+ species in these cells that, in the “QP” series of cells
discussed above, consistently correspond to material in the P2 (high speed) pellet fraction.
Some of this more-difficult-to-pellet material may derive from the relatively small GN+Rspecies (<10%) observed by microscopy at these times (Figure 6.7). We hypothesize that
the remainder of the material in the P2 fraction is from small aggregates generated by the
lysis procedure from labile G-RC+ species.
Overall, the cell fractionation data agrees remarkably well with the fluorescence
microscopy. These data comparisons can be used to address another important question
concerning the interpretation of the fluorescence microscopy data, the issue of whether
perinuclear, punctate, green fluorescent bodies are really composed of aggregates of htt
exon-1. As stated in Chapter 4, researchers often assume that punctate inclusions represent
aggregated protein, and in fact use the terms interchangeably [Fink 1998; Johnston et al.
1998; Lunkes and Mandel 1998; Garcia-Mata et al. 1999; Preisinger et al. 1999; Apostol et
al. 2003]. However, given the presence in the cell of a number of kinds of organelles, it is
formally possible that punctate fluorescence might sometimes be due to the organization of
monomers within a membranous compartment. The Western blot analysis revealed at this
same time point that ~10% of the 1C2-positive population was found in the soluble fraction
(Figure 8.8B), which was in remarkable agreement with the microscope data that revealed
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that ~5% of the cells contained diffuse staining interpreted as “monomeric” species (Figure
8.8A). If most of the GC/N+R- species were collections of monomers, much more material
would have been seen in the S2 fraction. We think these results justify our working
assumption, shared with most of the field, that punctate inclusions represent some kind of
aggregated material.
Some minor difficulties were encountered in the Western blot analysis. While
polyGln-positive bands always were mirrored by a GFP-reactive band, the latter was
often of a much lower intensity. This was especially evident in lysates produced from
cells 24-72 hours post-induction (Figure 8.10). This problem was addressed by testing
two different GFP antibodies: a rabbit polyclonal and a mouse monoclonal antibody.
Although we used both antibodies at the lowest dilution suggested (1:150), the antibodies
still failed to produce an intensity equal to that of the 1C2 antibody, even at extended
exposure time (data not shown). There are several possible reasons for the reduced
sensitivity: 1) the primary antibodies were not matched in their efficiencies, 2) the
secondary antibodies (which were different for the rabbit and mouse derived primaries)
could have also had different relative affinity, and 3) the GFP binding sites were either
less accessible than polyGln binding sites or may not have been present due to some
protein degradation. A proper GFP-positive control was never tested, so without this
piece of data, we cannot be certain why we experienced less intense GFP-reactive bands.
Importantly, the lower intensity of the anti-GFP bands cannot be interpreted as an
indication that some of the polyGln-containing proteins may have lost their GFP. If that
were the case, some of the 1C2 reactive bands would have been detected at lower MWs.
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Figure 8.10: GFP antibody was not as sensitive as the 1C2 antibody. Regardless of
antibody dilution or exposure time of the membrane to the x-ray film, the anti-GFP
antibody was not as effective in recognizing the GFP-tagged proteins as the 1C2
antibody. Abbreviations: W – whole cell lysate, P1w – pellet from 15,000xg, P2 – pellet
from 100,000xg, S2 – supernatant.
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DEMECOLCINE TREATED CELLS
Biochemical data was also obtained from stable cells treated with demecolcine.
As described in Chapter 7, the immunofluorescence data revealed that demecolcine had
little effect on 25QP, 47QP, and 103QP cells (Figures 7.5 and 7.6), but had a major effect
on Q103 cells. In view of this, fractionation studies were conducted on Q103 and 25QP
cell lysates. Cell lysates corresponding to 24 hour incubation with or without
demecolcine treatment were subjected to SDS-PAGE and Western blot analysis using the
protocol previously described in Section 3.7.
Analysis of 25QP cells with and without exposure to 50ng/ml demecolcine gave
cell fractionation results that not only agreed with the previous microscopy results in
showing no effect of demecolcine, but also exhibited remarkable quantitative agreement
with the microscopy analysis (Figure 8.11).
Analysis of demecolcine-treated Q103 cells also showed very good agreement
between the two measurement techniques. In the demecolcine treated cells, the relative
amounts of material in the M, GC-R+, and GC+R- species by microscopy were closely
matched by the amounts of material in the S2, P2, and P1w fractions (Figure 8.12). It is
interesting that there was a poorer agreement in the untreated cells.

As discussed

previously, this can be explained if the perinuclear GC+R- aggregates were somewhat
unstable, breaking apart into smaller aggregates and monomer under lysis conditions.
The better agreement of the demecolcine-treated cells may be due to the presence of a
substantial fraction of GC-R+ in these cells; as highly stable, mature amyloid fibrils, these
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Figure 8.11: Microscopic and densitometry comparison of 25QP cells treated with
demecolcine. (A) Microscopic analysis of 25QP cells treated with 0 or 50ng/ml
demecolcine. Percentage of cells expressing each species was normalized to 100%
expression. (B) Densitometry analysis of 25QP cell lysate fractions treated with 0 or
50ng/ml demecolcine. P1w- washed pellet from 15,000xg, P2 – pellet from 100,000xg,
S2 – supernatant.
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Figure 8.12: Microscopic and densitometry comparison of Q103 cells treated with
demecolcine. (A) Microscopic analysis of Q103 cells treated with 0 or 50ng/ml
demecolcine. Percentage of cells expressing each species was normalized to 100%
expression. (B) Densitometry analysis of Q103 cell lysate fractions treated with 0 or
50ng/ml demecolcine. P1w- washed pellet from 15,000xg, P2 – pellet from 100,000xg,
S2 – supernatant.
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aggregates were expected to withstand the lysis conditions and hence retained an
appropriately sized signal in the Western blot analysis of the P2 fraction.

8.5 Microtiter Plate Extension Assay of Various Polyglutamine Lengths:
In a functional assay, the centrifuged fractions were examined for their ability to
seed the fibrillogenesis of polyglutamine peptides. A modified protocol of a microtiter
plate polyGln extension assay (Section 3.8) that was previously designed in our lab
[Berthelier, Hamilton et al. 2001] was used. Immobilized cell lysate material and
preformed synthetic K2Q47K2 aggregates (positive control for polyGln elongation) were
incubated with 100nM biotinylated polyGln monomer (the same as used in the
microscopy experiments) for a determined amount of time. After which, the plates were
washed and incubated with a streptavidin-labeled Europium (Eu) solution. Euincorporation was then measured by time-resolved fluorescence and converted to
femtomoles using a determined standard curve.
Experiments were performed on 103QP cell lysate material from the 48 hour time
point. The reason for choosing this polyGln length and time point was because at 48
hours post-induction, multiple polyGln species (M, GC+R-, GC+RC+, and G-RC+) were
observed by immunofluorescence, including the AF fraction that is the only material we
expected to be positive in this assay. Logically this appeared to be the best cell line for
optimizing the elongation assay. Multiple experiments, however, yielded only
inconclusive and inconsistent results (data not shown), which were not a consequence of
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experimental technique as was evident by the consistent positive recruitment of our
positive control (data not shown).
The lack of reproducibility in the experimental data may be due to the fact that the
starting material was cell lysates. In general, cell lysates contain many contaminants such
as lipids, cell and nuclear membranes, and other cellular proteins, all of which might
interfere with the assay (although controls in which untransformed cell lysates were
added to control polyGln aggregates, to see if they affected elongation activity, were not
done). Another problem with cell lysates is that, because they are not homogenous,
aggregates may not dry in a monolayer when they are plated, such that superficial cell
debris material may mask potential polyGln binding sites.
For each assay, equivalent amounts of material were plated per well; however,
this amount did not actually reflect the amount of polyGln-containing proteins that was
immobilized. It simply represented the total protein that was plated. This is yet another
problem with the assay as it stands. While a great deal of time was spent attempting to
optimize this procedure, the data produced from these experiments were equivocal.
Nonetheless, these efforts should provide a good foundation for future work using this
assay on cell lysates.
One suggestion for improving the microplate assay would be to improve the cell
lysate preparation. By introducing a purification step, such as immunoprecipitation with
1C2 antibody (which would remove any non-polyGln containing or associated proteins
from the mixture), or by the use of a density gradient for protein separation, one might
expected a better outcome for the elongation assay. However, even if conditions were
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optimal, there is still the question of quantity regarding polyGln recruitment-competent
proteins within the lysate. Fluorescence microscopy and Western blotting are very
sensitive techniques, and we have no independent estimate of how much protein is being
made in these cells on a molar or weight basis. Therefore, although these cell lines were
of high clonal integrity, it is possible that the quantities of aggregates are simply too low
to give a positive result in the microplate assay. As mentioned previously, it is also
possible that other cellular factors, associated with the aggregates upon cell disruption,
inhibit the aggregates’ ability to stick to the plates or their ability to bind monomer.
Despite the pitfalls along the way, we identified a method (differential
centrifugation) that was effective for the crude separation of the polyGln species. Taken
together, these biochemical experiments clarified a number of uncertainties about the true
natures of the species observed in fluorescence microscopy, providing a critical
foundation for the interpretation of this data.

The knowledge acquired from the

biochemical characterization has provided important details on the larger GFP-positive
aggregates and insights about the aggregation pathway of Huntington’s disease. Finally,
these results have provided a solid basis for future attempts at the chemical
characterization of these polyGln species.
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CHAPTER 9
DISCUSSION AND CONCLUSIONS
9.1 Possible Aggregation Mechanisms:
Experimentation with the stable cell lines led to the identification of several
polyGln species (M, G-RC+, GC+RC+, GC+R-, and GN+R-) some of which were recruitmentcompetent and others that were recruitment-inert. These species could be found either in
isolation or within the same microscopic field, and in some instances even within the
same cell. The identification of multiple aggregated polyGln species corroborated other
findings from in vitro experiments with isolated protein that such structures do exist
[Poirier, Li et al. 2002; Wacker et al. 2004; Mukai et al. 2005; Thakur unpublished data].
There are many possibilities for how the assembly pathways of the various species are
intertwined (Figure 9.1). One possible mechanism is that AF are online intermediates in
GFP inclusion formation (Figure 9.1A), while another possibility is that, conversely,
recruitment-inert GFP inclusions are precursors to amyloid-like AF (Figure 9.1C). A
third mechanism is that the two species are formed via kinetically competing pathways
(Figure 9.1B). In this chapter we will discuss those possible modes of aggregation and
speculate on the implications of these various models. We will then review some of our
experimental work, namely the response of htt exon1 expression patterns to certain
compounds and to sequence variation within htt exon1, and discuss the results in the
context of these models.

199

Figure 9.1: Possible modes of polyglutamine aggregation. M - diffuse, monomeric
protein; G-RC+ - aggregation foci; GC/N+R- - aggregates that showed cytosolic or nuclear
GFP formation but did not exhibit recruitment-capabilities; GC+RC+ - aggregates that were
large enough to be visualized via their GFP component but also exhibited polyGln
recruitment (only observed in the cytoplasm). This schematic represents possible
pathways for polyGln aggregation. Part A shows all proposed models without picture
representation, where Part B provides visual aides. Models A-C address possible
aggregation mechanisms for cytoplasmic species. Model A proposes a linear relationship
where aggregation foci (G-RC+) are precursors to mature polyGln aggregates (GC/N+R-)
[Osmand 2004]. Model B suggests a competitive pathway for G-RC+ and GC/N+Rformation. The rapid conversion of M Æ GC+R- appears to be a reversible process
governed by the lack of aggregate stability. Model C represents a linear pathway, based
on in vitro data, where recruitment-inert aggregates occur prior to the formation of
recruitment-positive fibrils [Thakur unpublished data]. Schematics D-F parallel models
A-C with the inclusion of GN+R- species being on a separate assembly mechanism
(observation from treatment with demecolcine).
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Figure 9.1A. Continued.
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G-RC+

Why are AF not always green? During many of the experiments, AF were
detected in species that did not exhibit detectible GFP fluorescence. There are several
possible interpretations of this counterintuitive finding. One hypothesis is that AF did not
accumulate enough mass to be visualized by their GFP fluorescence. The fluorescence
yield of AF on a mass basis is expected to be determined by (a) the number of
biotinylated polyGln monomers residing on each aggregate after staining, (b) the number
of dye molecules per streptavidin, and (c) the quantum yield of the dye. It may be that
this produces a fluorescence yield, per htt exon1 molecule in the aggregate, that is
substantially brighter than the yield of the GFP associated with each exon1 molecule.
Another possibility is that AF are composed largely of htt-exon-1 constructs that have
lost all or part of their GFP component due to intracellular proteolysis (not consistent,
however, with the SDS gel data). A third, related possibility is that, although AF retain
the GFP component of the htt exon1 fusion, the GFP has lost its fluorescence due to its
becoming unfolded during the amyloid formation process intrinsic to AF formation.
While it would be interesting to know the reason for the poor GFP fluorescence of AF,
this property does not impact any of the key interpretations of this data discussed here.

9.2 Effects of Curcumin Treatment on the Aggregation Pathway:
The effects of curcumin were explored in cells expressing a benign polyGln
repeat length (25QP) and a physiologically relevant polyGln repeat length (47QP). Each
of these cell lines, in the absence of curcumin, produced an abundant mix of M protein
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and G-RC+ aggregates. Curcumin treatment inhibited the formation of G-RC+ in a dosedependent fashion, while only slightly altering the percentage of cells producing M.
Other experiments suggest that curcumin is specifically an anti-amyloid inhibitor,
rather than being non-specific [Frautschy et al. 2001; Nakagami et al. 2002; Lim, Jin et
al. 2005; Yang, Lim et al. 2005]. Because of their strong ability to grow by monomer
addition, a property unique among aggregates to amyloid and amyloid-like fibrils, we
think that G-RC+ aggregates are amyloid in nature. The ability of curcumin to effectively
knock down G-RC+ production in cells is consistent with their expected amyloid-like
structure. While it is clear from our results that curcumin down-regulates AF in cells, it
could be that this is a result, not of the inhibition of their formation from M, but rather a
result of altering the aggregate morphology to interfere with its ability to recruit, or in
fact to simply bind to AF and directly inhibit their recruitment of M in the AF stain.
Curcumin treatment was only investigated in cells expressing 25QP and 47QP,
which never exhibited any GC+R- aggregates. These experiments simply address the
relationship of M and AF, and therefore, do not specifically address the central question
of whether AF and GFP-positive aggregates are on linear or competing pathways.

9.3 Effects of Demecolcine Treatment on the Aggregation Pathway:
The central meaning of the data presented in this dissertation can best be
considered by focusing attention on stable PC12 cells expressing Q103. These cells very
rapidly formed punctate, predominantly cytoplasmic, GFP-positive inclusions, resulting
in a corresponding decrease in cells with other forms of htt exon1 (Figure 6.2). By 144
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hours post-induction, >70% of the cell population exhibited GC/N+R- aggregates with no
cells exhibiting detectable M species. Furthermore, AF were present in less than 1% of
the cells.
We examined the effects of two modifications with Q103-producing cells. The
first set of modifications of Q103 producing cells involves the addition of cell-pathway
modifying compounds to the cells in culture.

Because GC+R- aggregates resemble

perinuclear aggresomes that require microtubules for their formation [Johnston et al.
1998; Webb et al. 2004], we treated Q103-producing cells with the microtubuledisrupting agent demecolcine. Demecolcine treatment significantly changed the
aggregation pattern in cells in both expected and unexpected ways. First, as expected,
drug treatment almost completely eliminated GC+R- aggregates in cells. Second, as
expected, this resulted in cells harboring greatly increased amounts of M and smaller
aggregates.

Surprisingly, however, the smaller aggregates turn out to be G-RC+

aggregates (AF) rather than smaller versions of GC+R- aggregates (Figure 7.7).
The fact that demecolcine-treated Q103 producing cells contain essentially no
GC+R- aggregates, but large amounts of both M and G-RC+ aggregates, has profound
implications for intracellular aggregation mechanisms. Here we consider, in turn, the
aggregation mechanisms outlined in Figure 9.1 A-C. If one of the pathways (A or C)
containing GC+R- and G-RC+ in a precursor-product relationship represents the correct
assembly mechanism, then demecolcine treatment should have had different effects than
what was observed. Pathway A posits that M is converted entirely to G-RC+, which
subsequently are converted to GC+R-, presumably by virtue of being collected into
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aggresomes. (This mechanism doesn’t explain why simple collecting AF into aggresomes
should allow them to acquire GFP fluorescence while at the same time losing recruitment
ability.) According to this mechanism, the blocking of GC+R- formation by demecolcine
should lead to an accumulation of 100% of the htt exon-1 material in G-RC+. Since G-RC+
represent very stable, polyGln-core amyloid fibrils [Berthelier et al. 2001; Chen et al.
2001], it is very unlikely that, once formed, any significant amount of these G-RC+
aggregates will dissociate to M within the cell.
Pathway C posits that M is first efficiently converted to GC+R-, which
subsequently are converted directly into G-RC+. As in pathway A, there seems to be no
simple way under this mechanism to explain the formation of M in response to
demecolcine treatment. If GC+R- are the initial aggregates – formed from M as mediated
by the microtubule network, and if they are also obligate intermediates in the formation
of G-RC+, one would expect disruption of the microtubule network by demecolcine to
lead to a complete reversal of aggregation to regenerate 100% M.
The only mechanism that seems to be capable of producing, in response to
demecolcine elimination of GC+R-, a mixture of both M and G-RC+ aggregates, is pathway
B. In this mechanism, in Q103 cells, formation of GC+R- aggregates is so rapid that the
more slowly developing G-RC+ aggregates do not form; in the competition for M, G-RC+
aggregates lose. However, if the stabilization of GC+R- within aggresomes is blocked by
demecolcine treatment, monomers persist and partially convert to G-RC+, now no longer
in competition with GC+R-.
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The poor stability of the GC+R- aggregates implicit in this analysis is consistent
both with the literature [Muchowski et al. 2000; Muchowski et al. 2002] and with the cell
fractionation experimental results described in Chapter 8 and highlighted in Figures 8.9
and 8.12. As discussed in Chapter 1, growth of htt exon-1 aggregates in vitro leads to two
classes of aggregates – those that are soluble by SDS-treatment and those that are not
[Muchowski, Schaffar et al. 2000]. Growth in the presence of some molecular chaperones
increases the fraction of SDS-soluble aggregates, suggesting that these are the earliest
formed in the assembly pathway. Only the amyloid-like end products of htt exon-1
aggregation are SDS-stable [Cooper et al. 1998; Kazantsev et al. 1999; Chen et al. 2001].
In our cell fractionation experiments (Figures 8.9 and 8.12), disrupting Q103 cells rich in
GC+R- aggregates was sufficient to render about half of the htt exon1 material incapable
of being sedimented by a high-speed centrifugation step (and hence, we assume,
monomeric).
The affects of demecolcine were examined in the other stable cells as well.
Compound treatment did not alter the aggregate balance in any of these cells, which
suggested that the polyproline stretch modulated the types of aggregates being produced.

9.3 PolyGln Flanking Sequences Influence Aggregation:
The second modification was contained within the construct itself and consisted
of a direct examination of the role of the proline-rich region neighboring the polyGln
sequence of htt exon-1. While the 103QP cells expressed intact exon-1, including the
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proline-rich segment, the Q103 cells expressed htt exon-1 constructs lacking this flanking
sequence.
It has been consistently shown that polyGln flanking sequences have profound
effects on polyGln aggregation kinetics [Bhattacharyya, Thakur et al. 2006], aggregation
mechanism [Ellisdon, Thomas et al. 2006], protein stability [Bhattacharyya, Thakur et al.
2006], toxicity [Dehay and Bertolotti 2006], and subcellular localization [Rockabrand,
Slepko et al. 2007]. In vitro, it has also been shown that various lengths of synthetic
polyGln lacking any other htt sequences, always produce aggregates, at all stages of the
aggregate assembly reaction, that are fibril-like and recruitment-competent [Chen,
Berthelier et al. 2001; Chen et al. 2002; Thakur and Wetzel 2002; Yang, Dunlap et al.
2002].

When peptides including a proline-rich sequence following polyGln are

examined, the aggregation kinetics are slowed and the aggregates formed appear to be
less stable [Bhattacharyya, Thakur et al. 2006]. This effect is also observed in peptides
also containing the N-terminal 17 amino acids of htt, even though this sequence alone
radically affects the aggregation mechanism. Thus, in contrast to simple polyGln
peptides, when the first 17 amino acids of the huntingtin protein are included along with
polyGln, these peptides result in much more rapid aggregation kinetics than for a
comparable polyGln sequence and lead to an initial aggregated product that is neither
fibril-like nor recruitment-competent (thus resembling protofibrils/oligomers); with
recruitment-competent, amyloid-like fibrils forming later in the aggregation reaction
[Thakur unpublished data]. When a proline rich sequence is included in the peptide
containing both polyGln and the N-terminal 17 amino acids, the initial aggregation rate
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significantly decreases, but the assembly mechanism, including various non-fibrillar early
intermediates, is retained2 [Thakur unpublished data].

Thus, regardless of the

aggregation mechanism and the nature of the aggregated products, addition of a prolinerich sequence on the C-terminal side of the polyGln consistently slows aggregation.
Consistent with these in vitro findings, our data demonstrate that the presence of
flanking oligoproline sequences significantly decreases the rate at which GC+Raggregates form. Rather than simply leading to a buildup of diffuse GFP monomers in
cells, however, the ability of the proline-rich sequence to inhibit formation of GC+Raggregates surprisingly leads to the accumulation of substantial levels of G-RC+
aggregates (AF) that are not detected in cells expressing oligoproline-minus htt exon-1.
Information we acquired from cells expressing 103QP suggest that G-RC+ and GC+R- are
on parallel assembly pathways (Figure 9.1B) and that the presence of polyproline affects
the formation of GFP-positive inclusions while not altering the formation of AF. If the
species were on a linear pathway, where AF were precursors to GC+R- aggregates, then
one would expect that the presence of oligoproline would, indeed, slow down the
aggregation reaction, and fewer GFP inclusions would be observed, which is consistent
with Mechanism A. However, one would also expect that if this model were true, then
eventually, all the G-RC+ aggregates would be converted to GC+R- aggregates. Our data
show that while aggregation does occur more slowly in the absence of proline and that

2

While we did not specifically address the importance of the first 17 aa of htt, it has been shown that this
sequence can act as a cytoplasmic retention signal even in the presence of a nuclear localization signal
[Seffan, J.S., et al. 2004]. Our findings that the aggregated species were predominantly found in the
cytoplasm are supported by these data.
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GFP-positive aggregates become more abundant with increasing time (Figure 6.2), AF
levels remained constant (~20%) throughout the time course, which would be
inconsistent with Mechanism A.
As in Mechanism A, Mechanism C would also be inconsistent with our findings
that the presence of polyproline slows down the aggregation mechanism. In this case, if
Mechanism C were viable, then G-RC+ aggregates would form much later than the initial
times at which they were observed (Figure 6.2), and there would be an early abundance
of GC+R- aggregates, which would more slowly convert to G-RC+ aggregates.
Therefore, the mechanism that seems the most possible is Mechanism B, where GRC+ and GC+R- are on competing pathways, producing a more diverse mixture of polyGln
species.

9.4 Role of Nuclear Aggregates in the htt Exon-1 Aggregation Pathway:
The data we gathered from the treatment of Q103 cells with demecolcine also
brought forth the possibility that the two forms of recruitment-inert aggregates (GN+Rand GC+R-) were on separate, competing pathways (Figure 9.1D-F). While demecolcine
treatment significantly reduced GC+R-, the compound treatment did not significantly
affect GN+R- species (Figure 7.4B), suggesting that GN+R- aggregates formed via an
assembly pathway that did not involve microtubules. While nuclear aggregation appeared
to occur independently of compound treatment, GN+R- aggregate formation was prolinedependent. Nuclear aggregates were never seen in cells expressing complete exon-1 and
were only apparent in cells expressing Q103. Presumably monomeric protein gained
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access to the nucleus by an unspecified means where it then aggregated. It is unclear why
the nuclear aggregated species never exhibited recruitment-competency. However, one
possibility is that cells that formed recruitment-positive aggregates in the nucleus died
and were never visualized.
It is has been shown that nuclear penetration is necessary for cell death to occur
[Cooper et al. 1998; Hackam et al. 1998; Yang et al. 2002]. In most of these cases, the
nuclear aggregates are amyloid-like and are, therefore, recruitment-competent [Yang,
Dunlap et al. 2002]. Cells expressing truncated htt exon-1 fragments were the only cells
that generated GN+R- species; however, no nuclear AF were ever seen. These results are
consistent with published findings that nuclear amyloid aggregates are extremely
cytotoxic, and may thus explain why our cells did not exhibit toxicity.

9.5 Current Detection Methods May Ignore Important Indicators of Cell
Dystrophy:
In HD, there is a lack of correlation between polyGln inclusions and cell death
[Gutekunst, Li et al. 1999], suggesting that there may be other unreported species
responsible for cellular demise. Our model directly addresses this important question
lingering over HD research. The presence of AF in cells expressing 25QP demonstrate
that studies focusing strictly on the larger polyGln inclusions are not comprehensive in
their aggregate analysis. Often, AF form in the absence of GFP-positive inclusions and
may provide a better correlation with cell dystrophy in the human disease. Similarly, we
have shown that inclusions can be recruitment-positive or recruitment-inert. Previous
attempts to correlate cell death to inclusions did not take this characteristic into account.
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9.6 Future Directions:
While these data have provided many insights into the aggregation pathway, there
are many questions still unanswered and hypotheses incompletely proved. For example,
an important hypothesis coming out of this work is that the large, perinuclear GC+Raggregates are detergent-soluble and/or labile to mechanical stress. This hypothesis
emerges from the comparison of fluorescence microscopy data with cell fractionation
data, as summarized in Figures 8.9 and 8.12. The hypothesis is also consistent with the
apparent ability of microtubule disruption to block formation of, or destabilize, GC+R-.
Thus, providing more experimental support for this hypothesis would strengthen many of
the conclusions of this thesis. To further test this hypothesis, we would propose to
prepare cell lysates of demecolcine treated and untreated cells in the absence of detergent.
If the aggregates were indeed denatured by the presence of the detergent, then cells
disrupted in the absence of detergent should exhibit less monomer and more aggregate,
and perhaps more easily pelleted aggregates. This set of experiments would provide a
new set of biochemical data that may reflect the severe aggregate burden that we see
microscopically.
Results from our biochemical data have demonstrated that our method of cell lysis
in conjunction with differential centrifugation was sufficient for the crude preparation of
various protein fractions. It is, however, imperative to improve upon this method so that
the nature of each polyGln species can be more closely examined. As alluded to earlier
(Chapter 8), the introduction of an immunoprecipitation step prior to fractionation would
provide a much cleaner sample. For example, if the whole cell lysate material were
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immunoprecipitated with the 1C2 antibody, then the fractions would be rich in polyGlncontaining proteins. Then there are a host of experiments that could be conducted with
the purified material. For example, to address the critical question of which, if any, of the
species could further support fibril growth in vitro. One would expect that the only
species capable of this feat would be AF. It would also, then, be possible to examine the
samples by EM. This would provide more information about the amyloidogenic
properties the species actually possess. Alternately, one could also examine whether or
not the large aggregates freely dissociate to monomer.
Finally, the most definitive experiment to gain information regarding whether the
various species are formed “on-” or “off-pathway” would be to design an experiment
where live-cell imaging could be performed to monitor the formation or dissociation of
the various types of aggregates. In order to conduct such an experiment, one would need
to design a fluorochrome-labeled (preferably one of the stable red variants that are
offered from Molecular Probes) polyGln peptide of benign length that could be
introduced to the cells and detected by microscopy. Entry of biotinylated monomer into
the cell with our current AF staining method, as mentioned earlier, is dependent upon the
permeabilization of fixed cell material. Fixation and permeabilization, while useful for
many applications, does indeed kill the cell. There are, however, cell permeabilzing
agents (saponin) that can be used to introduce temporary pores in cell membranes without
killing the cell cultures, thus allowing aggregate formation to be studied in real-time. The
information gained from such experiments would provide direct evidence of the
interactions of M, GC+R-, and G-RC+ species.
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9.7 Conclusions:
In summary, we were successful in developing a novel polyGln stain that relies on
the recruitment-capabilities of polyGln sequences. This stain combines a functional assay
and a visual means for detecting recruitment-positive entities, which were not always
detected by normal polyGln staining methods. We were able to optimize an existing
stable, htt-inducible PC12 model for maximum protein expression in which we
implemented our polyGln-recruitment stain.
With the aid of our polyGln-recruitment stain, we were able to identify several
phenotypically distinct polyGln aggregates. We successfully tested the effects of two
compounds on their ability to modulate aggregation. One compound had a profound
effect on AF while the other compound significantly reduced GC+R- aggregates.
Our data have also shown that polyGln flanking sequences play important roles in
altering aggregation kinetics and protein stability. While the mechanism of polyGln
aggregation is still a mystery, our data suggest that GC+R-, GN+R-, and G-RC+ aggregates
form via alternate assembly pathways (Figure 9.1E). Further experimentation is needed to
determine which, if any of these species represent the toxic entity responsible for HD
pathogenesis.
Our data support a model of polyGln aggregation which defines three competitive
pathways that result in AF, large, perikaryal inclusions, and amorphous nuclear
microaggregates.
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